









Elliott, Emma P.J. (2021) Examining measurement properties of cognitive 
screening instruments used post-stroke. PhD thesis. 
 




Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 























Examining measurement properties of cognitive 




A Thesis by 
 
 
















The Institute of Cardiovascular and Medical Sciences 
 
College of Medical, Veterinary and Life Sciences 
 
University of Glasgow 
 







Background: Cognitive screening after a stroke is recommended by clinical 
guidelines, specialist societies and as part of national audit programs. However, 
due to vague recommendations, different cognitive syndromes, and differing 
opinions regarding cognitive screening instrument (CSI) choice and timing, a 
range of CSIs are being used in clinical practice and research. There are limited 
data related to the use of both brief CSIs (administered in ≤5 minutes) and 
stroke-specific CSIs. This means that some teams may be using CSIs without any 
supportive evidence that they are fit for purpose. I aimed to examine 
measurement properties of different brief generic CSIs and the Oxford Cognitive 
Screen (OCS). 
Methods: I first conducted a study into the feasibility of various brief CSIs on a 
hyper acute stroke unit; I examined the completion rates, reasons for being 
untestable and examined associations with being untestable. 
I conducted two systematic reviews of test accuracy; one to identify and 
evaluate shortened versions of the Montreal Cognitive Assessment (SF-MoCA) and 
the second to evaluate telephone-based CSIs. 
Using the data from the Assessing Post-Stroke Psychology Longitudinal Evaluation 
study (APPLE), I examined completion rates and floor/ceiling effects of a range 
of brief CSIs and the OCS. I examined the accuracy of brief CSIs to detect pre-
stroke cognitive impairment (against diagnosis in medical records) and to detect 
post-stroke single and multi-domain cognitive impairment, using the OCS as a 
reference standard. Finally, I investigated whether domain-specific results from 
the OCS completed at one-month post-stroke were associated with functional, 
mood and quality of life outcomes at six months.  
Findings: A quarter of participants were untestable on at least one cognitive 
test item. Across the different CSIs examined, the clock drawing test (CDT) had 
the lowest completion rate, whereas there were no missing data using the 4 A’s 
Test (4AT), due to scoring for untestable being incorporated. 
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In the first systematic review I identified thirteen SF-MoCAs. Across the 
published literature and in the external validation, the performance of the short 
forms varied but demonstrated a pattern of high sensitivity to detect multi-
domain cognitive impairment, according to different reference standards. 
In the second systematic review I identified 15 telephone-based CSIs to identify 
MCI or dementia. Four of these CSIs were used in participants post-stroke 
(Telephone Interview for Cognitive Status [TICS], TICS-modified, Telephone-
Montreal Cognitive Assessment [T-MoCA], T-MoCA short). Of the limited data 
available in stroke, the telephone CSIs demonstrated high sensitivity to detect 
multi-domain cognitive impairment. Outside of stroke, the TICS and TICS-m had 
the greatest supportive evidence base to screen for dementia. 
In the APPLE study, ceiling effects were highest for the Abbreviated Mental Test 
(AMT-4), Cog-4 and 4AT. Across eight brief CSIs, the pattern of accuracy for pre- 
and post-stroke cognitive syndromes was generally low sensitivity, high 
specificity, apart from the CDT and NINDS-CSN 5-min MoCA which exhibited the 
opposite pattern. The OCS had good completion rates, but fewer participants 
fully completed it in comparison to the brief CSIs. There were no issues of 
floor/ceiling effects. In unadjusted models, all OCS domains apart from memory 
were significantly associated with at least one six-month outcome. However, 
when controlling for confounding variables (such as age, education, pre-stroke 
disability and stroke severity), and adjusting for multiple testing, only one 
domain remained significant with one outcome: executive dysfunction had a 
modest association with reduced quality of life (measured using the EQ-5D). 
Conclusions: To summarise, in the context of stroke, incomplete cognitive 
screening assessments should be expected. CSIs with fewer items or stroke 
specific CSIs do not necessarily have a higher completion rate. Clinicians and 
researchers should therefore make a-priori plans on how to address incomplete 
assessments. 
Recommendations for CSI choice differ depending on the purpose of screening, 
including resources and plans for following up those with identified cognitive 
impairment. Most brief CSIs demonstrated low sensitivity, high specificity to 
detect post-stroke multi-domain cognitive impairment so would not be 
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recommended for clinical use. Telephone-based CSIs have some promising initial 
data in the stroke context, but further studies are needed before recommending 
for clinical use. There was insufficient evidence that results from the OCS at one 
month are associated with functional and mood outcomes at six months, but 
some evidence that executive dysfunction is independently associated with 
reduced quality of life. Further studies are necessary to understand the 
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Preface: Context and thesis outline 
All prospective data collection in this thesis were collected in a UK, NHS setting, 
therefore interpretations and recommendations are with this context in mind. 
The overarching objective of the work presented in this thesis is to examine the 
following measurement properties of different cognitive screening instruments 
(CSIs): feasibility, accuracy, floor/ceiling effects, prognostic utility. The focus is 
primarily on the use of CSIs on a hyper acute stroke unit (HASU) in patients after 
ischaemic/haemorrhagic stroke or a transient ischaemic attack, however the 
two systematic review chapters also review data from other disease areas, such 
as Alzheimer’s disease and multiple sclerosis, as comparators. 
The outline of the thesis is provided in Figure 1. Chapter 1 provides the 
background and rationale for the work carried out. Chapter 2 addresses 
completion rates of brief CSIs in all patients who were admitted to a HASU. This 
real-world data set gives us a unique insight into reasons given when a CSI 
cannot be completed. Chapters 3 and 4 are systematic reviews, examining the 
accuracy of short forms of the Montreal Cognitive Assessment (MoCA) and 
telephone-based CSIs. Chapters 5-7 cover the methods and results from a 
prospective, observational, longitudinal study: Assessing Post-stroke Psychology 
Longitudinal Evaluation (APPLE). These chapters provide measurement 
properties of a range of brief CSIs and a stroke-specific multi-domain CSI: the 
Oxford Cognitive Screen. From these results a set of evidence-based 





Figure 1 Thesis Structure 
 
Abbreviations: APPLE, Assessing Post-stroke Psychology Longitudinal Evaluation; CSI, Cognitive 
screening instrument; MoCA, Montreal Cognitive Assessment; OCS, Oxford Cognitive Screen. 
  
Chapt 2: Feasibility in 
acute stroke 
Chapt 5: APPLE 
methods 
Chapt 6: Use of brief 
CSIs in stroke: a 
longitudinal study 
Chapt 7: OCS feasibility 
& associations with later 
outcomes 
Chapt 8: Discussion of 
findings 
Chapt 4 Review: Accuracy 
of telephone-based CSIs 
Chapt 3 Review: Accuracy 
of short forms of MoCA 
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ACE: Addenbrooke’s cognitive examination (-R denotes Revised version) 
AD: Alzheimer’s Disease 
ADDTC: Alzheimer's Disease Diagnostic and Treatment Centers 
ADL: Activities of Daily Living 
AHA-ASA: American Heart Association-American Stroke Association  
AMT: Abbreviated Mental Test 
ANCOVA: Analysis of covariance 
APPLE: Assessing post-stroke psychology longitudinal evaluation 
AUROC (or AUC): Area under receiver operating characteristic curve 
BCoS: Birmingham cognitive screen 
BI: Barthel index 
BMET: Brief memory and executive test  
BNIS: Barrow Neurological Institute Screen for higher cerebral functions 
BNS: Brief Neuropsychological Screening 
CA: Conference abstract 
CAMCOG: Cambridge Cognition examination 
CAM-ICU: Confusion Assessment Method for the Intensive Care Unit 
CASP: Cognitive Assessment scale for Stroke Patients 
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CAT: Computerised adaptive testing 
CDT: Clock-drawing test 
CG: Claire Green  
CI: Confidence Interval 
ClinRO: Clinician-reported outcome 
COA: Clinical outcome assessment 
Cognitive-FIM: Cognitive-Functional Independence Measure 
CoMet: Cognitive screening Method for stroke patients 
CRF: Case report form 
CSI: Cognitive screening instrument 
CTT: Classical Test Theory 
DOC: Depression, Obstructive sleep apnoea and Cognitive impairment 
DOR: Diagnostic odds ratio 
DSM: Diagnostic and Statistical Manual (-V denotes version number) 
DTA: Diagnostic test accuracy 
EM-MoCA: Esclerose múltipla (Multiple sclerosis in Portuguese) Montreal 
Cognitive Assessment 
ESO: European Stroke Organisation 
FAI: Frenchay Activity Index 
FIM: Functional Independence Measure 
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FN: False negative 
FP: False positive 
GCS: Glasgow Coma Scale 
GP-cog: General Practitioner assessment of cognition  
HASU: Hyper acute stroke unit  
HCP: Healthcare professional 
HF: Heart Failure 
HSROC: Hierarchical summary receiver operating characteristic  
IADL: Instrumental activities of daily living 
ICH: Intracerebral haemorrhage 
IMCT: Information memory concentration test 
IQCODE: Informant questionnaire on Cognitive Decline in the Elderly 
IQR: Inter-quartile range 
IRT: Item Response Theory 
IS: Ischaemic stroke 
LACS: Lacunar syndrome 
MA: Myzoon Ali  
MCAS: Minnesota cognitive acuity screen 
MCI: Mild Cognitive Impairment 
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MEPS: Mental performance in acute stroke 
MMSE: Mini-Mental State Examination 
MoCA: Montreal Cognitive Assessment 
MoCA‐Blind: Version of MoCA with visual items removed 
mRS: Modified Rankin Scale 
MS: Multiple sclerosis 
MSQ: Mental status questionnaire 
MuSCoW: Must Should Could Won’t 
MVCI: Mild Vascular Cognitive Impairment 
NART: National Adult Reading Test 
NHS: National Health Service (UK) 
NIA-AA: National Institute on Aging and Alzheimer's Association 
NICE: National Institute for Health and Care Excellence 
NIHSS: National Institute of Health Stroke Scale 
NINDS-AIREN: Neurological disorders and Stroke and Association Internationale 
pour la Recherché et l'Enseignement en Neurosciences   
NINDS-CSN: National Institute of Neurological Disorders and Stroke and the 
Canadian Stroke Network  
NPB: Neuropsychological battery 
NPEC: Northwick Park Examination of Cognition 
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NPV: Negative predictive value 
OCSP: Bamford/Oxfordshire community stroke project classification system 
ObsRO: Observer-reported outcome 
OCS: Oxford Cognitive Screen  
OT: Occupational therapist 
PACS: Partial Anterior Circulation Stroke 
PCA: Principal Component Analysis 
PD: Parkinson’s disease 
PerfO: Performance-rated outcome 
PIS: Patient information sheet 
POCS: Posterior Circulation Stroke 
PPV:Ppositive predictive value 
PRECiS: Patient-reported evaluation of cognitive state 
PRISMA-DTA: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses of Diagnostic Test Accuracy Studies 
PRO: Patient-reported outcome 
QUADAS: Quality Assessment for Diagnostic Test Accuracy Studies  
RBANS: Repeatable Battery for the Assessment of Neuropsychological Status 
REC: Research ethics committee  
RMT: Rasch measurement theory 
25 
 
ROC: Receiver operating characteristic 
R-CAMCOG: Rotterdam Cambridge Cognition 
SF-MoCA: Short forms of the MoCA 
SPMSQ: Short Portable Mental Status Questionnaire 
SPSS: Statistical Package for Social Sciences 
SSNAP: Sentinel stroke national audit programme 
STARDdem: Standards for Reporting Diagnostic Test accuracy studies in dementia 
STIDA: Structured Telephone Interview for Dementia Assessment 
STROND: Standards of Reporting of Neurological Disorders 
SVD: Small vessel disease 
TAB: Telephone assessment battery 
TACS: Total Anterior Circulation Stroke 
TCAB: telephone cognitive assessment battery 
TIA: Transient ischaemic attack  
TICS: Telephone Interview for Cognitive Status 
TICS-m: Telephone Interview for Cognitive Status modified 
T-MoCA: Telephone version of Montreal Cognitive Assessment 
TN: True negative 
TP: True positive 
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TRIACOG: Cognitive Screening Instrument for evaluating poststroke adults 
T3MS: Telephone version of MMSE 
VaD: Vascular dementia 
VCI: Vascular Cognitive Impairment 
VISTA: Virtual International Stroke Trial Archive 
WAIS-III: Wechsler Adult Intelligence Scale (Version III) 
4AT: 4-A’s Test for rapid assessment of delirium 




1 Introduction  
1.1 What is cognition? 
Throughout this thesis, cognition refers to the range of mental processes we use 
to acquire, process, understand, store, and retrieve information (1). These 
processes are used to make sense of the world around us. Cognition is therefore 
not a unitary concept; under this umbrella term are various domains or 
functions, yet even referring to these domains alone is reductionist. Domains are 
multifaceted, comprising numerous sub-domains, and many functions are not 
independent of one another. This makes studying cognition complex, and indeed 
many researchers spend their entire career researching just one of these 
domains. 
There is no consensus regarding the classification of cognitive domains, although 
the domains of memory, language, attention, executive functioning, visuospatial 
processing, and processing speed are frequently differentiated. Cognitive 
abilities are also considered hierarchical in nature, for example executive 
functions are often referred to as higher order cognitive functions as they are 
more complex than the more basic perceptual abilities (2). Executive functioning 
abilities also exert control over more basic processes. 
One of the main diagnostic guidelines used for cognitive disorders is the 
Diagnostic and statistical manual (DSM). The 5th version (DSM-5) (3) refers to six 
cognitive domains that can be affected in neurocognitive or neurodevelopmental 
disorders(4) (Figure 1-1). 
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Figure 1-1 DSM-5 cognitive domains 
 
1.2 Post-stroke cognitive impairment 
Stroke is a risk factor for development of a cognitive disorder. Within the 
general population in the UK, over 100,000 people are diagnosed with a stroke 
(5) and 46,000 diagnosed with a transient ischaemic attack (TIA) each year, with 
an estimate of 1.2 million stroke survivors. 
The prevalence of cognitive impairment post-stroke depends on the 
measurement and criteria used and the timing of assessment. In the acute 
period after a stroke, up to 70% of patients exhibit cognitive difficulties (6-8), 
whereas in the year following a stroke, the prevalence is roughly 40% (9). 
Patients with cognitive impairment after a stroke are also at risk of developing 
dementia (10), with approximately 10% of patients diagnosed after their first 
stroke, rising to 30% after multiple strokes (11). The negative consequences of 
cognitive impairment are well established, including increased length of hospital 
stay (12), functional impairment (13), lower quality of life (14) and increased 
risk of post-stroke depression (15). 
There is a lack of consistent nomenclature describing post-stroke cognitive 
impairment in the literature, making it challenging and confusing for researchers 
to make comparisons across studies. This is due to varying severities in 
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impairment, different criteria being used and poor concordance between 
different diagnostic guidelines (16). 
The nature of diagnosis is to think of conditions in binary terms; they are either 
present or absent, yet the distinction may not be clear cut in practice. If 
cognitive abilities and cognitive impairment exist along a spectrum, how we 
define impairment depends on normative data and understanding the process of 
normal cognitive aging (17), which we are continually learning more about. A 
binary outcome of impairment as present or absent allows for ease of analysis in 
research studies but lacks granularity and may mask group differences. Other 
approaches include creating hierarchical categories, assessment as a continuous 
scale, and assessing against population normative data. 
Viewing cognitive impairment through a dementia paradigm alone is erroneous 
and one must differentiate between different syndromes, yet at the same time 
understand the relationship and potential overlap between them. These 
syndromes include dementia, mild cognitive impairment, delirium, and other 
non-degenerative types of post-stroke cognitive impairment, which will be 
discussed below. Within each of these syndromes, there are a variety of 
classifications. Throughout this thesis I will specify the syndrome of interest. 
Delirium is not the focus of any chapters, however since some chapters relate to 
cognitive screening on an acute medical unit, it should be taken into account 
when interpreting the results.  
Vascular cognitive impairment (VCI) is a wide-reaching term encompassing all 
vascular contribution (not just stroke) to cognitive problems. VCI is also not 
specific to severity and covers a spectrum of syndromes. Despite terminology, it 
also includes mixed pathology dementia (18, 19). 
1.2.1 Cognitive impairment, no dementia 
The majority of post-stroke cognitive impairment is distinct from dementia in 
that it improves over time and is therefore not neurodegenerative. Since stroke 
itself is heterogenous in nature (different types, aetiologies, extent of damage), 
the cognitive profile of post-stroke cognitive impairment is unsurprisingly 
diverse. However, deficits in executive function and visual perception are more 
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frequent and characteristic in this group of patients in comparison to those with 
Alzheimer’s Disease (AD), where memory impairments are more central (20-22). 
Examining subgroups of stroke could provide some patterns, for example the 
profile of cognitive impairment associated with small vessel disease (SVD) 
includes executive dysfunction and reduced processing speed (23), whereas focal 
cognitive impairments such as aphasia and visuospatial neglect were found to be 
more common following a cardioembolic stroke, in comparison to large vessel or 
small vessel disease (24). Improvements or recovery from focal impairments can 
occur spontaneously, as seen in apraxia (25) and visuospatial neglect (26), or 
may improve as a result of rehabilitation/intervention (27), although evidence 
for effectiveness of interventions is lacking. 
Mild cognitive impairment (MCI), referred to as minor neurocognitive disorder in 
the DSM-5, is a term used largely in non-stroke settings, yet has been adopted in 
some stroke studies, since it is a diagnostic term. In DSM-5 it is characterised by 
evidence of modest cognitive impairment that does not interfere with activities 
of daily living (ADL) (3, 28). Subtypes of MCI are sometimes described, including 
amnestic and non-amnestic (depending on whether memory is impaired) (19) and 
single or multi-domain MCI (depending on number of domains impaired). The 
syndrome of MCI is still considered a controversial and uninformative diagnostic 
label since the prognosis is unknown; some may return to their normal cognitive 
baseline (29), some may stay the same (30), whereas for others it is a 
transitional phase before progression to dementia (31).  
1.2.2 Dementia  
While dementia subtypes based on aetiology are still used, it is now well 
acknowledged that dementia is often not caused by a single pathology. Vascular 
pathology is found in more than half of diagnosed dementia cases, with many 
clinical diagnoses of AD confirmed as mixed or vascular on autopsy (32, 33). 
The main distinction between MCI and dementia is based on the degree of 
functional deficit - in dementia, impairment affects a patient’s independence to 
carry out daily tasks. Amongst the various diagnostic criteria for vascular 
dementia (VaD), the National Institute of Neurological Disorders and Stroke and 
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Association Internationale pour la Recherché et l'Enseignement en Neurosciences 
(NINDS-AIREN) requires memory to be impaired plus impairment in two other 
cognitive domains. However, in the American Heart Association-American Stroke 
Association (AHA-ASA) diagnostic criteria, a minimum of two domains must be 
impaired without the requirement of memory impairment. The DSM-5 includes a 
number of changes from its previous version; the term major neurocognitive 
disorder has replaced dementia, and memory impairment is no longer required 
for diagnosis. The four criteria used in DSM-5 are summarised in Figure 1-2. If 
these criteria are met, the subtype is then made based on aetiology. Other 
criteria also exist, for example those of the State of California Alzheimer's 
Disease Diagnostic and Treatment Centers (ADDTC) (34). 
 
It is easy to mis-label patients with cognitive problems after stroke as having 
dementia, since stroke commonly causes physical impairment affecting 
independence in activities of daily living. It is therefore recommended that a 
diagnosis of dementia should not be given until at least 6 months after stroke 
onset (18).  
1.2.3 Delirium 
Delirium is an acute, transient, state of confusion and a common complication of 
acute illness, affecting around 25% of patients after a stroke within the first 6 
weeks (35). Consideration and screening to detect delirium is therefore 
important in the acute stroke setting. Identifying delirium has implications for 
Major Neurocognitive disorder: 
 
A. Evidence of significant cognitive decline from a previous level of performance in 
one or more cognitive domains (complex attention, executive function, learning 
and memory, language, perceptual-motor, or social cognition) based on: 
1. Concern of the individual, a knowledgeable informant, or the clinician that 
there has been a significant decline in cognitive function; and 
2. A substantial impairment in cognitive performance, preferably documented by 
standardized neuropsychological testing or, in its absence, another quantified 
clinical assessment. 
B. The cognitive deficits interfere with independence in everyday activities (i.e., at a 
minimum, requiring assistance with complex instrumental activities of daily living 
such as paying bills or managing medications). 
C. The cognitive deficits do not occur exclusively in the context of a delirium. 
D. The cognitive deficits are not better explained by another mental disorder (e.g., 
major depressive disorder, schizophrenia). 
Figure 1-2 DSM-V Major cognitive disorder criteria (2) 
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both the short and longer term. Incident delirium can signal the emergence of a 
stroke-related complication, such as pneumonia, and in the longer term the 
presence of delirium is associated with poor outcomes. 
1.3 Risk factors/mechanisms of post-stroke cognitive 
impairment 
There are numerous potential mechanisms and risk factors involved in cognitive 
impairment post-stroke. Since this topic is not the focus of this thesis, only a 
brief overview will be provided. It is discussed in greater detail elsewhere (36-
38). 
Size and location of lesions impacts on the presence and type of cognitive 
impairment (36, 39, 40). Cerebral small vessel disease (SVD) is a common cause 
of cognitive impairment and dementia (41). SVD refers to lacunes, white matter 
hyperintensities, cerebral microbleeds, brain atrophy and enlarged perivascular 
spaces (42). SVD and AD pathology can also co-exist and overlap (38). 
Risk factors for dementia include those that are not modifiable (age, sex) and 
those that are potentially modifiable: fewer years of education, hearing loss, 
traumatic brain injury, hypertension, alcohol, obesity, smoking, depression, 
social isolation, physical inactivity, air pollution and diabetes (43). 
The concept of cognitive reserve is used to illustrate how protective factors may 
moderate the relationship between brain pathology and clinical outcomes (44), 
for example having a greater number of years in education (45), social support 
(46) and regular exercise (47). Years in education is commonly used as a proxy of 
cognitive reserve. A recent study found that when controlling for age and 
relative lesion size, the number of years in education predicted performance in 
alertness, which is considered to be ‘education independent’ as well as other 
tasks considered ‘education dependent’ (48). Years in education however did not 
predict the presence of spatial neglect. It is recommended that proxies of 
cognitive reserve are considered even as early as the acute stroke phase. 
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1.4 Clinical outcome assessments (COAs) 
There are four categories of clinical outcome assessments (COAs) used to 
measure patient outcomes and experience, based on how they are completed 
(Figure 1-3). Patient-reported outcomes (PROs) are measures completed by 
patients (self-report) to understand their experience of symptoms and the 
impact these have on their lives. These are commonly used to measure 
symptoms such as fatigue or pain. Clinician-reported outcomes (ClinROs) are 
measures carried out by a healthcare professional (HCP) or trained researcher. 
Most ClinROs involve some clinical judgement or interpretation of signs, 
symptoms, or behaviours. Performance outcomes (PerfOs) involve the patient 
carrying out a task, according to instructions that are administered by a 
healthcare professional/researcher. Observer-reported outcomes (ObsROs) are 
captured by someone who observes the patient in everyday life, for example a 
family member. 
 
Figure 1-3 Types of Clinical Outcome Assessments 
 
All four types of COAs will be used in this thesis. Cognition is the main focus and 
is measured using PerfOs, rather than any PRO scales that provide a subjective 
measure of cognitive decline, e.g. the cognitive change index (49) and the 
patient-reported evaluation of cognitive state (PRECiS) (50). PROs are used to 
measure quality of life, depression, and activities of daily living. ClinROs are 
used to measure disability and function and ObsROs are used for a family 
member’s perspective of the patient’s independence/function. 
  34 
 
1.5 Cognitive screening instruments (CSIs) 
Basic orientation questions are frequently used in clinical practice to determine 
a patient’s level of consciousness (e.g. in the Glasgow Coma Scale (GCS) (51)). 
The GCS however is not considered a cognitive screening instrument (CSI). A CSI 
is a test comprising any number of tasks that aim to determine cognitive 
impairment in a patient. Occasionally items are taken out of existing 
instruments to create a CSI, for example the Cog-4 comprises the four cognitive 
items of the National Institute of Health Stroke Scale (NIHSS), which is routinely 
undertaken to measure stroke-related neurological deficits. 
A distinction is made between CSIs and a full neuropsychological battery (NPB), 
which comprises numerous tests, requires expert interpretation and is 
considered the gold standard for detection of cognitive impairment. Most CSIs 
have one overall score and use a cut-off or threshold score to categorise patients 
into two groups (impaired or spared); they are referred to as global screening 
tests. Swartz et al. however suggest using an alternative method of using two 
cut-off scores to stratify patients into three groups (low, intermediate or high 
risk of cognitive impairment) (52). There are also a minority of CSIs that provide 
cut-off scores across different subtests/domains (domain-specific tests), with 
the attempt to create a halfway house between a CSI and NPB and to address 
the criticism of reducing cognition down to one single score. 
It should be clear that there is no perfect CSI. Each CSI has its strengths and 
weaknesses and there cannot be one recommendation to fit all scenarios, nor 
even one recommendation for post-stroke. The purpose for administering the CSI 
will be a central theme running throughout this thesis, and it is this purpose that 
will drive the choice of CSI. As explained in an earlier section, there are a range 
of syndromes that may be screened for and different CSIs will be suited for each 
of these. Hospital resources and intended next steps for follow-up also play into 
decision-making. Some generic criteria can be set for CSI use on an acute stroke 
unit (Table 1-1). 
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Table 1-1 MuSCoW chart (Must Should Could Won’t) detailing preferred properties for use of 
a CSI on an acute stroke unit 
 
Must have Should have 
- Administration <20 mins 
- Appropriate test accuracy (for 
syndrome of interest) 
- Aphasia friendly questions 
- Stroke normative values 
- Free training materials 
- Guidance on item non-completion 
Could have Won’t have 
- Translations 
- Adaptable to telephone or video 
calls 
- Parallel versions 
- Diagnostic purpose 
- Require specialist training 
- Copyright issues 
 
The current paradigm of cognitive assessment in stroke in the UK is a two-step 
system; patients scoring low on a CSI are triaged and often referred on to the 
neuropsychology department for more detailed, comprehensive testing (where 
staffing and resources allow). Therefore, for this system to work, good test 
accuracy of the CSI is vital so patients with impairment are not missed and those 
without any impairment are not subjected to unnecessary testing. There are two 
broad approaches to cognitive screening: universal (unselected) screening of all 
patients admitted to the stroke unit, or targeted assessment of a smaller group 
of people where there is concern about cognitive problems. The two approaches 
are not mutually exclusive, and a patient who passes a screening test but 
complains of cognitive issues should not be denied a more detailed assessment. 
Although we know that many institutions follow this 2-step paradigm, we also 
know that there is variability in terms of which patients are screened, the CSI 
used and the timing of administration. 
In the UK, cognitive screening in acute stroke is generally carried out by 
occupational therapists (OTs). It is rare that psychologists are available in acute 
settings, and patients usually will have to wait for an outpatient appointment to 
access a psychologist. We also know that evidence does not always drive CSI 
choice. A qualitative study completed with OTs found variation in CSI choice in 
the community stroke setting and noted that the choice of tool was primarily 
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based on availability and familiarity rather than any psychometric properties, 
and the interpretation is often subjective (53).  
Decision-making regarding the time-point most meaningful for screening 
(days/weeks/months after stroke event) is subject to debate and once again is 
dependent on the purpose of screening. Early identification of cognitive 
impairment is argued to have benefits, for example it should allow for 
targeted/personalised rehabilitation, appropriate goal setting and aid discharge 
planning (8). Informing and educating patients (and their families) about any 
cognitive issues is important so they understand how such problems could 
potentially affect them in their day to day lives. Finally, there is the argument 
that screening patients early on during their hospital admission is often the only 
opportunity to do so; patients can be discharged home quickly. Six-month 
reviews have been commissioned in England, Wales, and Northern Ireland but 
completion is far from universal. Those who argue against early cognitive 
screening cite the limited understanding of the natural history of post-stroke 
cognitive impairment, the variability of cognitive test performance during the 
acute period (18) (which could be due to the presence of delirium) and the lack 
of evidence regarding effectiveness of cognitive rehabilitation or treatments (54, 
55). 
There are many different CSIs to choose from, each varying in length, difficulty, 
and coverage of different cognitive domains. The Montreal Cognitive Assessment 
(MoCA) (56) and Mini-Mental State Examination (MMSE) (57) are often cited in 
stroke research (58, 59) as the two most commonly used CSIs, however the 
landscape is continually changing and since a charge was introduced with the 
MMSE, many clinicians have abandoned it, with the same expected to follow for 
the MoCA (60). Frequently, CSIs like the MoCA and MMSE that were developed for 
AD or MCI populations are used in the stroke setting. Any test used in a new 
context of use needs to be re-validated. The same is also true if any 
amendments are made to a CSI. CSIs that have not been developed with stroke 
patients in mind have a number of limitations that should be considered. They 
are often heavily reliant on language skills, which disadvantages aphasic 
patients, and there is often no assessment of neglect or apraxia. They were 
designed for outpatient settings and therefore may not be appropriate to 
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administer at the bedside on a busy acute medical unit, nor with patients with 
physical or speech impairments. Therefore, there is concern if a CSI used has not 
been validated in stroke patients. 
CSIs are sometimes categorised according to administration time. The shortest 
CSIs, referred to as brief CSIs throughout this thesis, are most suited to acute 
medical settings since they can be administered in ≤5 minutes. However, a 
limitation is that they mainly focus on orientation and memory. Examples 
include the Clock-drawing test, Abbreviated mental test (AMT) (61), Six item 
cognitive impairment test (6-CIT) (62), Mini-cog (63) and GP-cog (64). CSIs that 
cover more cognitive domains include the MoCA(56), Addenbrooke’s cognitive 
examination (ACE) (65), MMSE (57) and the Oxford Cognitive Screen (OCS) (66), 
but their administration time is longer. When choosing CSIs in both clinical 
practice and research, it is important to consider the trade-off between what is 
acceptable and feasible for both stroke patients and staff in these settings and 
what will provide the most meaningful data (for example, accurate, reliable, 
and prognostic). 
Standardisation of administration/scoring of psychometric tests is essential to 
interpret them accurately. Therefore, any clinician or researcher administering 
a CSI should read the manual that details administration/scoring instructions for 
each test. Additional in-person training may also be necessary for more complex 
tests. The need for training should not be underestimated as errors are 
commonly made. A study carried out with 104 psychiatrists and geriatricians 
found inconsistencies with their use of the Abbreviated Mental Test (AMT) (67). 
Specifically, only 22% of doctors used the original 10 items, while the others 
omitted items (often orientation and memory). When asked to score the test for 
a fictional patient, only 16% arrived at the correct score. This is concerning since 
on a short test like this, a single point difference can result in a different 
categorisation of impaired/not impaired. It is impossible to know the past or 
present extent of incorrect use of a test, either clinically or in research, and the 
resulting impact.  
Finally, it is important that caution is taken when interpreting scores from CSIs 
and scores should not be used in isolation. Despite CSIs not being diagnostic, low 
scores are often quoted to imply impairment (52) and are used as endpoints in 
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clinical trials. In comparison to detailed neuropsychological testing, CSIs have 
been found to underestimate cognitive impairment (68) and a single score 
provides a limited summary since it reflects a range of performance (52). Putting 
scores in context is essential as CSIs are affected by a variety of factors: age, 
education, socioeconomic status, culture and situational influences (emotional 
status, stress, fatigue, medication use) (28, 69). After receiving a stroke 
diagnosis, all these situational influences are likely to be present. CSIs also do 
not address the effect on function (52), nor do they take into account baseline 
cognitive status which is useful for comparison. 
1.5.1 The Montreal Cognitive Assessment (MoCA) 
The MoCA (56) was published in 2005 and developed with the purpose to identify 
MCI in community dwelling participants. Since then it has been utilised across a 
range of disease areas, such as multiple sclerosis (MS) (70), Parkinson’s disease 
(PD) (71), cancer (72), Huntington’s disease (73) and stroke (74). 
The total score is out of 30, with <26 being the recommended threshold score. A 
lower threshold score is sometimes employed post-stroke, but there is not a 
consensus on which score should be used (52, 74, 75). The following items are 
included: trail making test, cube copy, clock-draw, animal naming, immediate 
recall (unscored), digit span forwards and backwards, tap each time letter A is 
heard, serial 7 subtraction from 100, repeating two sentences, verbal fluency, 
abstraction, delayed recall, and orientation. An extra point is added to the 
patients score when they have 12 or fewer years in education. 
Strengths of the MoCA include evidence of content validity in Vascular Cognitive 
Impairment (VCI) (76), its wide validation with stroke patients, three alternative 
versions to allow for practice effects, and its translation into 65 languages (77). 
It is also preferred over other CSIs, such as the MMSE, because it is more 
sensitive to milder forms of cognitive impairment (76, 78, 79). 
However, as the MoCA was not designed for an acute stroke setting, it has 
limitations. It is largely a language-dependent test requiring verbal output, so all 
sections apart from the first (visuospatial/executive) may be compromised in a 
patient with aphasia or if it is not conducted in the patient’s native language. 
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The layout of the test is also not suited to patients with visual neglect as the 
items are not centralised. Finally, the lack of consensus regarding the cut-off 
score means there is uncertainty with interpretation. There is also some 
evidence that the MoCA has poorer sensitivity to right hemisphere deficits (80). 
1.5.2 Mini-Mental State Examination (MMSE) 
The MMSE (57) was published in 1975 and developed with the purpose to identify 
dementia. As previously discussed, it is one of the most commonly used CSIs and 
has been used across a wide range of disease areas including stroke (81), PD 
(81), and MS (82). 
The total score is out of 30, with <24 being the recommended threshold score. 
The following tasks are included: current year, season, date, day, month, 
location (including state, county, town/city, hospital, floor), immediate recall of 
3 unrelated words, serial 7 subtraction from 100 or spell ‘World’ backwards, 
delayed recall of 3 words, name 2 objects, repeat a phrase, follow a verbal 
instruction to fold a piece of paper in half with right hand and place it on the 
floor, follow a written instruction to close eyes, write a sentence and copy a 
figure of intersecting pentagons.  
In the stroke context, the MMSE has several limitations including low sensitivity 
to milder forms of cognitive impairment, no optimum threshold score (83) and, 
like the MoCA, many tasks require verbal output. 
1.5.3 Stroke specific CSIs  
Some CSIs have been developed specifically for stroke patients (Table 1-2). 
Theoretically these CSIs should be superior to generic MCI/dementia screens in a 
number of ways, including inclusivity and sensitivity to stroke-related 
impairments. In terms of inclusivity, many of these tests include vertical, 
centralised layouts to account for neglect and options to answer non-verbally, to 
account for aphasia. 
A systematic review published in 2019 found seven CSIs designed for stroke (59). 
However, one test (the Birmingham cognitive screen (BCoS)) takes roughly an 
hour to complete, which is too long for bedside screening and will not be 
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discussed further. From a search of the literature since this review was 
published, I found two additional stroke-specific CSIs. Many of these tests are 
unknown to those working in stroke, because the initial development paper is 
often the only available publication (e.g. Cognitive Screening Method for Stroke 
Patients (CoMet) (84), Brief Neuropsychological Screening (BNS) (85), Northwick 
Park Examination of Cognition (NPEC) (86)). While these screens have the 
potential to be useful measures, the lack of evidence means we know very little 
about their psychometric properties and therefore at present we cannot 
compare them and make recommendations. 
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Table 1-2 CSIs Designed for Stroke  
Test Name Designed or 
validated in acute 
settings (within 




Evidence level  
BMET No 13 mins  2 studies 
BNS Yes 5-10 mins 1 study 
CASP Yes 10 mins 2 studies 
CoMet No 20 mins 1 study 
MEPS Yes  Not specified 1 study 
MVCI Yes 5-13 mins 1 study 
NPEC Yes 30 mins 1 study 
OCS Yes 15 mins >10 studies 
TRIACOG Yes 20 mins 1 study 
 
Abbreviations: BCoS, Birmingham Cognitive Screen; BMET, Brief Memory and Executive Test; 
BNS, Brief Neuropsychological Screening; CoMet, Cognitive Screening Method for Stroke Patients; 
CASP, Cognitive Assessment for Stroke Patients; MEPS, Mental Performance in acute stroke; 
MVCI, Mild Vascular Cognitive Impairment; NPEC, Northwick Park examination of cognition; OCS, 
Oxford Cognitive Screen. 
Content based on the systematic review mentioned and my own literature search. 
1.5.3.1 Brief Memory and Executive Test (BMET) (23) 
The BMET was published in 2012. It comprises 6 tasks, with no maximum score, 
since one item is scored based on length of time to complete. It was designed to 
target cognitive impairment arising in the context of SVD, as the authors argue 
this pattern of impairment is distinct from that seen in large vessel stroke and 
cortical dementia. The items include orientation, letter-number matching, five 
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item repetition, sequencing (motor, letter, letter-number), five-item recall and 
five item recognition. 
The BMET was initially validated in patients with SVD and AD (23) and, in a 
second UK study, in 200 patients with lacunar stroke (87) (at an average of 20.5 
months post-stroke) and 303 healthy controls. In this second study the BMET was 
administered by doctors and research nurses rather than neuropsychologists, 
which is important as this is how it would be used in practice. 
1.5.3.2 Brief Neuropsychological Screening (BNS) (85) 
The BNS was published in 2009. It comprises 14 tasks, with a maximum score of 
68. The items include lexical decision and reading, shapes discrimination, 
incomplete letters, calculations, face recognition, auditory comprehension, 
written comprehension, naming of items and pantomime of use, matching 
objects, gesture imitation, verbal fluency, identifying coins from buttons, word 
recognition and proverb comprehension. 
The BNS was initially developed and validated in 134 acute stroke inpatients and 
247 healthy controls in Italy. Only those patients with severe aphasia were 
unable to complete the test. 
1.5.3.3 Cognitive Assessment scale for Stroke Patients (CASP) (88) 
The CASP was published in 2014, but there is a published conference abstract 
from 2012. It comprises 9 tasks, with a maximum score of 36. The items include 
naming, comprehension, cube copy, graphic series, inhibition/flexibility, line 
bisection, image recall, praxis, orientation.  
The CASP was initially validated in 44 stroke patients (mean 42 days post-stroke) 
in a rehabilitation centre in France. Verbal expression and comprehension 
disorders resulted in 18% of the sample having incomplete data. 
1.5.3.4 Cognitive Screening Method for Stroke Patients (CoMet) (84) 
The CoMet was published in 2019. It comprises 14 scored tasks and an unscored 
self-evaluation, with a maximum score of 147. The tasks include orientation, 
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writing sentences, understanding instructions, word fluency, episodic memory, 
drawing, delayed episodic memory, object naming, object memory, sentence 
repetition, object replacement, object recognition, visual finding, number 
arranging. 
The CoMet was initially validated in 77 stroke patients (mean of 51 days post-
stroke) in Finland. 
1.5.3.5 Mental Performance in acute stroke (MEPS) (89) 
The MEPS was published in 2020. It comprises 14 tasks with a total score of 82. 
The tasks include temporal orientation, spatial orientation, orders 
comprehension, segments discrimination, reading & comprehension of 
sentences, immediate visual memory, digit span, visual exploration and 
attention, words repetition, clock drawing test, similarity judgements, 
ideomotor apraxia, picture naming, ideational apraxia. It provides data on both 
a domain and global functioning level. 
The MEPS was initially validated in 129 acute stroke patients (mean of 5.5 days 
post-stroke) and 263 healthy control participants in Italy.  
1.5.3.6 Mild Vascular Cognitive Impairment (MVCI) (90) 
The MVCI was published in 2015. It comprises 13 tasks with a maximum score of 
30. The tasks include orientation (time & place), immediate recall, recent 
memory, prospect memory, delayed recall, repetition, verbal fluency, 
comprehension, counting numbers, calculation, abstraction, visuospatial ability, 
problem solving (situation play). Tasks were taken from other CSIs: MMSE, 
Cambridge Cognition (CAMCOG) examination for mental disorders of the elderly, 
MoCA and Telephone Interview for Cognitive Status (TICS) and chosen to also be 
deliverable over the telephone. 
The MVCI was initially validated in 60 stroke patients in South Korea, within 3 
months of stroke onset, and with no previous cognitive disability. 
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1.5.3.7 Northwick Park examination of cognition (NPEC) (86) 
The NPEC was published in 2016. It comprises 22 tasks and has a maximum score 
of 100. The following 5 domains are covered: orientation (5 points), 
reasoning/executive function (15 points), memory (20 points), language (25 
points) and perception (16 points). It includes tests to assess praxis and neglect.  
The NPEC was initially validated in 166 stroke patients admitted to a hyper acute 
stroke unit (HASU) (mean time to assessment was 5.6 days) and 100 healthy 
controls in the UK. The screen was used as part of routine clinical practice and 
as a result no data was available regarding the number of untestable patients.  
1.5.3.8 The Oxford Cognitive Screen (OCS) (66) 
The OCS was published in 2015 and comprises 10 tasks. There is no single 
maximum score, as each task has a different threshold score to indicate 
impairment. The tasks include picture naming, orientation, visual field test, 
sentence reading, number writing, calculations, broken hearts test, meaningless 
gesture imitation, delayed recall/recognition, and trails. The tasks are mapped 
onto the corresponding cognitive domain (language, attention, memory, praxis, 
and number processing). The administrator can use the visual snapshot of the 
patient’s profile for documentation of the patient’s strengths/weaknesses in the 
medical notes. 
The OCS was initially validated in 207 acute stroke patients in the UK. To date 
(2021) it has been translated and validated in eight languages: Italian (91), 
Dutch (92), Spanish (93), Russian (94), Danish (95), Putonghua (96), Cantonese 
(97), and Brazilian-Portuguese (98), with other cultural and language 
adaptations underway. There is a second version available that can be used for 
multiple testing with the same patient, and there are plans to develop a third 
parallel version. 
1.5.3.9 Cognitive screening (TRIACOG) instrument (99) 
The TRIACOG was published in 2020. It comprises 22 tasks, with a total score 
of 144. The tasks include orientation to time, episodic semantic verbal memory 
(immediate and delayed), praxis (clock-draw, reproduction of a figure), 
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ideomotor apraxia (use a fork), visual memory (reproduction of figure), 
attention/working memory (digit span forward and backward), executive 
function (verbal fluency letter V), processing speed (rapid serial naming of 
shapes), language (naming objects and actions), oral and written 
comprehension, vocabulary, phrase reading, inference processing, spelling, 
repletion and numerical processing. 
The TRIACOG was validated in 100 stroke patients (mean of 8.3 days post-stroke) 
and 100 healthy controls in Brazil.  
1.5.4 Telephone-based cognitive screens 
There are several CSIs which have been designed for telephone delivery, but 
evidence of their accuracy is lacking. The convenience of remote assessment 
means they are often used in studies with large samples, rather than clinical 
use. However, in recent times, remote CSIs are sought for clinical purposes too. 
Examples include the telephone interview for cognitive status (TICS)(100), its 
modified version (TICS-m)(101) and the telephone version of the MoCA (T-MoCA) 
(102). 
1.5.5 CSIs for delirium 
Screening tools for delirium are available, and many have good accuracy when 
compared with gold standard clinical assessment. The 4-A’s test (4AT) (available 
online: www.the4AT.com) is a short screening tool for delirium that is available 
in several languages and is quick to administer with little training; it has some 
supportive data in stroke (103, 104). The Confusion Assessment Method also has 
proven accuracy for diagnosis of delirium in stroke. For patients with aphasia or 
other communication problems, the Confusion Assessment Method modified for 
use in Intensive Care Settings (CAM-ICU) can be used because it does not require 
any verbal response for completion. 
1.5.6 Informant-based cognitive scales 
Questionnaires completed by a relative, partner or caregiver (ObsROs) can 
provide useful additional information to CSIs, for example to capture change in 
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cognition over time. When completed immediately after stroke the method can 
be used to understand the patient’s pre-morbid cognitive status. 
One example is the Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) (105). It consists of 26 tasks, which aim to measure change in cognition 
or functional performance over a 10-year period. There is limited literature on 
the use of informant assessment in stroke. A recent systematic review found no 
studies examining the accuracy of the IQCODE for assessing pre-stroke decline; 
the studies instead focused on its use in post-stroke assessment (106).  
There are, however, limitations to informant questionnaires. The availability of 
an informant who is willing or able to comment on the patient’s pre-stroke state 
is not guaranteed. If the tool is not used early after the stroke event, then recall 
bias can be an issue; informants may struggle to give an account of pre-stroke 
cognition and often describe the cognitive problems that they see after the 
stroke. 
1.6 Neuropsychological batteries (NPBs) 
Formal neuropsychological assessment is considered the gold standard for 
detection of cognitive impairment (58). Guidelines recommend that patients 
undergo this detailed testing if impairment is detected at the screening phase 
(107, 108). A NPB is not usually administered until much later in the stroke 
pathway (at least three months is recommended once the stroke has stabilised 
(6)), yet once again each institution varies with its approach. 
Batteries are made up of individual tasks to examine each cognitive domain in 
depth. As a result, assessment can last several hours, and is therefore 
considered impractical for inpatients. There is not a preferred test battery to 
use in stroke and often neuropsychologists will choose tests tailored to each 
patient. Even within each domain of cognition, there is no consensus on which 
tasks to use. The National Adult Reading Test (NART) is often used as a proxy of 
premorbid intelligence, as vocabulary is said to be better preserved in 
neurodegenerative conditions compared to other cognitive abilities (109).  
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1.7 NINDS-CSN VCI protocols  
In response to the lack of standardisation and to help detect VCI, a working 
group of the National Institute of Neurological Disorders and Stroke and the 
Canadian Stroke Network (NINDS-CSN) met in 2006 to produce clinical and 
research guidelines for vascular cognitive impairment. The neuropsychological 
working group produced three protocols of different lengths (5, 30 and 60 
minute protocols) (110). 
The publication states that the working group referred to the following test 
criteria to make recommendations: quality of the standardised sample, 
psychometric qualities, portability, cost, ease of use, domain specificity, 
availability of multiple forms, cross-cultural capability, lack of ceiling/floor 
effects and previous use in VCI samples. 
The 5-minute protocol consists of items taken from the MoCA: immediate and 
delayed recall, orientation, and fluency. The 30-minute protocol consists of the 
animal naming test, verbal fluency (letters F, A, S), Wechsler Adult Intelligence 
Scale Version III (WAIS-III) digit-symbol coding, and Hopkin’s verbal learning test, 
with the trail making test A and B listed as a supplemental test. The 60-minute 
protocol includes all the 30-minute protocol tests, with the addition of the 
Boston naming test and the Rey-Osterreith complex figure.  
1.8 Clinical Guidelines and other recommendations 
Clinical guidelines regarding cognitive assessment in stroke all recognise the 
importance of screening and detection but often provide quite general 
recommendations (Table 1-3). In the UK, the National Clinical Guidelines for 
Stroke (111) recommend routine cognitive screening to be undertaken using 
standardised measures but do not specify which particular screening tool to use, 
nor the time-point that screening will be most useful or informative. The UK NHS 
Improvement guidance is more specific with recommendations (timeframe for 
assessment within 6 weeks) and offers a cognitive assessment pathway where 
specific cognitive screening tests and timings are recommended (108). While this 
provides a useful guide for healthcare professionals, no empirical evidence is 
cited justifying the specific recommendations. 
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Details regarding cognitive screening are not mentioned in the latest European 
Stroke Organisation (ESO) guidelines (112). They state that there is insufficient 
evidence to support cognitive rehabilitation, therefore assessment is considered 
“desirable” since there are no proven treatments.  
The AHA-ASA guideline (107) recommends routine assessment of cognition. The 
neurobehavioural cognitive status examination (now known as the ‘cognistat’) is 
the only screening tool specifically mentioned. The pathway detailed in the 
guideline mirrors the UK’s approach; following detection of cognitive 
impairment with a screening tool, formal neuropsychological assessment is 
recommended. The guideline states that assessment should be sensitive to a 
wide range of abilities, acknowledging that screening tools inadequately assess 
higher-level cognitive functions.  
The Stroke Foundation Australian guidelines (113) recommend for all patients to 
be screened after a stroke, but do not suggest which screening tests to use. 
Finally, the guideline from the Canadian stroke strategy (2019) (114) states that 
all patients with stroke or TIA should be considered at risk for VCI and 
considered for screening prior to discharge from acute care, using a validated 
CSI such as the MoCA. The recommendations provide a summary of the MoCA and 
other suggested screening tests, along with evidence of their psychometric 
properties. Other CSIs considered include the NINDS-CSN VCI protocols, the 
Cognitive-Functional Independence Measure (Cognitive-FIM), CAMCOG, the 
‘Depression, Obstructive sleep apnoea and Cognitive impairment’ (DOC) screen, 
Frontal Assessment Battery, MMSE, and Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS). 
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Table 1-3 Clinical guidelines 
Guideline Statement regarding cognitive 
screening 
UK National Clinical Guideline for 
Stroke 2016 
“Routine screening should be 
undertaken… using standardised 
measures” 
UK NHS Improvement 2011 Weeks 1-3: MoCA or ACE-R. Week 4: 
RBANS or Ravens coloured matrices if 
patient aphasic 
European Stroke Organisation (ESO) 
2008 
“Assessment for cognitive deficits 
appears desirable” 
American Heart Association-American 
Stroke Association (AHA-ASA) 2016 
“Screening for cognitive deficits is 
recommended for all stroke patients 
before discharge home” 
The Canadian Stroke Strategy 2019 “Screening for vascular cognitive 
impairment should be conducted using 
a validated screening tool, such as the 
Montreal Cognitive Assessment 
[Evidence level B]” 
The Stroke Foundation (Australia) 
2017 
“All stroke survivors should be 
screened for cognitive and perceptual 
deficits by a trained person…using 
validated and reliable screening tools, 
ideally prior to discharge from 
hospital” 
Abbreviations: ACE-R, Addenbrooke’s cognitive evaluation revised; MoCA, Montreal 
Cognitive Assessment; NHS, National Health Service (UK); RBANS, Repeatable Battery 
for the Assessment of Neuropsychological Status. 
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1.9 Psychometrics and Clinimetrics 
Psychometrics refers to the theory of psychological measurement. The term 
clinimetrics is sometimes used with regards to clinical measurements in 
medicine. 
1.9.1 Classical test theory (CTT) 
CTT is considered the first theory of measurement and sometimes referred to as 
the true score model. This approach relies on a small set of assumptions. Each 
person has an innate true score, summarised as X = T + E. X is an observed score, 
T is the true score, E is random error. The errors are assumed to be normally 
distributed with a mean of 0. CTT is widely used and considered an essential 
part of the development process of a scale. 
CTT is a different approach to modern test theory, which includes item response 
theory and Rasch measurement theory (RMT). RMT conceptualises measurement 
scales like a ruler and, while this thesis does not employ RMT methodology, 
considering cognitive abilities and measurements across a ruler is helpful (Figure 
1-4). Within cognitive tests, items will span a range of difficulty levels, and will 
therefore target different severities of impairment. 
 
Figure 1-4 Spectrum of cognitive impairment and relation to measurement.  
This schematic illustrates the spectrum of cognitive impairment (lines indicating MCI and dementia 
are arbitrary and for illustrative purposes only). This illustrates that different CSIs (and different CSI 
items) have varying levels of difficulty and will therefore target different ends of the spectrum. 
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1.9.2 Reliability 
Reliability refers to the consistency of a measure. It is not a fixed property of a 
test; it is affected by aspects such as the rater, environment, administration 
method and sample (115). This is important to bear in mind with CSIs, where 
those administering the screen may have varying experience and the ward 
setting may compromise the reliability. There are different types of reliability 
(Table 1-4), however inter-rater and test-retest will not be covered in this 
thesis, since changes in cognitive scores are to be expected during the acute 
period, therefore it would be inappropriate. 
Table 1-4 Reliability types 
Type of reliability Definition Measure 
Internal consistency The degree of inter-
relatedness amongst 
items and whether they 
measure the same 
construct 
Cronbach’s alpha 
Inter-rater Agreement of scoring 
between two or more 
raters  
Kappa coefficient 






1.9.3 Validity  
Validity refers to whether the scale measures what is intended, in this case 
cognitive abilities. An example where validity may be compromised in post-
stroke cognitive testing is where limb weakness causes a patient to poorly 
complete a cognitive task. Some examples of the main types of validity are in 
Table 1-5.  
  52 
 
Table 1-5 Validity measures 
Type of validity Definition Measure(s) 
Content validity The degree in which a 
measure includes the 
necessary items to 
represent the concept 
Mainly using qualitative 
methods 
Criterion validity How the score compares 






How well the items 
represent the construct 
Correlations, mean 
scores across groups 
and associated p value 
 
1.9.4 Floor and ceiling effects 
Floor and ceiling effects are a measure of targeting of the CSI; the extent to 
which the range of cognitive abilities measured by the CSI matches the range of 
cognitive abilities in the sample. Floor/ceiling effects are defined as the 
proportion of participants scoring the highest (ceiling) or lowest (floor) possible 
score. Criteria is usually set at >15% (116). It is important to check whether 
these effects are present as they indicate the inability of the CSI to differentiate 
those at the low/high end of the spectrum, e.g., if a high proportion of 
participants score full marks, it suggests they all have the same cognitive ability. 
These effects are also important if the CSI is to be used longitudinally, as a CSI 
demonstrating ceiling effects leaves no room to identify any improvement in 
impairment over time. 
1.9.5 Diagnostic test accuracy (DTA) 
Test accuracy refers to the test’s ability to discriminate between patients with 
the target condition/disease and those without it. The test of interest, in this 
case a CSI, is referred to as the ‘index test’. Results of the index test are 
compared to a gold (or reference) standard. A reference standard should be the 
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best available method for detecting the target condition. The results of both the 
index test and reference standard are tabulated, as illustrated in Table 1-6. 
Table 1-6 2x2 contingency table 
 
 
From this table several different test accuracy metrics can be calculated. The 
formulas for each test metric are given in Table 1-7. Paired measures are most 
frequently used (e.g., sensitivity and specificity, positive predictive value (PPV) 
and negative predictive value (NPV)). Sensitivity refers to the true positive rate: 
the proportion of those with the condition that are correctly identified by the 
index test as cases, for example sensitivity of 80% means that 80% of individuals 
with the condition will test positive. Specificity refers to the true negative rate: 
the proportion of people without the condition that are correctly identified as 
non-cases, for example specificity of 80% means 80% of individuals without the 
condition will test negative. The two metrics are inversely proportional and 
depend on the cut-off value used; a higher cut-off will result in greater 
sensitivity but lower specificity. A highly sensitive test helps one rule out a 
condition when test negative, whereas a highly specific test helps one rule a 
condition in when test positive. Sensitivity and specificity are not affected by 
prevalence whereas PPV and NPV are. PPV and NPV can be thought of as the 
clinical relevance of a test. PPV is the probability that an individual with a 
positive test result, truly has the condition. NPV is the probability that an 
individual with a negative test result, truly does not have the condition. 
  






Index test positive True positive (a) False positive (b) 
Index test negative False negative (c) True negative (d) 
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Table 1-7 Test accuracy indicators 
 






Positive likelihood ratio (LR+) Sensitivity/(1 – specificity) 
Negative likelihood ratio (LR-) (1 – sensitivity)/specificity 
Unitary/single measures 
Accuracy (a+d)/(a+b+c+d) 
Youden index (Sensitivity + Specificity) – 1 
ROC curve 
False positive rate (1 – Specificity) on 
the x axis plotted against sensitivity on 
the y axis 
AUC or AUROC Area underneath the ROC curve 
DOR ad/bc 
Abbreviations: AUC: Area under curve; DOR, Diagnostic odds ratio; NPV, negative predictive 
value; PPV, positive predictive value; ROC, receiver operating characteristic. 
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Occasionally a single measure of test accuracy is preferred and there are several 
global/unitary metrics. Each have limitations so one global accuracy measure 
cannot be considered superior (117). For example, test accuracy and the Youden 
index are affected by prevalence, whereas the diagnostic odds ratio (DOR) is 
not, but gives the most optimistic results, ignoring the test’s weaknesses. Test 
sensitivity is often plotted against 1-specificity, on a graph called a receiver 
operating characteristic (ROC) plot (Example taken from Takwoingi & Quinn 2018 
(118) in Figure 1-5). When the data for each cut-off point is plotted, it creates a 
ROC curve. The area underneath this curve (AUROC or AUC) is used as a global 
measure (higher values indicate greater accuracy).  
 
1.10 Accuracy of CSIs post-stroke (evidence-base) 
The syndrome of interest (defined by the reference standard) impacts on the 
accuracy metrics, so it is important that this is clear and well defined. Most 
often, studies targeting more severe cognitive impairment, for example 
dementia or impairment across more than one domain, will have inflated 
Figure 1-5 Example of a ROC curve using data for the MMSE (111) 
The numbers in green illustrate the various threshold scores of the MMSE, and the 
corresponding sensitivity/specificity. 
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sensitivity, since many CSIs are better at detecting this end of the spectrum 
(119). 
The reviews that have examined properties of CSIs post-stroke have variations in 
the choice of target syndrome and reference standard, which can explain any 
apparently different results. A review focusing on accuracy of CSIs for multi-
domain cognitive impairment and clinical diagnosis of dementia after stroke 
found 35 studies covering 25 different CSIs (120). Pooled analysis used the 
following number of studies for each CSI: MMSE (12 studies), MoCA (6 studies) 
ACE-R (2 studies), Rotterdam-CAMCOG (R-CAMCOG) (2 studies). Sensitivity was 
highest for the ACE-R and MoCA, whereas specificity was highest using the MMSE 
or R-CAMCOG. Timing of CSI administration was compared; acute testing had 
higher sensitivity, but lower specificity. There was insufficient evidence 
regarding the use of brief CSIs in stroke, since only three studies were found and 
no studies using stroke-specific CSIs were found.  
Other reviews have focused on comparing CSIs to NPB only and have included 
studies targeting single-domain cognitive impairment. Stolwyk et al. (58) 
reviewed 16 studies that used a CSI to detect either single or multi-domain 
cognitive impairment. Most of the studies noted to have adequate accuracy had 
a target condition of ≥2 domains rather than single domain. Use of the MMSE was 
discouraged, yet preliminary support was given to the MoCA (5 studies), the 
Repeatable battery for the Assessment of Neuropsychological status (RBANS) (1 
study), Cognistat (1 study) and Barrow Neurological Institute Screen for Higher 
Cerebral Functions (BNIS) (1 study). Another systematic review with similar aims, 
included 21 papers examining 12 CSIs (121). Recommendations were made based 
on the syndrome of interest, although some scales recommended by the authors 
have limited evidence. Recommendations to detect any level of cognitive 
impairment are the Addenbrooke’s cognitive evaluation revised (ACE-R), BNIS 
and Cognistat. For multi-domain impairments: ACE-R, T-MoCA, TICS-m. For 
dementia: TICS, CAMCOG, R-CAMCOG. 
Finally, another review published in 2019 found 55 papers examining the 
psychometric properties of 26 CSIs in stroke (59). Most of these studies focused 
on validity rather than reliability and the data related to stroke-specific CSIs, 
(albeit a small amount) indicated encouraging findings. 
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Overall, the literature indicates that there are many studies examining 
properties of the MoCA and MMSE in stroke but few examining the many other 
CSIs that are available, including those designed for stroke. Studies addressing 
measurement properties of other CSIs should therefore be carried out, to meet 
this gap. As previously discussed, interpreting results across studies can be 
challenging, due to inconsistent definitions and differing reference standards. 
Limitations should also be acknowledged, such as case-control methodology and 
narrow inclusion criteria (limiting generalisability to those patients with more 
severe strokes, aphasia, and dementia). 
1.11 Feasibility and acceptability 
Feasibility and acceptability are terms often used in the context of completing 
questionnaires, for example PRO measures. Feasibility is typically defined as the 
time and cost needed to administer, score and interpret a measure, therefore 
capturing the burden and disruption for clinical staff, whereas acceptability is 
typically defined as the willingness or ability to complete an instrument from the 
patient perspective (122). Acceptability is often assessed through instrument 
completion, response rates and missing values.  
In the context of administering CSIs post stroke, there is more overlap in 
feasibility and acceptability, which is why they are often used interchangeably. I 
therefore use the term feasibility in this thesis to cover both patient- and 
clinician- related barriers to completion. CSIs need to be acceptable to both 
patients and staff, but they also need to be feasible for the setting of an acute 
medical unit. In addition to these aspects, patient’s physical stroke 
impairments, such as limb weakness, may affect both feasibility and 
acceptability. 
Recent research has indicated that some patients after a stroke struggle or are 
unable to fully complete CSIs such as the MoCA (123, 124). However, there is 
evidence that they can be completed in mild to moderate strokes (125). 
Therefore, feasibility is a particular concern if you want to administer the same 
CSI to all stroke patients. It is thought that shorter tests taking less than 10 
minutes to administer, or tests designed for stroke may perform better in terms 
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of feasibility and acceptability, although there is insufficient evidence available 
to confirm this.  
1.12 Prognostic utility  
The prognostic utility of a CSI relates to its ability to predict future outcomes. 
Outcomes of interest may be wide ranging and not limited to future cognitive 
issues, for example the ability to indicate future functional abilities, mood, and 
quality of life. 
The PICOTS framework can be used as guidance for formulating a prognostic 
study. It involves defining the following components: Population, Index 
prognostic factor or model, Comparator prognostic factor or model, Outcomes, 
Timing and Setting. Different analysis methods may be used in prognostic 
studies; in this thesis I will use test accuracy and regression methods to 
understand the potential prognostic value of CSIs. 
A review of the MoCA in stroke details that, when administered in the acute or 
subacute period, it provides a good prediction of later cognitive impairment at 
3, 6 and 12 months (accuracy ≥90%) (74). Further research is needed to evaluate 
other CSIs and other outcome measures beyond cognition. 
1.13 Summary 
To summarise, there are limited data concerning psychometric properties of 
both brief CSIs (administered in ≤5 minutes) and stroke-specific CSIs in patients 
after stroke. This means that some teams may be using CSIs without supportive 
evidence that they are fit for purpose. The work that follows addresses these 
two research gaps. 
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2 Who are classified untestable on brief cognitive 
screening instruments in an acute stroke 
setting? 
2.1 Introduction 
As discussed in chapter 1, clinical guidelines recommend cognitive screening for 
all patients following a stroke, yet there are scenarios where a full cognitive 
screening instrument (CSI) or sections of a CSI cannot be completed. There can 
be various reasons for this, including individuals being too unwell, post-stroke 
fatigue or using tests which have not been designed for acute stroke. However 
regardless of test choice it should be acknowledged that completion of cognitive 
screening in a medically unwell person with recent neurological insult is 
challenging and, in some cases, inappropriate. If some people following a stroke 
are unable to be tested, this proves problematic for research studies using 
cognitive outcome measures and national audits such as the Sentinel Stroke 
National Audit Programme (SSNAP) (https://www.strokeaudit.org/) where each 
hospital’s performance is monitored/benchmarked based on aspects such as 
whether cognitive screening has been carried out. 
To examine completion rates in previous research, I carried out a scoping search 
in PubMed in 2019 to identify studies reporting on completion rates (Table 2-1). 
This was not a systematic search and should not be considered exhaustive. 
Previous research indicates that around 20% of people after a stroke cannot fully 
complete the CSIs that are routinely used, for example the MoCA and MMSE (125-
127). However, since many studies do not report data on those who are 
untestable, it is difficult to ascertain the true incidence and characteristics of 
these individuals. Whilst non-completion can be a greater issue in acute settings, 
it is also reported later in the stroke pathway (Table 2-1). Results from previous 
studies can at times appear conflicting, with some studies concluding that it is 
feasible to administer a full battery of tests in acute stroke. It is important to 
emphasise that being able to complete such assessments with participants within 
a research study does not equate to feasibility for all stroke patients in all 
settings. Examining the participant characteristics of studies can help explain 
the apparently contradictory findings in the literature. Participants included in 
these studies are often not representative of a typical stroke unit population. 
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For example, studies may consciously or unconsciously favour the inclusion of 
those with minor strokes, little pre-morbid disability, and ability to provide 
written informed consent themselves, whilst patients with severe aphasia, or 
dementia are often excluded (128). The number of untestable patients is 
therefore reduced due to this selection bias. 
Table 2-1 Previous Research on completion of Cognitive Tests in Stroke 





















OCS 155 Unclear 5 days 89% 
Horstmann 
2014 (127) 
MoCA 842 IS and ICH 2 days 81% 
Pasi 2013 
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51  IS, ICH 36 days ACE-III 27% 
MMSE 43% MoCA 
39% 
Author’s own table based on a scoping search of one database. 
Abbreviations: ACE-III, Addenbrooke’s cognitive evaluation; AMT, Abbreviated Mental test; CA, 
conference abstract; CAMCOG, Cambridge Cognition; CASP, Cognitive Evaluation for Stroke 
Patients; OCS, Oxford Cognitive Screen; MMSE, Mini-Mental State Examination; MoCA, Montreal 
Cognitive Assessment; NPB, Neuropsychological battery. 
 
For data outside of a research study, SSNAP is a valuable, freely available 
resource. For patients admitted to and/or discharged from hospital between 
August 2017-November 2017, 15.9% were classified as ‘not applicable’ for 
cognitive screening for reasons of declining assessment or medically unwell for 
the entire admission and their total length of stay was ≥7 days (138). Of the 
patients where cognitive screening was deemed appropriate, 94.2% received an 
assessment. It is not documented why the other 5.8% were not screened. 
Feasibility and acceptability of completing cognitive screens is multifactorial. 
Some aspects are specific to the environment (limited time and quiet space for 
testing on acute medical wards) and the stroke itself (extent of neurological 
damage, presence of aphasia or limb weakness). Other factors relate more 
generally to the nature of testing older adults with other comorbidities (e.g. 
hearing or visual impairment, arthritis and fatigue). 
Incomplete assessments have clinical implications as, ultimately, they can risk a 
false positive or false negative categorisation of cognitive impairment. This is 
because the items which cannot be completed will either be assigned a score of 
zero or not scored at all. This can unintendedly cause harm, as patients without 
cognitive impairment may be asked to come back in for more detailed 
assessment and those with cognitive impairment with an unscored test may be 
missed. Test incompletion also complicates and biases research and audit; often 
patients with incomplete data are excluded from analyses and treated as missing 
(since a total score cannot be calculated and the recommended test threshold 
score cannot be used). Various approaches exist to incorporate incomplete data 
but there is no consensus on the best method (137). 
There are different ways to address feasibility or acceptability issues, but the 
approach taken will depend on the aspect of greatest relevance. For example, 
one may decide to choose a test specifically designed for use in stroke. This 
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approach recognises that many traditional cognitive screens were designed for a 
memory clinic setting and are not suited to the specific challenges encountered 
in acute stroke settings. The stroke specific cognitive tests detailed in the 
introduction may be less biased by physical, communication and visuospatial 
impairments. A different approach would be to choose a shorter cognitive 
screen. This approach is attractive for time limited settings and where there is a 
shortage of trained staff. Shorter tests may also be attractive to patients as 
there is reduced test burden. 
Stroke care is continuously evolving and differs internationally, yet there is a 
currently a paucity of feasibility evidence in an acute, National Health Service 
(NHS) context. No previous studies have explored feasibility of the shortest 
cognitive tests available within a stroke setting. This study aimed to meet these 
two gaps. 
My primary aim was to describe the rate of full and partial test completion of 
various short cognitive screening tests in consecutive patients admitted to a UK 
hyper-acute stroke unit (HASU). My secondary aims were to explore the reasons 
for assessors assigning an untestable label and to describe factors associated 
with being untestable.  
2.2 Methods 
I conducted a cross-sectional study using routinely collected clinical data from a 
UK, teaching hospital. The database used for this study was designed in liaison 
with the Research Ethics Committee (REC); the data collected for this work did 
not go above routine, clinical care and data were fully anonymised before 
archiving, therefore written informed consent was not required for data usage. 
Collection of data was approved by the West of Scotland REC (ws/16/0001) on 
04/02/16 (Appendix 1). I followed best practice guidelines (Standards of 
Reporting of Neurological Disorders (STROND) for the design, conduct and 
reporting of the study. I collected data alongside four other University of 
Glasgow students who were enrolled on one of the following courses: Psychology 
PhD/Neuroscience MSc/undergraduate MBChB. We were all trained prior to 
collecting data. One researcher went daily onto the HASU to check for new 
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admissions on weekdays and checked for new admissions over the weekend at 
the start of the week. 
2.2.1 Setting and population 
Participants were consecutive admissions to the Glasgow Royal Infirmary HASU. 
The unit admits all individuals with suspected stroke or TIA, without any age, 
disability, or comorbidity exclusions. Data from patients admitted during four 
timepoints were included: May 2016-Febraury 2017, April-June 2017, October-
December 2017, and July-August 2018. These timepoints were based on when a 
researcher was available to go daily to the HASU to collect data. The only 
inclusion criteria set was that participants had to be treated (but not necessarily 
subsequently confirmed) as a suspected stroke at the time of assessment in 
order to be included. 
2.2.2 Clinical and demographic data  
Anonymised demographic data (age at time of admission, sex) and a range of 
clinical data were collected from the medical case notes or through prospective 
assessment. Data were collected onto a proforma which was approved by REC 
(Appendix 2). Only relevant variables from the proforma were used for this 
study. Medical history included previous stroke/TIA and previous diagnosis of 
dementia. The Bamford/Oxfordshire Community Stroke Project classification 
system (OCSP) (139) was completed for participants who had an ischaemic or 
haemorrhagic stroke. There are four syndromes: total anterior circulation stroke 
(TACS), partial anterior circulation stroke (PACS), posterior circulation stroke 
(POCS) and lacunar stroke (LACS). Classification can be made on clinical 
symptoms, without imaging data. 
Stroke severity was measured using the National Institutes for Health Stroke 
Scale (NIHSS) score completed on hospital admission. In cases where the NIHSS 
was not completed and documented by the clinical team, it was retrospectively 
scored using the details of their symptoms on admission. Although not as 
accurate as direct assessment, this method of obtaining scores has high 
reliability and validity (140). The NIHSS is a ClinRO scored from 0-42, with higher 
scores indicating greater stroke severity. The areas covered are level of 
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consciousness, questions, commands, gaze, visual fields, facial palsy, motor arm 
(left & right), motor leg (left & right), ataxia, sensory, language, dysarthria, and 
extinction/inattention. This measure is considered the gold standard for rating 
stroke severity (141) and is widely used, both in clinical practice and research. 
Limitations, however, are that the items covered are biased towards left 
hemispheric strokes (these score higher than right hemispheric strokes of a 
larger volume) (142) and the symptoms associated with posterior circulation 
strokes are largely neglected (143). 
Pre-stroke functioning was measured using the modified Rankin Scale (mRS). The 
mRS is a ClinRO and was designed to measure post-stroke global disability on a 
scale of 0 (no disability) to 6 (death). It is the most widely used measure of 
function in stroke clinical research, and many clinical trials have used it to 
measure pre-stroke function for inclusion criteria, as well as using is an outcome 
measure for post-stroke function. The scale performs well in measuring post-
stroke disability in terms of high test-retest reliability and construct and 
convergent validity (144) but inter-rater reliability ranges from poor to near 
perfect across different studies (145). Its performance to measure pre-stroke 
function is limited in terms of inter-rater reliability and construct validity (146). 
In cases where the mRS was not documented by the clinical team, scoring was 
attempted using details recorded in the medical notes (e.g. living 
independently) or directly asking the patient. 
2.2.3 Cognitive assessment 
The cognitive assessment was attempted during the first week of stroke unit 
admission. The assessment consisted of a set of 13 questions which are included 
within nine different CSIs. These questions were asked in the same order for all 
patients (order presented in Figure 2-4). After completion of these 13 questions, 
the nine CSIs could be scored. 
The CSIs compared were: the Clock-drawing test (CDT), Mini-Cog (63), 
Abbreviated MoCA (147), National Institute of Neurological Disorders and Stroke-
Canadian Stroke Network (NINDS-CSN) 5-min MoCA (110), 10-point Abbreviated 
Mental Test (AMT-10) (61) and its shorter version AMT-4, General Practitioner 
Assessment of Cognition (GPCOG) (patient section), Six-item Cognitive 
  65 
 
Impairment test (6-CIT), and the 4 ‘A’s Test (4AT) (Available online: 
www.the4AT.com). The justification for choosing these CSIs is that the 
administration time to deliver these tests individually is under 5 minutes, making 
them all suitable for acute clinical practice. They are generic cognitive screens 
(not specifically designed for stroke) but have some supporting validation work 
in primary and geriatric care (148) and they share a number of tasks in common. 
Tasks within each test are detailed in Table 2-2. 
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Table 2-2 Items within each cognitive test  
Test Tasks 
Clock-drawing test  1. Clock draw  
Mini-Cog (63) 2. 3-word delayed recall 
3. Clock draw 
Abbreviated MoCA (147) 1. 5-word delayed recall 
2. Clock draw 
AMT-4 (149) 1. Age 
2. Year 
3. Place 
4. Date of Birth 




3. Date of Birth 
4. Place 
5. Year 
6. Months of the year backwards 
6-CIT (62) 1. Time 
2. Month 
3. Year 
4. Count backwards from 20 
5. 5-part delayed recall 
6. Months of the year backwards 
GPCOG (64) 1. Date 
2. Month 
3. Year 
4. Date of Birth 
5. 5-part delayed recall 
6. Clock draw (numbers, hands) 
7. News item 








7. 5-word delayed recall 
8. Fluency (letter F) 
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5. 2-person recognition 
6. Date of Birth 
7. Year of WW1 
8. Current prime minister 
9. Count backwards from 20 
10. 2-part delayed recall 
 
Abbreviations: AMT, Abbreviated mental test; GPCOG, General Practitioner assessment of 
cognition; NINDS-CSN, National Institute of Neurological Disorders and Stroke-Canadian Stroke 
Network; 4AT, the 4 ‘A’s Test; 6-CIT, Six-item Cognitive Impairment test. 
Participants were only approached once for assessment, apart from the 
following scenarios: the assessment was interrupted for another clinical 
investigation (e.g., scan), the participant requested for the assessment to be 
done at a later time-point or over two sessions. Participants were not 
approached at all (and categorised as fully untestable) if the parent clinical 
team reported that the participant was too unwell to undergo a cognitive screen 
or if the assessor felt that any form of direct testing would not be possible. If 
participants could not be directly assessed, we examined the medical notes to 
check if a cognitive screen had already been completed and documented since 
admission.  
2.2.4 Defining Untestable Outcomes 
In discussion with my supervisor and based on literature, I created descriptions 
to categorise completion of CSIs. These were created before I began analysis of 
the data.  The operationalised definition for ‘fully untestable’ was where no 
part of the cognitive assessment was attempted with the participant or where 
there was no response to questions when testing was attempted. Partially 
untestable was defined where at least one item within the cognitive assessment 
could not be completed or was not attempted (a decision made by either by the 
participant, parent clinical team or researcher) but at least one question was 
completed.  
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If a participant could not be screened, all researchers were instructed to 
document on the data collection proforma; and to provide a reason. These free 
text responses detailing reasons why a participant could not be assessed 
(untestable) were collated and assessed. A list of untestable categories was 
created based on the combination of previous literature, clinical experience, 
and initial scoping of free text responses. I went through the free text reasons 
documented for each untestable participant and collated them into categories 
(e.g., aphasia and dysarthria both captured under speech problems). These 
decisions were made in discussion with the stroke consultant (Dr Quinn). Where 
an assessor had listed more than one reason for being untestable, one primary 
factor was chosen that was deemed to have the greatest impact (e.g., a 
participant documented as both acutely confused and dysarthric, was 
categorised under confusion). In cases where a test item was attempted but 
poorly completed, for example, a participant with limb weakness who 
attempted the clock-drawing task with their weak or non-dominant hand, were 
classified as testable.  
2.2.5 Statistical Analysis 
I determined the completion rates for each question, and these were used to 
determine the completion rates for each of the various tests. I included the full 
sample of participants in all analyses. The decision to retain participants whose 
diagnosis was later determined to be non-stroke was to understand feasibility of 
the measures within all participants admitted with a suspected stroke in a real-
world setting. We also retained the admission NIHSS for these participants where 
it was completed. 
I carried out univariate and multivariate logistic regression. I chose variables for 
inclusion in the model based on previous literature (126, 132) and plausible 
associations with feasibility. I included the following 12 covariates in both 
univariate and multivariate analyses: age, sex, NIHSS, Bamford stroke 
classification, (TIA, PACS, TACS, POCS, LACS and non-stroke (used as reference 
group)), pre-morbid mRS, presence of intracerebral haemorrhage (ICH), previous 
diagnosis of dementia and previous stroke or TIA. I did not include delirium in 
the model since the only consistently applied measure of delirium available was 
the 4AT and this was one of the tests under investigation. I described 
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associations as odds ratios (OR) with corresponding 95% confidence intervals. I 
used the rule of 10 outcome events per predictor variable to determine the 
number of covariates we could include in the model and so required 120 ‘cases’. 
I ran analyses twice to account for how partially untestable participants are 
treated differently in the literature; in the first analysis they were treated as 
testable and in the second treated as untestable (grouped with fully untestable). 
I performed all data analyses using the statistical software package SPSS (version 
25 IBM, Armonk, NY, USA). 
2.3 Results  
The total sample included 703 participants. Participants had a mean age of 69.4 
years (SD 13.7); 392 (54%) were male; 429 (61%) had an ischaemic stroke, 22 (3%) 
had an ICH; median NIHSS 2 (interquartile range (IQR) 1-5). There were 119 
(17%) participants classified as fully untestable (they did not attempt or 
complete any of the questions within the assessment) and 58 (8%) participants 
classified as partially untestable (≥1 question was not attempted). Full 
characteristics of the total sample, testable and untestable participants are 
available in Table 2-3. 
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Table 2-3 Characteristics of the Sample 
 














69.4 (13.7) 66.9 (13.5) 76.6 (9.7) 76.8 (12.5) 




























































2 (1-5) 2 (1-3) 4 (3-7) 8 (4-16) 
Pre-morbid mRS 
(Median, IQR) 
1 (0-3) 1 (0-2) 2 (0-3) 3 (0-3) 
Previous stroke 
(IS/ICH) or TIA 
(N, %) 
218 (31%) 162 (30%) 20 (34%) 36 (30%) 
Previous 
diagnosis of 
dementia (N, %) 
61 (9%) 23 (4%) 8 (14%) 30 (25%) 
Abbreviations: ICH, intracerebral haemorrhage; IS, ischaemic stroke; IQR, interquartile range; 
LACS, lacunar stroke; mRS, modified Rankin scale; N, Number; NIHSS, National Institutes for 
Health Stroke Scale; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; 
TACS, total anterior circulation stroke; TIA, transient ischaemic attack; SD, standard deviation. 
2.3.1 Reasons for untestable status 
The reasons documented by the assessors for categorisation of fully untestable 
fell under 8 categories, with neurological deterioration (e.g., participants who 
were unresponsive, medically unwell, palliative) being the main reason (over 
half of the sample: 54%). The other reasons are detailed in Figure 2-1. 




The reasons documented by the assessors for categorisation of partially 
untestable fell under 9 categories (8 of these the same as fully untestable) but 
the main two reasons were limb weakness (26%) and speech problems (22%) 
(Figure 2-2). Only 12 participants (2%) within the full sample declined the 
cognitive assessment; three declined the full assessment and nine declined 
certain questions. Characteristics of those that declined: 7 (58%) male, mean 
age of 74.3 years (SD 13.9), median NIHSS of 3 (IQR 2-5), and diagnoses consisted 
of 1 non-stroke, 3 TIAs, 3 PACS, 3 POCS and 2 LACS. Participants whose final 
diagnosis was non-stroke were a diverse group; diagnoses included migraine, 
subarachnoid haemorrhage, and vasovagal events. Of these 20 (18%) were 























Deaf/blind or visual problem
due to stroke
Figure 2-1 Reasons for Participants classified as fully untestable (n=119) 
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For the participants in the partially untestable group, I examined the completion 
of each question within the assessment. Age was completed by the greatest 
number of participants (57/58 (98%)) and clock-drawing by the fewest (7/58 
(12%)) (Figure 2-4). In 25/58 (43%) of participants, the clock-draw was the only 
task that they did not attempt for the following reasons: limb weakness (N=14), 
visual impairment (N=4), declined (N=5) and no reason documented (N=2). There 
was a general downward trend of completion, with items at the beginning of the 
test having the highest completion. 


















Deaf/blind or visual problem due
to stroke
Limb weakness
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Using this data, I could calculate the completion rate of each test across the full 
sample. Completion rates ranged 75-100%. The only test which could be scored 
in full for all participants was the 4AT. The tests with the lowest completion 
rate were the clock-drawing test and other tests which also include this item: 











Figure 2-4 Items completed by those in the partially untestable group (listed in order of 
administration) (N=58) 
 












































Fewer items More items
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2.3.2 Associations with untestable status 
In the univariate analyses: higher age, TACS, ICH, higher NIHSS, higher pre-
morbid mRS and a pre-stroke diagnosis of dementia were associated with being 
untestable whilst a lacunar stroke was associated with being testable. In the 
first multivariate regression analysis (n=680), independent associations with fully 
untestable status were: higher NIHSS score (OR 1.18, 95% CI 1.11-1.26), higher 
pre-morbid mRS (OR 1.28, 95% CI 1.02-1.60) and pre-stroke dementia (OR 3.35, 
95% CI 1.53-7.32). A lacunar stroke diagnosis was associated with being testable 
(OR 0.19, 95% CI 0.06-0.65) (Figure 2-5). In the second analysis (where partially 
untestable and fully untestable groups were combined), the above variables 
remained significant. In addition, the following associations were found for being 
untestable: older age (OR 1.04, 95% CI 1.02-1.06) and presence of ICH (OR 3.44, 
95% CI 1.13-10.44), whilst a TIA classification was associated with being testable 
(OR 0.45, 95% CI 0.20-0.997) (Table 2-4). 
 
  
Figure 2-5 Independent associations for fully untestable  
Odds ratios (OR) for each variable in the multivariate analysis for status of fully untestable 
(*p<0.05) 
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Table 2-4 Associations with untestable status 








OR (95% CI) 
Age (years) 1.06 (1.04-1.08)* 1.02 (1.00-1.04) 1.04 (1.02-1.06)* 
Sex (Male) 0.80 (0.54-1.18) 1.32 (0.77-2.26) 0.97 (0.62-1.51) 





















ICH 2.96 (1.21-7.23)* 2.48 (0.72-8.59) 3.44 (1.13-10.44)* 
NIHSS 1.30 (1.23-1.36)* 1.18 (1.11-1.26)* 1.23 (1.14-1.31)* 
Pre-morbid 
mRS 




6.01 (3.47-10.42)* 3.35 (1.53-7.32)* 2.74 (1.32-5.70)* 
Previous 
stroke (IS, 
ICH) or TIA 
0.96 (0.62-1.47) 0.82 (0.45-1.48) 0.91 (0.56-1.49) 
*significant at p<0.05 
Abbreviations: CI, confidence interval; ICH, intracerebral haemorrhage; IS, ischaemic stroke; 
LACS, lacunar stroke; mRS, modified Rankin scale; NIHSS, National Institutes for Health Stroke 
Scale; OR, odds ratio; PACS, partial anterior circulation stroke; POCS, posterior circulation 
stroke; TACS, total anterior circulation stroke; TIA, transient ischaemic attack.  
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2.4 Discussion 
In an unselected sample of 703 participants admitted to our HASU, a quarter 
were classified as partially or fully untestable on a range of brief cognitive 
screening tests. The completion rate was lowest for the clock-drawing task so 
tests which include this (Abbreviated MoCA, Mini-Cog, GP-COG) had the lowest 
completion rate. The 4AT was the only test which could be scored in full for all 
participants as it includes scoring for untestable. Factors associated with being 
fully untestable were previous diagnosis of dementia, higher pre-morbid mRS 
and higher NIHSS on admission, whilst a diagnosis of lacunar stroke was 
associated with being testable. 
2.4.1 Research in context 
The results are generally in keeping with the limited literature on test 
completion. The associations of non-completion with stroke severity and 
dementia have face validity and the reasons given by the assessors for a label of 
untestable were similar to those described in previous studies (limb weakness 
(125, 126, 137), aphasia (125, 126), pre-morbid functional status (125) and 
reduced consciousness (126)). These results reinforce that non-completion is 
driven by both stroke specific and non-stroke related factors. 
This work focused on some of the shortest cognitive screens available, in the 
anticipation that they would be more practical for both the participant and 
clinician. The completion rates were found to be similar to that quoted in 
previous studies which used longer, multi-domain screens (e.g., MoCA). As this 
work did not directly compare with these tests in our sample, one cannot 
assume that the rate of incompletion is equivalent. I can however comment on 
varying test length since the number of items ranged 1-10 across the nine CSIs. 
In one sense length is an important factor, since tasks placed later in the 
assessment generally had lower completion. On the other hand, the screens with 
the fewest items in our study (Mini-cog and Abbreviated MoCA) had the lowest 
completion rate. Therefore, within short screens, a focus on length alone is too 
simplistic and test content should be considered equally important. 
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The poor completion of the clock-drawing task mirrors previous findings; this 
task was more frequently refused by older medical inpatients (150) and tasks 
requiring copying or drawing were found to have the lowest rates of completion 
in a stroke population (137). While the decision to immediately remove drawing 
tasks may be tempting, it is one that should be considered carefully; the 
decision should be informed by other psychometric properties and always 
depend on the specific research question, since there is evidence that such tasks 
(when completed) can predict later outcomes (151) and can be highly sensitive 
as explored in Chapter 6.  
With regards to test choice in an acute stroke setting, one may wonder whether 
a stroke specific test would have higher completion rates. Considering the 
reasons for participants having a fully untestable label, it is likely that the rates 
would be similar regardless of which screening tool was used. In the partially 
untestable group however, limb weakness and speech impairment were the two 
main reasons for non-completion, therefore a stroke-specific test, designed with 
these impairments in mind, may be superior. 
2.4.2 Strengths and limitations 
A major strength of this study is that I had access to an unbiased, real-world 
sample; something which is essential for work addressing feasibility. Once the 
process of written informed consent is involved, you inevitably have a biased 
sample to a certain extent. Therefore, I had valuable data on participants who 
are often excluded from research (e.g., those with dementia or severe aphasia). 
Whilst using clinical data have these benefits, I also acknowledge that due to the 
messy reality of acute clinical practice, data are often missing. The approach I 
took allowed me to retrospectively derive some of this missing data from various 
sources, including inpatient medical records, primary care data and consultation 
with the parent clinical team. As discussed in the methods, with the example of 
the NIHSS, retrospective scoring is considered to be a valid and reliable method. 
However, this assumes that a comprehensive examination was done and that 
findings were documented in detail. With this in mind, NIHSS scores may have 
been underestimated, since there is uncertainty whether all areas covered on 
the NIHSS were assessed in the initial clinical examination (e.g., neglect and 
ataxia).  
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There were some interesting aspects of testing where data were not recorded. It 
would be useful to know the frequency of participants with limb weakness that 
attempted a drawing task (classified as testable) and whether they used their 
weak or non-dominant hand. Many of these participants lose points or score zero 
for poor completion. We also did not record if an assessment had to be 
completed over two sessions or if any part of the assessment was interrupted. In 
the context of a research study, scenarios such as these should be anticipated, 
with guidance provided at the start of a study, to ensure consistency.  
Although the concept of partially and fully untestable was operationalised, there 
is subjectivity in the interpretation. In psychometrics, completion rates are 
referred to as data completeness. Cognitive tests are different to other clinical 
outcome assessments or patient reported outcomes, due to this subjectivity of 
deciding whether a participant can complete a question. Therefore, the same 
participant could have missing data or a full data set depending on who is 
administering it. It is essentially a judgement call by the clinician whether 
participants with aphasia, limb weakness and visual problems can complete a 
task (if the participant does not decline themselves). The same individual could 
therefore be classified differently purely based on who assessed them. This is 
particularly relevant in this study, where like in clinical practice and large 
research studies, differing assessors performed the cognitive testing. It should 
be acknowledged that while all assessors received training, we each have 
varying levels of experience and therefore could make different judgements. 
A final important limitation is the methodology of administering the 13 questions 
in the same order for each participant (without any randomisation). I 
acknowledge that this approach inherently introduces bias. However, test items 
included in each of the eight tests were generally spread out (e.g., the two tasks 
used in the shortest tests were not the first two questions). The aim of the 
database used for this study was to utilise clinical data collected as part of 
standard of care. Introducing randomisation of test items would therefore not be 
possible, without the work being undertaken as part of a research study 
requiring written informed consent, which as discussed earlier has limitations. 
Data collection for the database also commenced prior to my work on this study, 
so I could not change aspects of its design. 
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2.4.3 Recommendations for future research and practice 
The strict administration and scoring criteria required for cognitive tests can be 
problematic for use in the stroke setting. Clinicians and researchers can 
therefore expect to encounter a number of people that will be untestable on 
certain tasks, or those who are testable, but their stroke-related impairments 
result in a misleading test score. This will also be the case in other neurological 
conditions which affect motor function or language (e.g., multiple sclerosis, 
Parkinson’s disease, primary progressive aphasia). Whilst in clinical practice, an 
assessment is put into context of these other impairments to create a diagnostic 
formulation, in research test data are absolute and so it is important that a-
priori rules are set for dealing with incomplete tests. The importance of doing 
this is highlighted by the fact that our analyses showed different results 
depending on how partially untestable participants were classified. Numerous 
approaches exist to deal with missing data (137), but to maximise the utility of 
the data collected, we recommend that researchers make full use of incomplete 
participant data where possible, rather than applying a complete case-analysis 
approach. This is also arguably the most ethical approach to avoid data wastage 
when patients have spent time providing it. 
The results of this work have implications for cognitive test design. Firstly, with 
regards to how test items are ordered. It may be beneficial to have items placed 
in a priority order, since items placed earlier have higher completion. 
Assessment may end prematurely due to fatigue (a frequent complaint following 
stroke) or poor concentration (ward settings are often noisy). The assessment 
could also be interrupted for another clinical investigation. Another area regards 
acknowledging that, even with a very modified test that is designed for stroke 
impairments, some people will still be classified untestable. The 4AT is unique 
to other cognitive screens in that it incorporates scoring for untestable and 
refusal of tasks. The Mini-Cog (63) also includes scoring for “inability or refusal 
to draw a clock” but not for the delayed recall component. This approach is 
helpful and pragmatic and should be adopted when designing new screens. For 
existing screening tools, some consensus guidance and resources should be made 
available for challenging cases to improve reliability, since different assessors 
can score the same patient differently. These types of resources exist for scoring 
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other stroke scales, such as the NIHSS, in patients who are comatose, intubated, 
or aphasic. 
Test completion rates are just one measure of feasibility/acceptability. There 
are numerous factors, relating to the person being assessed, the assessor and the 
ward setting which affect cognitive screening (examples in Figure 2-6) and all of 
these perspectives should be considered in decision-making. To date, there has 
been little data published about the patient and clinician’s experience of 
cognitive assessment and how environmental factors can affect assessment on 
the ward (noise, space, interruptions). Qualitative or mixed methods research is 
vital to explore and understand these factors in a stroke setting. Some recent 
work, completed with patients with brain tumours, compared the feasibility and 
acceptance of the MoCA administered pre- and post-operatively through use of a 
questionnaire (152). Patients indicated feeling distracted at the pre-operative 
time-point, highlighting an increased burden prior to a procedure. This scenario 
could be viewed similarly to acute stroke when patients are often awaiting 
multiple investigations and results and is therefore a distressing time.  
With the increased use of computerised versions of cognitive screens in the 
future, many factors from the clinician/assessor’s perspective are likely to 
improve, both in terms of efficiency (automatic scoring saves time) and in terms 
of accuracy (reducing scoring errors and subjectivity). Future work should also 
make use of routinely collected clinical data, such as that collected in SSNAP. 
One could also argue that any study using a researcher to administer a scale (or 
collect data), rather than a clinical member of staff, does not truly address 
broader feasibility and implementation issues. Finally, in terms of CSI choice, 
other psychometric properties should be considered which will be discussed in 
the following chapters. 




To conclude, in a real-world sample of people admitted to our HASU, a quarter 
were classified as fully or partially untestable on cognitive screening (comprised 
of 9 brief CSIs). Cognitive screens with fewer items do not necessarily have a 
higher completion rate and the 4AT was the only test which could be scored in 
full for all participants. Clinicians and researchers should make a-priori plans on 
how to address incomplete assessments.  
 
Figure 2-6 Examples of factors affecting delivery and interpretation of cognitive screening 
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3 Accuracy of short forms of the Montreal 
Cognitive Assessment: Systematic review and 
validation 
3.1 Introduction  
In the previous chapter I focused on the feasibility of completing brief cognitive 
screening instruments (CSIs). Accuracy of a CSI is another important 
measurement property to assess which will be the focus in this chapter. The 
time required to administer a CSI is considered a key determinant as to whether 
it will be used in clinical practice (153) and it has been suggested that short 
tests achieve better cooperation from patients (61). Certain clinical factors, 
such as if an individual has physical, speech or cognitive impairments, make the 
duration of assessment longer than what is documented in the literature (21) or 
even cause them to be untestable on certain items, as illustrated in Chapter 2.  
As discussed in the introduction chapter, the MoCA has been recommended for 
use after stroke due to sensitivity to milder forms of cognitive impairment (79) 
and as a result is a popular choice for both clinical and research use. The 
administration time of the MoCA is quoted as 10 minutes (154), however this can 
be an unrepresentative estimate in practice, since no two patients are the same 
and completion can take up to 30 minutes for some individuals after a stroke 
(21). Therefore, this can make completion of CSIs a challenge in acute medical 
settings, where time is limited, caseloads are high, and other investigations are 
prioritised.  
If a suitable short test does not already exist, one possibility is to derive one 
from an established, validated test. The goal of any shortened version is to 
increase feasibility and acceptability of testing, while maintaining classification 
accuracy. For tests comprising many items, one may choose to retain only those 
items that have a high discriminative value, and discard those which do not. 
Discriminative ability will depend on the purpose and the clinical population in 
which the test will be used. There may be other reasons to derive a short form 
of course; one may want to discard items which are not suitable for individuals 
who have hearing or visual impairment.  
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Shortened versions of popular scales can be found across different areas, for 
example there are short forms of the Beck Depression Index (155), Stroke Impact 
scale (156) and Barthel Index (157). The same is true for popular cognitive tests 
and shortened versions of the MoCA (SF-MoCA) have been described in the 
literature (158). As discussed in Chapter 1, researchers in the National Institute 
of Neurological Disorders and Stroke and the Canadian Stroke Network (NINDS-
CSN) met in 2006 to produce test protocols to assess vascular cognitive 
impairment (110). The 5-minute protocol that they recommended consists of 
subtests taken from the MoCA and is therefore a shortened version. The number 
of shortened variations of the MoCA is currently unknown, and no paper has 
compared all SF-MoCAs against each other using the same cohort. Despite much 
interest in a SF-MoCA, validity should not be assumed. Even if the process of 
developing the shortened version is robust and accuracy metrics favourable, it is 
still necessary to externally validate the test in an independent sample and 
across different settings. 
I first aimed to carry out a systematic review to determine the number of 
different SF-MoCA versions used across the literature and to collate their 
published evidence on test accuracy for detecting cognitive impairment. The 
second aim was to carry out an external validation of the SF-MoCA versions using 
two independent data sets. 
3.2 Methods 
3.2.1 Systematic review  
I carried out a systematic review of the literature, following best practice 
guidelines in all aspects of design, conduct and reporting: Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy 
Studies (PRISMA-DTA) (see Appendix 3 for PRISMA checklist) (159). All aspects of 
screening, data extraction and quality assessment, were performed 
independently by at least two researchers (Dr Jennifer McDicken, Dr Gareth 
Blayney or myself), and using a third arbitrator (Dr Terry Quinn) to resolve 
conflicts as required. The protocol is registered with the research registry 




A Cochrane information specialist assisted with the search strategy. The search 
terms were developed using a concept-based approach. The first concept of 
interest was the MoCA and its synonyms, including names of existing short forms 
known. The second concept was around short-form tests and item reduction. The 
terms used for the second concept were taken from a previous systematic review 
addressing shortened versions of the Barthel index (157). The full search strategy 
is available in Appendix 4. I searched the following multidisciplinary electronic 
databases from 2005 (year of publication of the original MoCA paper) to April 
2017: MEDLINE (Ovid), Embase (Ovid), Health and Psychosocial Instruments 
(Ovid), PsycINFO (EBSCO), and CINAHL (EBSCO) and applied no language 
restrictions. In addition to the database search, I screened papers already known 
to me. I included published conference abstracts in the initial data synthesis in 
the attempt to identify all shortened versions of MoCA being used across the 
literature, however I did not assess the quality of reporting or risk of bias in the 
abstracts, due to insufficient details. 
I screened the titles and abstracts generated by the initial searches for 
relevance and proceeded to full-text review for potentially eligible studies that I 
checked against the inclusion criteria. I also screened reference lists of included 
studies and relevant reviews, repeating the process until no new titles were 
found. 
The index test of interest was any SF-MoCA. I defined the SF-MoCA as any test 
including >1 question from the original MoCA and designed to detect any level of 
cognitive impairment. I did not include the MoCA-Basic(160) under this 
definition, since it has different test items designed specifically for individuals 
who are illiterate or have less than 5 years of education and therefore not 
classed as a shortened version. I included studies which used a test accuracy 
design, comparing the SF-MoCA to either clinical diagnosis or another longer 
cognitive screen (of which I included the full MoCA). Studies in any setting 
(primary, secondary, community) and for any intended use were also included. 
I extracted data to a study specific proforma. I created tables describing the 
characteristics of included studies, with details of the index tests and the 
method used to derive the short form. Where accuracy data were not presented 
in the paper, I created 2 x 2 contingency tables to derive metrics of sensitivity 
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and specificity (161). I contacted authors to obtain data or clarify methods, 
where needed. For data synthesis, I grouped studies by disease area and 
examined the target cognitive syndrome, index test, threshold score and 
reference standard, to determine whether a meta-analysis could be undertaken. 
I assessed methodological quality and risk of bias using the Quality Assessment 
for Diagnostic Test Accuracy Studies (QUADAS‐2) tool 
(www.bris.ac.uk/quadas/quadas‐2) (162) as recommended by the Cochrane 
Collaboration (https://methods.cochrane.org/sdt/handbook-dta-reviews). 
QUADAS‐2 assesses four key domains: patient selection, application of index 
test, application of reference standard, and patient flow/timing. I assessed 
quality of reporting using the dementia‐specific extension to the Standards for 
Reporting of Diagnostic Accuracy (STARDdem) tool (163). 
3.2.2 External Validation  
Working with a research collaborator (Dr Myzoon Ali [MA]), I examined the 
psychometric properties of the MoCA and the SF-MoCAs identified using two 
independent data sets. The first data set included people with a diagnosis of 
ischaemic stroke (IS), intracerebral haemorrhage (ICH) or transient ischaemic 
attack (TIA) and was obtained from the Virtual International Stroke Trials 
Archive (VISTA), a not‐for‐profit repository of anonymized data from stroke trials 
or observational cohorts (164). I included data from any VISTA studies containing 
MoCA assessment and an appropriate reference standard. Recognizing the 
difficulty of applying a dementia label in an acute stroke setting, and to align 
with the systematic review, I included data sets where the comparator was 
another multidomain cognitive assessment (other than the MoCA). All 
participants in this data set had MMSE data, so this was used as the reference 
standard. 
The second data set was provided from a memory clinic (the Walton Centre, 
Liverpool, UK). This data set was included to examine whether test properties 
differed in another population. It provided a representative cohort as the data 
was routinely collected as part of clinical practice. The data set included two 
patient cohorts. The first cohort covered new patient referrals consecutively 
recruited between September 2009-March 2011 and the second recruited 
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between June 2015-May 2016. The MoCA was administered in clinic and then a 
clinical diagnosis (according to DSM-IV criteria) was made by a clinician, blinded 
to the MoCA score (165, 166). 
The data sets contained individual patient level data on each scored item of the 
MoCA and a reference standard comparator. This data was used to score each 
SF‐MoCA identified through the systematic review. Therefore, there were 
numerous index tests (each differing SF‐MoCA version). To align with the 
systematic review, the reference standard was clinical diagnosis of dementia or 
scores from an alternative multi-domain cognitive assessment. 
The MoCA has individual test items that are grouped into 8 categories/domains 
(visuospatial/executive, naming, memory, attention, language, abstraction, 
delayed recall, orientation). In this work where I refer to ‘each MoCA item’ this 
does not necessarily refer to each individual subdomain question. For some 
domains (e.g., visuospatial/executive) each individual question was examined 
separately, whereas other domains (e.g., animal naming) were grouped 
together. This resulted in 12 items: trails, cube copy, clock-draw, naming (3 sub-
items), digit list (2 sub-items), list of letters, serial 7 subtraction (5 sub-items), 
sentence repetition (2 sub-items), fluency, abstraction, delayed recall (5 sub-
items), orientation (6 sub-items).  
I examined the floor (number and percentage of participants scoring the 
minimum score (0)) and ceiling effects (number and percentage of participants 
with the maximum score) of each of the 12 MoCA items. I used Cronbach’s alpha 
as a measure of internal consistency (reliability) of the MoCA. To identify 
potentially redundant items in the MoCA, I used Spearman coefficient to 
describe the correlation between individual test items and total MoCA score 
(item-total correlation) and then described the effect on internal consistency if 
that item was removed. If internal consistency of the complete scale is 
unchanged when an item is removed, it suggests that the item is not 
contributing independent of other items and could potentially be removed 
without compromising test performance. I described rank correlation of each 
MoCA item with another (item-item correlations).  
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MA formatted the data and ran the validation analyses due to data access. My 
role was to assist with the design of the analysis plan and interpretation of the 
statistical read-out. Validation analyses were undertaken using SAS version 9.4 
(SAS Institute, Cary) software. 
Principal component analysis and exploratory factor analysis were used to assess 
the underlying structure of the MoCA, i.e., how many differing constructs were 
being assessed by the scale. Factor loadings are standardized regression 
coefficients; high loadings were defined as >0.7. MA also ran the following 
analyses: correlation of each SF‐MoCA with the original MoCA and sensitivity, 
specificity, negative/positive predictive values (NPV/PPV) and classification 
accuracy for each SF‐MoCA (using recommended threshold scores from the 
literature) against clinical reference standard. 
3.3 Results 
3.3.1 Systematic review  
The search retrieved 710 titles. Once duplicates were removed, 578 titles were 
screened, and 140 full text articles reviewed. Three additional papers were 
identified separately, resulting in 21 studies being eligible and included (18 full 
papers and three conference abstracts (102, 147, 158, 166-182)) (Figure 3-1). 






There were 13 different published SF-MoCAs, each with differing content or 
scoring. The number of test items included ranged 2-8 and total scores ranged 8-
Figure 3-1 PRISMA flow diagram 
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30. All SF-MoCAs retained the delayed recall item, whilst the ‘lion’ and ‘camel’ 
items within the animal naming section were omitted by all versions (Figure 
3-2). The most frequently described SF-MoCA was the 5-minute protocol 
recommended by the National Institute of Neurological Disorders and Stroke and 
the Canadian Stroke Network (NINDS-CSN) (n=7 papers). Three SF-MoCA versions, 
with the same content and scoring, were given different names by different 
authors, for example the ‘New short MoCA’ and ‘Mini-MoCA’ both comprised 
trails, cube copy, delayed recall, fluency, and abstraction. There were also SF-
MoCA versions with different items but sharing the same title, for example two 
‘Mini-MoCAs’, both with a total score of 10, but comprising different items 
(Table 3-1). 
 
Figure 3-2 Items retained across different SF-MoCA versions 
 
Different methods were used to derive the items retained in each SF-MoCA: 
regression (170, 173, 182), item response theory (IRT) and computerised 
adaptive testing (CAT) (158), Cramer’s V (168), receiver operating characteristic 
(ROC) analysis (147, 181), random forest analysis (183), z scores (171), analysis 
of covariance (ANCOVA) (175) and expert opinion (110). Two papers removed all 
visual MoCA items, but were designed for different purposes; One for use with 

































Visuospatial Naming Attention Language Abstraction Memory Orientation
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being deliverable over the telephone (102). The other included studies chose to 
validate existing SF-MoCAs. 
Scoring and content of the MoCA 5-min protocol(167) was not consistent with the 
original MoCA; an extra scoring component was added for immediate recall and 
the verbal fluency component was altered to animal fluency rather than letter 
and used a scoring system of 0.5 points for each word. Some shortened versions 
split up the MoCA domains, for example retaining one out of three animals 
(rhino) for the naming section in the MoCA reduced (173) and S-MoCA (158). 
Threshold scores used to categorise patients with cognitive impairment varied 
across the papers, even where the same short form was used (Table 3-1) and 
some studies did not state a threshold score. I did not attempt to pool data to 
create summary estimates of SF‐MoCA test accuracy, due to the significant 









Test items and scoring Threshold scores 





2 Clock draw (3) 
Delayed recall (5) 
 












Total score: 12 
Lim 2017 (Dementia): 
<7 
Bocti 2013a (CI), 
Cameron 2016 (CI), 
Pendlebury 2013 
(MCI): <10 
Kaur 2013 (CI): <11 
Dong 2015 (CI): <13 
Lin 2016 (CI) 
Mini-MoCA (170, 
182) 
3 Clock-draw (3) 
Delayed recall (5) 
Abstraction (2) 
 
Total score: 10 
Mai 2013 (CI): <7 
 
SF-MoCA (168) 3 Delayed recall (5) 
Serial 7s (3) 
Orientation (6) 
 
Total score: 14 
Horton 2015: <9 (AD) 
or <12 (MCI) 
MoCA 5-min 
protocol (167) 
4 Immediate recall (5) 




Total score: 30 
*2 points for each free recall, 1 
point for cued recall 
**Animal Fluency, 0.5 point for 
each word (max 9 points) 
Wong 2015 (CI): <15 
MoCA reduced 
(173) 
4 Clock-draw (3) 
Animal naming (rhino) (1) 
Delayed recall (5) 
Orientation (6) 
 





4 Cube copy (1) 
Delayed recall (5) 
Serial 7s (3) 
Fluency (1) 
 
Total score: 10 
Bocti 2012 (MCI): <9 
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5 Trails (1) 
Cube copy (1) 




Total score: 10 
Bocti 2013, Campbell 
2016 (CI): <7 
5-min MoCA (172) 5 Clock-draw (3) 
Delayed recall (5) 




Total score: 18 
Dong 2015 (CI): <13 
EM-MoCA (175) 7 Trails (1) 
Cube copy (1) 
Clock-draw (3) 





Total score: 19 
Freitas 2018 (CI): <17 
MoCA reduced 
(173) 
7 Animal naming (rhino) (1) 
Delayed recall (5) 
Tap at letter A (1) 





Total score: 18 
Cecato 2016 (MCI): 
<14 
S-MoCA (158) 8 Trails (1) 
Clock-draw (3) 
Animal naming (rhino) (1) 
Delayed recall (5) 
Serial 7s (3) 
Fluency (1) 
Abstraction (watch) (1) 
Orientation (place) (1) 
 
Total score: 16 
Roalf 2017, Larner 






8 Delayed recall (5) 
Digit span (2) 
Tap at letter A (1) 
Serial 7s (3) 





Total score: 22 
Wittich 2010 





Abbreviations: AD, Alzheimer’s Disease; CI, Cognitive impairment; EM-MoCA, Esclerose múltipla 
(Multiple sclerosis in Portuguese) Montreal Cognitive Assessment; MCI, Mild Cognitive 
Impairment; S-MoCA, Short form MoCA; T-MoCA, Telephone Montreal Cognitive Assessment; 





3.3.1.1 Cognitive impairment post-stroke  
Nine studies (N=2,514 participants) used six different SF-MoCAs to evaluate 
cognition post-stroke (Table 3-2). Settings and timing of assessment using the 
index test (SF‐MoCA) post-stroke varied: the majority of papers administered the 
tests more than 3 months post stroke, one paper used the SF‐MoCA in the acute 
period following stroke (less than or equal to 2 weeks) (169), and two papers in 
the setting of a stroke prevention clinic (therefore, some non-stroke patients 
were also included) (170, 182). 
Different studies used a SF-MoCA to target varying severities of cognitive 
impairment, with accuracy data available for single and multi-domain mild 
cognitive impairment combined through to dementia. The reported accuracy 
varied across the included studies: median sensitivity was 0.88 (range: 0.70-
1.00) and median specificity was 0.70 (range: 0.39-0.92). 
3.3.1.2 Cognitive impairment in older adults  
Eight studies (N=4,367 participants) used seven SF-MoCAs to evaluate cognition 
in older adults (Table 3-3). Once again, different severities of cognitive 
impairment were targeted. In studies where a SF‐MoCA was used to identify 
dementia in older adults (N=7), median sensitivity was 0.87 (range: 0.62-0.98) 
and specificity was 0.87 (range: 0.07-0.98). In studies where a SF-MoCA was used 
to identify MCI (N=3), median sensitivity was 0.84 (range 0.82-0.89) and 
specificity was 0.72 (range 0.64-0.85). 
3.3.1.3 Cognitive impairment in other conditions 
Four studies (N=461 participants) used two SF-MoCAs to evaluate cognition in the 
context of other health conditions: two in multiple sclerosis (MS), one in heart 
failure (HF) and one in Parkinson’s disease (PD) (Table 3-4). Both sensitivity and 
specificity were higher in the two MS studies (175, 177), compared to the HF and 
PD studies. 
Heterogeneity across the conditions, index tests, thresholds and reference 
standards precluded a meta-analysis being undertaken. 
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3.3.1.4 Quality Assessment and study reporting 
Using QUADAS‐2, one study was considered to have a low risk of bias in all four 
areas(166). Potential for bias in the other studies was generally around patient 
selection (n=17) (inappropriate exclusions and non-consecutive samples), use of 
index test (n=11) (no pre‐specified cut-off), and the timing between the index 
test and reference standard not reported or ambiguous (n=9) (Figure 3-3). Eight 
papers were of particular concern (rated high or unclear risk of bias across three 
areas). Study reporting was variable, and no study reported all items 
recommended in STARDdem guidance (Table 3-5).
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Table 3-2 Stroke Papers (N=9) 
 
Study Participants (n) 
Target 
condition 






Bocti 2013 386 CI 
New Short MoCA 
3 months MoCA 
<7/10 91% 83% 
NINDS-CSN 5 min 
protocol 
<10/12 87% 74% 
Campbell 2016 72 CI Mini-MoCA Rehab unit Cognistat <7/10 93% 92% 




MoCA not reported not reported not reported 
Dong 2015 (CA) 327 CI 5 min MoCA 3-6 months NPB <13/20 70% 87% 
Lim 2017 308 Dementia 
NINDS-CSN 5 min 
protocol 
≤2 weeks NPB <7/12 82% 67% 
Lin 2016 83 CI 
NINDS-CSN 5 min 
protocol 
3-18 months MDT Consensus <15/30 81% 55% 













<19/22 89% 46% 
T-MoCA Short 
(NINDS-CSN) 





T-MoCA <18/22 100% 52% 
T-MoCA Short 
(NINDS-CSN) 
<10/12 83% 48% 
Wong 2015 104 CI 
MoCA 5 min 
protocol 
39 days CDR <15/30 84%a 73%a 
 
aData obtained through contacting the author.  
Abbreviations: CA, conference abstract; CDR, Clinical dementia rating; CI, Cognitive impairment; MCI, Mild cognitive impairment; MDT, Multidisciplinary team; MoCA, Montreal 




Table 3-3 Older Adults Papers (N=8) 
Study Participants (N) Target condition Index test Reference 
standard 
Threshold score Sensitivity Specificity 
Bocti 2012 (CA) 341 MCI vs HC Mini-MoCA 
MDT workup 
including MoCA 




AD vs MCI+HC SF-MoCA MDT Consensus 
Unknown 95%a 87%a 
Validation Group 
= 91 
unknown 80%a 95%a 
Cecato 2016 
Total = 136 
AD = 53 
MCI = 44 
HC = 39 
AD vs MCI 
Reduced MoCA DSM IV 
<8.5/18 85% 87% 
MCI vs HC <13.5/18 82% 72% 
Larner 2017 
Cohort 1: 150 
Dementia vs MCI S-MoCA DSM IV <12/16 
94% 25% 
Cohort 2: 260 98% 7% 
Panenkova 2016 540 MCI 
Abbreviated 
MoCA 
MoCA* <4/8 89% 64% 
Roalf 2017 1850 
All cause 
dementia vs HC 
s-MoCA DSM IV <12/16 62% 86% 
Wittich 2010 277 AD MoCA-Blind NPB <18/22 87% 98% 
Xu 2016 405 CIND, dementia 
NINDS-CSN 5 min 
protocol 
MDT Consensus Not reported Not reported Not reported 
 
*Defined as one standard deviation (SD) below the norm. 
aData obtained from ROC curve. 
Abbreviations: AD, Alzheimer’s Disease; CI, Cognitive impairment; CIND, Cognitive impairment no dementia; DSM, Diagnostic and Statistical Manual; HC, Healthy 
Control; MCI, Mild Cognitive Impairment; MDT, Multidisciplinary team; MoCA, Montreal Cognitive Assessment; NINDS-CSN, National Institute of Neurological 













Cameron 2016 221 HF 
NINDS-CSN 5-
min protocol 
MoCA <10/12 89% 71% 
Dong 2015 101 PD 
NINDS-CSN 5-
min protocol 
CDR <9/12 77% 78% 




<17/19 94% 87% 
Kaur 2013 80 MS 
NINDS-CSN 5-
min protocol 
Not reported <10.5/12 97% 90% 
 
 
Abbreviations: CDR, Clinical Dementia Rating; EM-MoCA, Multiple Sclerosis (Portuguese)-MoCA; HF, Heart Failure; MoCA, Montreal Cognitive Assessment; NINDS-




QUADAS-2 criteria are detailed in Appendix 6. 
 





Reporting of each STARDdem item: Y = yes; N = no. STARDdem items available in Appendix 5. 
 




3.3.2  External Validation  
The stroke data set included 787 patients with a median age of 70, median NIHSS 
of 4, median MoCA of 21, and 289 (37%) had dementia or post stroke cognitive 
impairment (Table 3-6). Assessments were performed in the acute period (first 
weeks) following stroke. The memory clinic data set included 410 patients, with 
median age of 60 (IQR 51, 58), median MoCA of 23 (IQR 18, 26) and 79 (19%) had 
dementia. 
Table 3-6 Characteristics of the stroke sample 
Variable IS (N=728) ICH (N=59) Total (N=787) 
Age (Median, IQR) 70 (62, 78) 67 (56, 77) 70 (62, 78) 
Sex, male N (%) 421 (58%) 45 (%) 466 (59%) 
Baseline NIHSS 
 










MoCA (Median, IQR) 21 (16, 25) 21 (15, 25) 21 (16, 25) 
MMSE (Median, IQR) 26 (22, 28) 26 (21, 28) 26 (22, 28) 
TIA (N, %) 15 (2%) - 15 (2%) 
Hypertension (N, %) 502 (69%) 46 (78%) 548 (70%) 
Diabetes (N, %) 275 (38%) 18 (31%) 293 (37%) 
Abbreviations: ICH, Intracerebral haemorrhage; IQR, Interquartile range; IS, Ischaemic stroke; 
MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment, NIHSS, National 
Institute of Health Stroke Scale; TIA, Transient ischaemic attack. 
The validation work focused on 12 of the 13 differing versions of SF‐MoCA found 
in the systematic review. The 13th version includes an additional scoring 
component which is not recorded as part of the original MoCA (immediate 
recall)(184) and I could not retrospectively score it. The 12 index tests resulted 
in varying numbers of patients being assigned as impaired (test positive). In 
stroke participants the percentage of those screening positive ranged 37-92%, 




Figure 3-4 Comparison of percentage of patients classified impaired on the MoCA and the 
12 different SF-MoCA versions across the two data sets.  
SF-MoCA versions are listed under the author that originally published the scale 
 
In the memory clinic cohort, the task with the highest floor effect was verbal 
fluency (56%), whereas the task with the highest ceiling effect was animal 
naming (78%). In the stroke cohort, the task with the highest floor effect was 
cube copy (71%), whereas sentence repetition had the highest ceiling effect 





























Table 3-7 Floor & Ceiling effects of each item 
Item (score 
range) 



















Trails (0-1) 3  202 (50%) 205 (50%) 3 423 (54%) 361 (46%) 
Cube copy 
(0-1) 
3 164 (40%) 243 (60%) 3 553 (71%) 231 (29%) 
Clock-draw 
(0-3) 
3 8 (2%) 277 (68%) 3 93 (12%) 326 (29%) 
Naming (0-
3) 
3 2 (<1%) 316 (78%) 0 51 (6%) 430 (55%) 
Digit span 
(0-2) 
3 30 (7%) 273 (67%) 0 41 (5%) 514 (65%) 
Letters (0-
1) 
3 109 (27%) 298 (73%) 0 248 (32%) 539 (68%) 
Serial 7s (0-
3) 




3 41 (10%) 253 (62%) 0 17 (2%) 680 (86%) 
Fluency (0-
1) 
3 226 (56%) 181 (44%) 0 293 (37%) 494 (63%) 
Abstraction 
(0-2) 
3 83 (20%) 156 (38%) 0 489 (62%) 85 (11%) 
Delayed 
recall (0-5) 
3 154 (38%) 34 (8%) 1 312 (40%) 46 (6%) 
Orientation 
(0-6) 
3 2 (<1%) 218 (54%) 0 7 (1%) 468 (59%) 
No reasons were available for missing data. Floor effects refer to the number of participants 
scoring the lowest value (0). Ceiling effects refer to the number of participants scoring the 
highest value for the test item. 
Cronbach’s alpha for the full MoCA was 0.88 in the stroke data set. This value 
decreased if any of the items were deleted. Cronbach’s alpha for the full MoCA 
was 0.82 in the memory clinic and similarly this decreased for all items when 
deleted, apart from ‘letters – tapping for letter A’ attentional task, where alpha 
stayed the same (Table 3-8). In the stroke data set, clock drawing was the single 
item most correlated with total score, while sentence repetition was least 
correlated. In the memory clinic data set, orientation questions were most 
correlated and ‘letters – tapping for letter A’ was least correlated (Table 3-8). 
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Table 3-8 Table of correlation with full MoCA and Cronbach’s alpha if item deleted 
  
Item 









 Alpha if item 
deleted 
Trails 0.60 0.85 0.54 0.80 
Cube 0.51 0.86 0.47 0.81 
Clock 0.71 0.85 0.53 0.80 
Naming 0.58 0.85 0.39 0.81 
Digits 0.55 0.87 0.45 0.81 
Letters 0.55 0.86 0.36 0.82 
Subtrac
tion 
0.64 0.85 0.54 0.80 
Repetit
ion 
0.31 0.87 0.45 0.81 
Fluency 0.55 0.86 0.40 0.81 
Abstrac
tion 
0.42 0.86 0.49 0.81 
Recall 0.57 0.86 0.46 0.81 
Orienta
tion 
0.60 0.85 0.55 0.80 
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Table 3-9 Rank correlation between items of the MoCA 
 
Grey cells = stroke data, white cells = memory clinic data.   
No items were highly correlated (>0.8). Those items where correlation was not significant at <0.0001 are in bold type 
  
 TRAILS CUBE CLOCK  NAMING  DIGITS LETTERS SUBTRACTION  REPEAT FLUENCY ABSTRACTION RECALL ORIENTATION 
TRAILS 1 0.48 0.50 0.39 0.38 0.38 0.46 0.17 0.38 0.30 0.38 0.40 
CUBE 0.40 1 0.46 0.31 0.30 0.28 0.35 0.14 0.29 0.35 0.36 0.31 
CLOCK 0.38 0.38 1 0.53 0.46 0.44 0.54 0.27 0.43 0.31 0.45 0.51 
NAMING 0.23 0.24 0.23 1 0.39 0.40 0.41 0.20 0.39 0.28 0.37 0.42 
DIGITS 0.27 0.17 0.19 0.23 1 0.33 0.49 0.27 0.31 0.26 0.36 0.35 
LETTERS 0.24 0.16 0.23 0.15 0.30 1 0.42 0.21 0.36 0.28 0.34 0.42 
SUBTRACTION 0.37 0.33 0.40 0.38 0.31 0.27 1 0.22 0.44 0.30 0.38 0.51 
REPEAT 0.27 0.15 0.34 0.22 0.36 0.23 0.26 1 0.18 0.11 0.21 0.20 
FLUENCY 0.30 0.24 0.21 0.14 0.33 0.23 0.26 0.26 1 0.25 0.44 0.20 
ABSTRACTION 0.29 0.32 0.28 0.29 0.23 0.21 0.32 0.33 0.19 1 0.31 0.27 
RECALL 0.32 0.30 0.28 0.19 0.24 0.16 0.26 0.23 0.20 0.36 1 0.41 
ORIENTATION 0.38 0.31 0.46 0.23 0.26 0.19 0.39 0.29 0.26 0.31 0.45 1 
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In both data sets, correlation of one item with another did not suggest a 
redundant item (no correlation greater than 0.6); (Table 3-9). Exploratory factor 
analyses and principal components analysis suggested a unidimensional scale, 
with only clock drawing highly loaded (0.76) in the stroke data set and no items 
highly loaded in the memory clinic data (Table 3-10).  



















The test accuracy of the published SF‐MoCAs varied when assessed in the 
independent data sets (Table 3-11). Test accuracy of the full MoCA was included 
for comparison at the conventional threshold of less than 26. Accuracy of MoCA 
was similar in the two data sets: sensitivity: 1.00 in both, specificity: 0.22 in 
stroke, and 0.26 in the memory clinic data set. In both data sets, the SF‐MoCA 
versions were highly correlated with the full MoCA (all were greater than 0.80).  
In the stroke trial data set, median sensitivity was: 1.00 (range: 0.80‐1.00); 
median specificity: 0.39 (range: 0.14‐0.87), PPV: 0.49 (range: 0.40‐0.77), NPV: 
1.00 (range: 0.88‐1.00). In the memory clinic data set, median sensitivity: 0.96 
(range: 0.72‐1.00); median specificity: 0.40 (range: 0.14‐0.86), PPV: 0.28 (range: 
0.24‐0.55), and NPV: 0.98 (range: 0.93‐1.00). In both data sets Cecato’s MoCA 
reduced (AD) had the lowest sensitivity: 0.80 in stroke and 0.72 in memory 
clinic. Classification accuracy was highest using Cecato’s AD version in the 
memory clinic cohort and using Horton’s version in the stroke cohort.
 Stroke Memory Clinic 
TRAILS 0.649 0.597 
CUBE 0.556 0.527 
CLOCK 0.762 0.600 
NAMING 0.628 0.434 
DIGITS 0.590 0.488 
LETTERS 0.587 0.400 
SUBTRACTION 0.697 0.609 
REPEAT 0.331 0.501 
FLUENCY 0.594 0.441 
ABSTRACTION 0.446 0.535 
DELAYED RECALL 0.607 0.525 
ORIENTATION 0.653 0.623 
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Stroke patients        
Full MoCA <26/30 - 1.00 0.22 0.43 1.00 0.51 
NINDS-CSN <10/12 0.88 0.98 0.40 0.49 0.97 0.61 
BOCTI 2012 <9/10 0.92 1.00 0.16 0.41 1.00 0.47 
BOCTI 2013 <7/10 0.92 1.00 0.25 0.43 1.00 0.53 
CECATO 2016 (AD) <9/15 0.98 0.80 0.87 0.77 0.88 0.84 
CECATO 2016 (MCI) <14/18 0.95 0.98 0.42 0.49 0.97 0.62 
DAVIES 2011 <7/10 0.92 0.99 0.32 0.46 0.99 0.57 
DONG 2015 <13/20 0.96 0.92 0.72 0.65 0.94 0.79 
FREITAS 2018 <17/19 0.97 1.00 0.14 0.40 1.00 0.45 
HORTON 2015 <9/14 0.91 0.82 0.89 0.82 0.90 0.87 
PANENKOVA 2016 <4/8 0.89 0.87 0.70 0.62 0.90 0.76 
ROALF 2017 <12/16 0.97 1.00 0.42 0.50 1.00 0.64 
WITTICH 2010 <19/22 0.97 1.00 0.28 0.45 1.00 0.55 
Memory clinic patients     
 
Full MoCA <26/30 - 1.00 0.26 0.24 1.00 0.40 
NINDS-CSN <10/12 0.87 0.95 0.33 0.25 0.97 0.45 
BOCTI 2012 <9/10 0.91 1.00 0.14 0.27 1.00 0.30 
BOCTI 2013 <7/10 0.92 0.96 0.36 0.26 0.97 0.48 
CECATO 2016 (AD) <9/15 0.89 0.72 0.86 0.55 0.93 0.83 
CECATO 2016 (MCI) <14/18 0.95 0.96 0.44 0.29 0.98 0.54 
DAVIES 2011 <7/10 0.89 0.94 0.47 0.30 0.97 0.56 
DONG 2015 <13/20 0.94 0.91 0.62 0.36 0.97 0.68 
FREITAS 2018 <17/19 0.96 1.00 0.22 0.24 1.00 0.37 
HORTON 2015 <9/14 0.90 0.78 0.74 0.42 0.93 0.75 
PANENKOVA  2016 <4/8 0.84 0.80 0.66 0.36 0.93 0.69 
ROALF 2017 <12/16 0.96 0.96 0.46 0.30 0.98 0.56 




Thirteen cognitive screens purport to be a shortened form of the MoCA. The 
available SF‐MoCAs are not interchangeable as they have differing test items, 
application, and test properties. The external validation of the SF‐MoCA 
confirmed differences in test properties and across different settings (stroke 
setting vs memory clinic). In general, the SF‐MoCAs had a pattern of high 
sensitivity and lower specificity, with corresponding high NPV and lower PPV.  
In terms of psychometrics, it is debatable whether the MoCA content should be 
reduced at all. The analyses suggested no obviously redundant item in the 
original MoCA and do not necessarily favour the creation of a shorter form. Aside 
from test properties, it is important to acknowledge there are different 
motivations for a shortened form. In spite of whether one should shorten tests, 
certain scenarios, such as test administration by telephone or assessing a blind 
person, necessitate that certain items from the original scale are discarded, 
effectively creating a short‐form assessment.  
Various approaches to developing short versions of longer tests are described 
(185) and the processes used to develop the various published SF‐MoCA varied. 
The process of developing the SF-MoCA should also be evaluated, as this aspect 
is not captured through QUADAS-2. Modern psychometric approaches (i.e., item 
response theory (IRT)) are more robust and stringent to classical test theory 
(CTT). For example, a test may perform well according to CTT, while IRT may 
reveal problematic items. Only one SF-MoCA was developed through this method 
(158). The SF-MoCA with the greatest validation work (NINDS-CSN 5-min 
protocol) was derived through expert opinion. While the authors state that 
aspects such as psychometric qualities, cost, ease of use, availability of multiple 
forms, deliverable over the telephone, cross-cultural capability, and previous 
use in VCI were considered in making the recommendations, there is no 
supportive data of these aspects provided in the paper. 
3.4.1 Research in context 
In addition to the literature found in the systematic review, three relevant 
studies have been published more recently. Seven of the SF-MoCAs found in this 
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review were compared in a large sample of 4,606 participants recruited from 
Alzheimer disease (AD) centres across the US(186). The study authors concluded 
that the only short version comparable to the full MoCA was the s-MoCA, created 
by Roalf et al (158). 
Another recently published study used IRT methods to create another SF-MoCA 
for use in mild cognitive impairment in PD (187). The 8 items included in this SF-
MoCA were unique to SF-MoCA versions found in this review, comprising trail 
making, clock-draw, digit span backwards, serial 7s, repeat sentence (cat), 
verbal fluency, abstraction (watch) and delayed recall. The team who developed 
the original MoCA have also recently added a shortened version online, along 
with accuracy data comparing the test to the full MoCA, however this work is yet 
to be published. This 5-minute version has the same items as the NINDS-CSN 
version, however scoring for the fluency item is altered (scored out of four 
rather than one), so the total score is 15. Including these additional versions 
brings the total number of SF-MoCA versions to 15. Work is also currently 
underway to develop alternative versions of the MoCA for those with hearing 
impairment (188). 
There have been limited studies using modern psychometric methods to address 
properties of the MoCA, but those that have employed these methods provide 
useful insight. Using the Rasch model, Freitas et al. in one study found an overall 
good fit of both the items and the person’s values (189) and in another study 
found that ‘delayed recall’ was the most difficult item, whereas ‘orientation’ 
was the easiest (190). IRT methods have also identified tasks which are more or 
less influenced by education (191). The tasks ‘cube copy’ and ‘clock-draw’ 
(numbers and hands) were found to be less influenced by education. 
3.4.2 Strengths and limitations 
I acknowledge some limitations in this work. For the systematic review, I was 
constrained by the methodology and reporting of the original research. Many of 
the original papers had substantial risk of bias. I adopted an inclusive approach 
and accepted papers where SF-MoCA was compared to the original MoCA. This is 
problematic, since the MoCA itself has limitations and is a poor choice of 
reference standard. In the external validation, I derived SF‐MoCA data from the 
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original MoCA test data. I recognize that the properties of a SF‐MoCA may differ 
if used directly rather than if retrospectively derived. I also used a mixed 
reference standard of clinical diagnosis or multi-domain assessment. While this 
could be criticised, this approach is representative of real‐world practice where 
a diagnosis of post stroke dementia is rarely made in the acute period. I also 
acknowledge that using a neurology‐led memory clinic population for validation 
has some limitations. These patients are likely to be selected and may have 
already been triaged using a cognitive screen, so brief screens are less useful in 
this specialist setting. These factors all potentially limit the generalisability of 
these findings. 
The different rates of accuracy found in the validation analyses in comparison 
with the studies identified in the systematic review are likely due to 
methodological limitations, differing case‐mix, and differing comparator groups. 
Finally, due to the validation being a secondary analysis, I was unable to adjust 
the results for education, which would usually be done in practice. Strengths of 
this work include the use of a comprehensive search strategy allied with 
comprehensive assessments of reporting and bias. The SF-MoCA tests were 
validated in a large sample across two settings, one being a real-world sample.  
3.4.3 Implications for research and clinical practice 
The terminology used to describe the short versions of the MoCA is potentially 
confusing. Some of the short‐form tests were presented under the same name 
yet contained different items, for example, there were two versions of the 
“mini‐MoCA” (170, 182)  and two of the “MoCA reduced” (173). Conversely, some 
SF‐MoCA had identical content and scoring but had a different title, for 
example, the “new short MoCA” and “mini‐MoCA” were the same test (171, 174). 
Abbreviations also potentially add to the confusion with “MoCA‐B” being used to 
describe both the “MoCA‐Basic” and “MoCA‐Blind” tests (160, 176). I encourage 
researchers and clinicians to be explicit about the test content and scoring when 
using a SF‐MoCA.  
This work has a number of clinical implications. The SF‐MoCAs were used in a 
variety of patient populations. Many of the populations assessed represented 
neurodegenerative diseases where patients are likely to have mixed physical and 
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cognitive impairments (MS, PD and stroke). In these settings, a short cognitive 
test may have particular utility as patients may struggle to complete a longer 
assessment (137). More specifically, the choice of SF‐MoCA could be tailored, for 
example, removing the first three questions which require drawing for patients 
with limb weakness. The MoCA test items that were most discriminating differed 
between stroke and memory clinic patients. This finding has biological 
plausibility as the predominant dementia pathologies will also differ in these 
patient groups, with greater impairment of executive function in the stroke 
group (120). This suggests that the optimal short form will depend on the 
population to be tested. The NINDS‐CSN 5‐minute protocol was recommended 
specifically for vascular cognitive impairment (VCI); however, this was also the 
choice of test in papers studying non-vascular groups, e.g., MS and PD 
populations. 
Across the different SF‐MoCA versions, a general pattern of high sensitivity and 
lower specificity was demonstrated, with corresponding high NPV and lower PPV. 
These results are not surprising since the MoCA was designed to detect mild 
cognitive impairment and this work had a focus on dementia. The preferred 
trade‐off of test accuracy metrics depends on the purpose of testing and the 
context of use (161). The test accuracy findings for the SF‐MoCAs suggest that 
some of these CSIs would be useful for ruling out dementia. This means that 
testing negative for dementia on a SF‐MoCA makes it unlikely that a person has 
dementia. However, with specificity being low across many of the SF‐MoCAs, a 
test positive (or abnormal) result is less helpful and will need to be followed by 
further assessment, since there will be many false positives. In this regard, the 
properties of SF-MoCA are similar to the original MoCA, where sensitivity for a 
dementia diagnosis is around 94% and specificity less than 60% (192). 
All SF-MoCAs retained the delayed recall memory item, however the number of 
other tasks in between where the words are first introduced (immediate recall) 
and where they are tested (delayed recall) varied. Therefore, a practical, yet 
important consideration facing clinicians and researchers should be to consider 
timing between immediate and delayed recall parts of the test. For example, a 
test only including clock-draw and delayed recall, like the ‘Abbreviated MoCA’ 
(147), will result in a shorter duration of recall, compared to the full MoCA. This 
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would make it easier to remember the five words and likely not comparable to 
the full version.  
While short tests have a theoretical advantage of increased feasibility and 
acceptability, the results from Chapter 2 illustrated that test content was more 
important than length of test in terms of completion rates. It is also important 
to acknowledge the limitations of shortening tests. As discussed in Chapter 1, 
cognitive ability and cognitive impairment exist on a spectrum. Tests with fewer 
items will inevitably have less conceptual coverage, which could lead to 
conceptual gaps or the ‘ruler being too short’. Shortening a test may therefore 
risk content validity. Previous work has also demonstrated that there is a trade-
off between speed and accuracy in cognitive screening (193). The context of use 
(targeted concept, targeted population, decision to be informed) should guide 
the trade-off. 
Computerised adaptive testing (CAT) could provide the answer to these issues. A 
recent study administered the Cambridge Cognition examination (CAMCOG) via 
CAT and then administered the full CAMCOG supplemented with extra 
neuropsychological tests (194). Testing time of the CAMCOG through CAT was 
reduced by 37% or more, in comparison to using the full test and there was 
excellent agreement between the estimated cognitive ability levels of both 
approaches. The CAT method provides a promising area for future research.  
3.4.4 Conclusion  
The cognitive screens named ‘mini‐MoCA’, ‘short‐form MoCA’, ‘5 minute‐MoCA’ 
etc. describe a variety of differing CSIs with differing content and test 
properties. The psychometric properties of the MoCA do not suggest a preferred 
content of a shorter version and so choice of SF‐MoCA should be based on the 
context of use. Test accuracy of the various published SF‐MoCAs suggest that 
they may be useful as initial CSIs if the purpose of testing is to rule out 
dementia. However, such an approach should be prospectively validated in an 




4 Accuracy of telephone-based cognitive 
screening instruments: Systematic review and 
meta-analysis 
4.1 Introduction 
The previous chapters have investigated feasibility and accuracy of CSIs which 
are delivered in person. Chapter 2 illustrated that not all patients can be 
screened in full, or at all, at an early time-point following a stroke. In addition, 
hyper-acute stroke units have a fast turnaround, with some patients discharged 
home within a day. It is therefore likely that these individuals will not have been 
screened for cognitive impairment. Cognitive screening is also not routinely 
undertaken in TIA clinics, although a third of patients with a TIA diagnosis have 
cognitive impairment (195). These scenarios are concerning as without formal 
screening, problems may go undetected, leaving patients unsupported once they 
are home. One method to improve rates of cognitive screening would be to 
remotely screen patients following discharge using a telephone-based cognitive 
screen but whether this a valid mode of screening is yet to be determined. 
Telephone-based assessments of cognition were first published over thirty years 
ago, offering a practical, time and cost-effective alternative to in-person 
assessment. Telephone assessments are particularly suited to assessing high 
volume or geographically dispersed populations. They have been used in seminal 
trials and observational cohorts, for example the Health and Retirement study 
(196). 
Certain groups are particularly disadvantaged when it comes to accessing 
healthcare. For instance, people living in remote areas, people with limited 
mobility or people with chronic health issues may all struggle to attend an 
assessment centre or clinic (197). With regard to these aspects, feasibility and 
acceptability may therefore be improved through telephone delivery. However, 
in a stroke setting, since aphasia rates are reported as one in three in the acute 
phase (198), a telephone-based test may not be suitable for all.  
Despite the convenience of telephone assessments, they are not routinely used 
in clinical practice (stroke, dementia, or other settings). This may be due to a 
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general lack of awareness and familiarity of telephonic cognitive screens 
amongst healthcare professionals or concerns that accuracy is inferior to 
screening in person. Their use is therefore generally confined to research. 
Improved feasibility should not be at the cost of poor accuracy. As discussed in 
Chapter 1, the focus of cognitive screening post-stroke is not necessarily to 
identify dementia. This is also the case in other neurological conditions with 
heightened risk of cognitive impairment (e.g., PD and MS). With this in mind, 
accuracy of screening tools must be demonstrated in identifying milder forms of 
cognitive impairment, in order for them to be recommended in such settings. 
In light of this complexity, a review of telephone-based cognitive tests, and their 
accuracy, is needed. Previous systematic reviews on this topic (197, 199-201) 
have described several different tools, yet no quantitative synthesis of their 
accuracy has been presented. Greater clarity on the accuracy of telephone-
based tests would assist clinicians and researchers in determining the optimal 
test strategy. My objective was to determine the test accuracy of telephone-
based cognitive screening tools for the identification of dementia or MCI. 
4.2 Methods 
I carried out a systematic review of the literature addressing telephone-based 
cognitive screens. I followed best practice guidelines in all aspects of design, 
conduct and reporting (see Appendix 8 for PRISMA checklist) (159, 202). All 
aspects of title searching, data extraction and quality assessment, were 
performed independently by myself and another researcher trained in systematic 
review (Claire Green [CG]), using a third arbitrator (Dr Quinn)) for any conflicts. 
The protocol is registered with PROSPERO: CRD42017055967. 
4.2.1 Search strategy 
The search terms were developed using a concept-based approach. Concepts 
were dementia, cognition, telephone assessment. In addition, names of specific 
telephone administered cognitive screening tests were also used as search terms 
(see Appendix 7 for search strategy). I searched the following multidisciplinary, 
international, electronic databases from inception to 29th July 2018: ALOIS 
(Cochrane Dementia and Cognitive Improvement Group), CINAHL (EBSCOhost), 
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EMBASE (OvidSP), MEDLINE (OvidSP) and PsycINFO (EBSCOhost). I applied no 
language or date restrictions but only included full-text papers published in peer 
reviewed scientific journals. I checked reference lists of relevant studies and 
reviews for potentially eligible studies, repeating the process until no new titles 
were found. 
The search strategy was checked by an information specialist. Despite using a 
sensitive search strategy, there is always a risk that some relevant studies are 
not detected. Therefore, any studies identified through other sources were also 
screened. 
4.2.2 Study Selection 
I carried out screening using the Covidence systematic review software (203). 
The target condition was all-cause dementia or MCI (resulting from any 
neurological event or disorder). The index tests of interest were any telephone-
based cognitive, screening test assessing more than one cognitive domain. 
Studies using CSIs incorporating an informant section were included only where 
this was an additional component (not replacement) to the participant section. 
If data for participant/informant sections were presented separately, we 
extracted the participant only section. The reference standard was formal, face 
to face diagnostic assessment, using neuropsychological testing and/or clinical 
diagnosis. Within this diagnostic rubric, I accepted any validated, multi-domain 
neuropsychological battery that provided quantitative data and any clinical 
diagnosis made according to accepted international criteria. These could be 
disease specific (e.g. National Institute of Neurological Disorders and Stroke-the 
Association Internationale pour la Recherche et l'Enseignement en Neurosciences 
(NINDS-AIREN) (204)) or general (e.g. Diagnostic and Statistical Manual (DSM) 
(3)). 
I excluded studies that set out to assess cognition or intelligence in a cognitively 
healthy population; studies using single-domain cognitive tests; studies using the 
same telephone screen or another screening test as the in-person reference 
standard; studies where only index ‘test positive’ participants received the 
reference standard testing and studies that used other information technology or 
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telehealth as a means of assessing cognition such as smart phone applications or 
videoconferencing. 
4.2.3 Data extraction 
Data were extracted to a study specific proforma. I created tables describing the 
characteristics of included studies, with details of the index test and threshold, 
reference standard, sensitivity, specificity, positive and negative predictive 
values. I contacted authors to obtain data or clarify methods, where needed. 
4.2.4 Risk of bias and applicability 
I assessed methodological quality using the revised Quality Assessment of 
Diagnostic Accuracy Studies tool (QUADAS-2) (www.bris.ac.uk/quadas/quadas-2) 
(162). QUADAS-2 assesses studies in terms of internal and external validity across 
four domains (patient selection, index test, reference standard, flow, and 
timing). I used the standard QUADAS-2 anchoring questions and developed 
review specific criteria (202). 
4.2.5 Synthesis and analysis  
Study data were grouped based on whether the target condition was dementia, 
MCI or any level of cognitive impairment (dementia and MCI groups combined). I 
created forest plots of sensitivity and specificity for all the possible 
combinations of tests, thresholds, and diagnoses. I calculated positive and 
negative predictive values for all studies apart from those using a case-control 
design, since this type of sampling only provides indirect estimates (205). This is 
because the investigator chooses the ratio of cases to controls, and this 
determines the ‘prevalence’. 
There are two hierarchical methods that can be used for meta-analysis when 
studies report sensitivity and specificity: the bivariate and the hierarchical 
summary receiver operating characteristic (HSROC) models. The two approaches 
share statistical properties and are mathematically equivalent but have different 
aims and parameters (206). The focus of the bivariate approach is the summary 
sensitivity and specificity point at a common threshold, whereas the focus of the 
HSROC model is the estimation of a summary curve from studies using different 
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thresholds. Where >1 study reported accuracy data using the same telephone 
screen (or where minor changes had been made to the screen) and a common 
threshold score, I created summary estimates of pooled sensitivity and 
specificity using a random effects bivariate model. I plotted summary estimates 
in ROC space and described 95% confidence intervals of the summary estimate. 
Where studies included accuracy data at various cut-off points, I carried out 
multiple bivariate analyses to explore different thresholds common to more than 
one study. As a separate subgroup analysis, I examined studies with an exclusive 
stroke population, to evaluate whether accuracy is compromised within this 
group.  
As a post-hoc analysis I explored the effect of varying TICS threshold, plotting 
diagnostic odds ratios (DORs), then sensitivity and specificity, against threshold 
score for TICS dementia studies in a meta-regression. DORs provide a single, 
overall accuracy metric as described in Chapter 1. Where sensitivity or 
specificity was reported as 100% in any of the studies, I added a correction 
factor of 0.5 to cells in the 2 by 2 table (true positive, false positive, true 
negative, false negative) as recommended (207). I used RevMan (version 5.3) 
(208), a bespoke test accuracy software (MetaDTA: Diagnostic Test Accuracy 
meta-analysis (version 1.2) (209)) and Comprehensive Meta-Analysis (version 3) 
to carry out analyses. 
4.3 Results 
Of 11,731 titles screened, 34 studies were eligible and included, 17 of which 
contained data suitable for meta-analyses (Figure 4-1 for PRISMA flow diagram).  
There were 26 studies providing data on dementia, 5 studies providing data on 
any level of cognitive impairment and 14 studies providing data on MCI. Some 
studies provided data for more than one of these three groups. Thirteen studies 
(n=1437) were included in meta-analyses for dementia, eight studies (n=791) in 




Figure 4-1 PRISMA flow diagram 
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Research was undertaken in the context of older adults (n=30 studies) and stroke 
(n=4 studies). Aetiology of dementia was largely Alzheimer’s disease (AD) in the 
samples. Different diagnostic criteria were used for dementia diagnosis, the 
National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorder Association criteria (NINCDS-ADRDA) 
being most common (11 studies). For MCI diagnosis, Petersen or its modified 
criteria were used across most studies (11 studies). Assessments were carried 
out in seven different languages (English, Dutch, Finnish, Korean, Italian, 
Japanese, Portuguese). 
Fifteen different telephone assessments of cognition were used across the 
studies. The length, component tasks and cognitive domains tested varied across 
the included tests. The most prevalent test was based on the MMSE: The 
Telephone Interview for Cognitive Status (TICS) or one of its two modified 
versions (18 studies (101, 102, 210-226)). There was heterogeneity in TICS 
interpretation, with optimal threshold scores in included studies ranging from 20 
to 33 (out of 41) to differentiate dementia from MCI or cognitively intact, and 30 
to 37 (out of 41) to differentiate MCI from cognitively intact individuals. 
Threshold scores for the TICS-m also varied across included studies, ranging from 
24 to 31 (out of 50) to differentiate dementia and 25 to 34 (out of 50) to 
differentiate MCI. Of the other telephone-based screens, two were also derived 
from the MMSE (184, 227) two from the MoCA (102), two from the Mental Status 
Questionnaire (228, 229), one designed as a self-test (230) and the remainder 




Table 4-1 Telephone-based CSIs 
Measure Description Studies 
Mini-Mental State Examination (MMSE) based (n=2) 
26-point Telephone-MMSE 26 items, score/26 Wong 2009 
Telephone modified MMSE 
(T3MS) 
34 items, score/100 
Alexopoulos 2006 
 
Montreal Cognitive Assessment (MoCA) based (n=2) 








Telephone Interview for Cognitive Status (TICS) based (n=3) 
TICS 
11 items, score/41 
 
Brandt 1988 
Dal Forno 2006 (Italian) 
Desmond 1994 
Go 1997 
Kempen 2007 (Dutch) 
Konagaya 2007 (Japanese) 
Lipton 2003 
Manly 2011 
Seo 2011 (Korean) 
TICS 
11 items, score/38 
 
(Modifications: Name scored 
out of 1 instead of 2. House 
number and vice-president 
removed) 
Jarvenpaa 2002 









Seo 2011 (Korean) 
Welsh 1993 
Vercambre 2010 
Mental Status Questionnaire (MSQ) based (n=2) 
Short Portable Mental Status 
Questionnaire (SPMSQ) 
10 items, score/10 Roccaforte 1994 






concentration test (IMCT) 
27 items, score/37 Zhou 2004 
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Minnesota Cognitive Acuity 
Screen (MCAS) 
9 items, score/no upper limit 
as dependent on words 




As above but changes to 
instructions, delayed recall 
and recognition added 
Pillimer 2018 
Structured Telephone 
Interview for Dementia 
Assessment (STIDA) 




assessment battery (TCAB) 
6 Neuropsychological tests 
combined 
Debanne 1997 
Telephone cognitive self-test 8 items, score/45 Van Mierlo 2017 
 
4.3.1 Quality Assessment 
No studies were considered to have low risk of bias across all four QUADAS-2 
areas (231). Common issues of concern were present across both dementia and 
MCI studies: case control methodology (n=16 studies), no pre-specified threshold 
score for the index test (n=19 studies) and time between index test and 
reference standard unspecified (n=17 studies) (Figure 4-2). 
 




Figure 4-3 Risk of Bias in each individual study 
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4.3.2 Accuracy in dementia 
In total 26 studies (n=3129 participants) assessed the accuracy of telephone 
screens in identifying dementia (Table 4-2). Twelve different CSIs were 
examined: IMCT (1 study), TCAB (1 study), TELE (3 studies) TICS (11 studies), 
TICS-m (6 studies), T3MS (1 study), T-CMMSE (1 study), T-MoCA short (1 study), 
MCAS (2 studies), telephone self-test (1 study). STIDA (1 study). SPMSQ (1 study) 
(Full names of the CSIs are available in Table 4-1). Often studies reported 
accuracy across numerous thresholds, for example 6 of the 11 TICS studies (55%) 
had data for more than one threshold score.   
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Sensitivity Specificity PPV NPV 




T3M3 (85) 1.00 1.00 N/A N/A 
Brandt 1988* 49 16 (48%) AD 
NINCDS-
ADRDA 
TICS (31) 0.94 1.00 N/A N/A 
Crooks 2005* 38 6 (16%) AD, mixed 
NINCDS-
ADRDA 
TICS-m (28) 0.83 1.00 1.00 0.97 
Dal Forno 2006* 109 45 (41%) AD 
NINCDS-
ADRDA 
TICS (28) 0.84 0.86 N/A N/A 





0.98 0.85 0.87 0.98 
Desmond 1994*^ 72 6 (8%) 
Post-stroke 
dementia 
Unclear TICS (25) 1.00 0.83 N/A N/A 





1.00 0.91 N/A N/A 





TELE (16) 0.86 0.90 0.43 0.99 
Go 1997 28 15 (54%) AD CDR ≥ 0.5 
TICS (29) 0.80 0.77 0.80 0.77 
STIDA (10) 0.80 0.85 0.86 0.79 
Jarvenpaa 2002* 56 30 (54%) AD 
NINCDS-
ADRDA 
TICS (26) 0.87 0.89 
N/A N/A 
TELE (17) 0.90 0.89 
Johnston 2011 27 13 (48%) Unspecified DSM-IV-TR TICS (31) 0.92 0.50 0.63 0.87 
Kempen 2007 51 14 (28%) Unspecified DSM-IV TICS (28) 0.87 0.78 0.60 0.94 
Knopman 2010 167 42 (25%) AD, other cause DSM-IV TICS-m (29) 0.83 0.82 0.61 0.93 
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Knopman 2000* 210 99 (47%) 








1.00 0.87 N/A N/A 




TICS (33) 0.98 0.91 N/A N/A 
Lipton 2003 300 27 (9%) 
AD, VaD, LBD, 
frontotemporal 
DSM-III-R TICS (28) 0.74 0.86 0.74 0.86 
Manly 2011 377 53 (14%) 
AD, VaD, 
Parkinsons, DLB 
DSM-III TICS (23) 0.88 0.87 0.53 0.98 
Meng 2005* 116 64 (55%) Unclear Unclear TICS-m (28) 0.99 0.90 N/A N/A 







Correlational data between NPB tests & TICS-m, range 0.27-0.8 
Roccaforte 1994 100 66 (66%) Unspecified CDR ≥1 SPMSQ (8) 0.74 0.79 0.88 0.61 




TICS (25) 0.87 0.90 0.87 0.90 
TICS-m (24) 0.88 0.90 0.91 0.86 
Tremont 2011* 150 50 (33%) AD 
NINCDS-
ADRDA 
MCAS (43) 0.86 0.77 N/A N/A 
Welsh 1993 208 20 (10%) AD 
NINCDS-
ADRDA 
TICS-m (31) 0.85 0.83 0.35 0.98 
Wong 2009* 65 34 (52%) Unspecified DSM-IV T-CMMSE (16) 1.00 0.97 N/A N/A 







0.84 0.73 0.75 0.83 
Zhou 2004 132 65 (49%) 






0.80 0.81 0.80 0.81 
 
*Case-Control methodology. ^Stroke studies. Abbreviations: CDR, Clinical Dementia Rating; NPB, neuropsychological battery; TICS, Telephone interview for cognitive status; MCAS, Minnesota 
cognitive acuity screen; NIA-AA, National Institute on Aging-Alzheimer’s Association; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorder Association criteria; NPB, neuropsychological battery; N/A, Not Applicable; SPMSQ, Short Portable Mental Status Questionnaire; STIDA, Structured Interview for 
dementia Assessment; TAB, Telephone Assessment Battery; TCAB, Telephone cognitive assessment battery; T3MS, Modified Mini-mental State Examination; TICS, Telephone interview for 
cognitive status; T-MoCA, Telephone Montreal Cognitive Assessment 
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Across the range of telephone screening tests, sensitivity ranged 67-100%, 
specificity ranged 50-100%. I included thirteen studies (n=1437) in the dementia 
meta-analyses and pooled test accuracy data for three tests: TICS (4 thresholds: 
<31, <29, <28, <25), TICS-m (2 thresholds: <31 and <28) and TELE (threshold <16) 
(Table 4-3 and Figure 4-4). One study was included in all TICS meta-
analyses(218). The balance of sensitivity, specificity differed according to cut-
off score, however sensitivity was greatest using the original cut-off score of 31. 
Only one meta-analysis did not include case-control studies: TICS at threshold of 
29. 














































































































Figure 4-4 Summary receiver operating characteristic (ROC) curve and forest plot 
describing test accuracy studies of (A) Telephone Interview for Cognitive Status (TICS) at 
threshold of <31/40; and (B) TICS-m at threshold of <28/50 to identify dementia 
Circles = individual studies; square = summary estimate; dotted line = confidence interval 
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4.3.3 Accuracy in Dementia/MCI combined 
In total 5 studies (n=957 participants) assessed the accuracy of telephone 
screens in identifying any level of cognitive impairment (MCI and dementia 
groups combined) (Table 4-4). The rest of the sample in the study by Van Mierlo 
et al. were described as participants with subjective cognitive decline. 










Threshold Sens Spec PPV NPV 
Manly 
2011 
377 121 TICS 
Clinical 
diagnosis 
<27 0.73 0.77 0.73 0.77 
Knopman 
2010 
167 84 TICS-m 
Clinical 
diagnosis 
<32 0.83 0.78 0.79 0.82 
Vercambre 
2010 
120 10 TICS-m NPB <30 0.89 0.68 0.20 0.99 
Tremont 
2011 












0.73 0.73 0.85 0.56 
 
4.3.4 Accuracy in Mild Cognitive Impairment 
In total 14 studies (n=1,684 participants) assessed the accuracy of telephone 
screens in identifying MCI (Table 4-5). Eight different tests were examined: TICS 
(3 studies), TICS-m (8 studies), T3MS (1 study), T-MoCA (2 studies), T-MoCA short 
(1 study), MCAS (2 studies), MCAS modified (1 study), telephone self-test (1 
study). Eight studies (n=791) were included in meta-analyses. I pooled test 
accuracy data for one test: TICS-m (3 thresholds: <33, <29, <28) (Table 4-6, 
Figure 4-5).   
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Table 4-5 Test Accuracy in MCI 
Study Subjects 
(N) 
N (%) with 
Dementia 






Sensitivity Specificity PPV NPV 
Alexopoulos 2006* 32 18 (56%) MCI Petersen T3MS (89) 0.83 1.00 N/A N/A 
Cook 2009 71 17 (24%) aMCI Petersen TICS-m (34) 0.82 0.87 0.67 0.94 
Crooks 2005* 38 4 (11%) MCI Petersen TICS-m (28) 0.50 0.93 N/A N/A 
Graff-Radford 2006 128 8 (6%) MCI Petersen TICS-m (29) 0.63 0.86 0.23 0.97 
Knopman 2010 125 42 (34%) MCI Petersen TICS-m (32) 0.71 0.78 0.62 0.84 
Manly 2011 324 68 (21%) MCI Petersen TICS (30) 0.79 0.58 0.33 0.91 
Meng 2005* 116 18 (16%) MCI Unclear TICS-m (33) 0.89 0.92 N/A N/A 








TICS-m (25) 0.85 0.56 0.56 0.85 
T-MoCA (19) 0.89 0.46 0.52 0.86 




T-MoCA (18) 1.00 0.52 0.31 1.00 
T-MoCA short (10) 0.83 0.48 0.26 0.93 
Pillemer 2018 60 30 (50%) aMCI Petersen 
MCAS (not stated) 0.97 0.87 0.88 0.97 
MCAS modified (not 
stated) 
0.97 0.97 0.97 0.97 





TICS-m (28) Not reported N/A N/A 
Seo 2011 145 75 (52%) MCI Petersen 
TICS (29) 0.69 0.69 0.70 0.68 
TICS-m (29) 0.73 0.67 0.70 0.70 
Tremont 2011* 200 100 (50%) aMCI Petersen MCAS (53) 0.86 0.78 N/A N/A 
Van Mierlo 2017 93 22 (24%) MCI NIA-AA 
Telephone self-test 
(Z value cut-off) 
0.59 0.73 0.40 0.85 








TICS (37) 0.82 0.44 0.29 0.90 
T-MoCA (19) 0.81 0.73 0.45 0.94 
8 (8%) Multi-domain 
TICS (36) 0.87 0.61 0.18 0.98 
T-MoCA (18) 0.87 0.82 0.33 0.98 
 
*Case-control. ^Stroke studies. Abbreviations: MCAS, Minnesota cognitive acuity screen; NIA-AA, National Institute on Aging-Alzheimer’s Association; NPB, neuropsychological 
battery; N/A, Not Applicable; SPMSQ, Short Portable Mental Status Questionnaire; TAB, Telephone Assessment Battery; T3MS, Modified Mini-mental State Examination; TICS, 
Telephone interview for cognitive status; T-MoCA, Telephone Montreal Cognitive Assessment
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4.3.5 Subgroup analysis: Accuracy in stroke population 
In total 4 studies (n=344 participants) addressed post-stroke cognitive 
impairment. In terms of cognitive impairment severity, two studies described 
post-stroke dementia, and the other two provided data for multi-domain MCI and 
single and multi-domain MCI combined. No studies addressed the impact of 
aphasia on assessment. I pooled data for T-MoCA (threshold <19) for any type of 
MCI (single and multi-domain combined) and T-MoCA (2 thresholds <17, <18) for 




























































Figure 4-5 Summary receiver operating characteristic (ROC) curve and forest plot 
describing test accuracy studies of (A) Telephone Interview for Cognitive Status 
modified (TICS-m) at threshold of <33/50 to detect MCI; and (B)T-MoCA at 




The diagnostic odds ratios used for the meta-regression are listed in Table 4-8. 
Meta-regression suggested no relationship between TICS threshold score and 
overall accuracy in identifying dementia (slope -0.07, [SE, 0.05]; p=0.1525). 
Subsequent meta-regression found a trade-off between sensitivity and specificity 
across TICS thresholds. A significant relationship was found between threshold 
score and sensitivity (slope 0.02, [SE, 0.01]; p<0.0001) and a significant inverse 
relationship for specificity (slope -0.04, [SE, 0.01]; p<0.0001). Thus, as TICS 
threshold score increased, sensitivity for identification of dementia increased 
and specificity decreased (Figure 4-6). 
Table 4-8 Diagnostic odds ratios used in meta-regression 
Study Threshold DOR (95% CI) 
Konagaya 2007 33 468.0 (56.8 – 3859.1) 
Jarvenpaa 2002 33 9.1 (0.4-184.6) 
32 10.7 (1.2-93.9) 
31 6.6 (1.6-27.4) 
30 9.0 (2.2-37.2) 
29 9.0 (2.2-37.2) 
28 17.0 (4.0-71.8) 
27 37.8 (8.1-176.5) 
26 49.8 (10.1-246.5) 
25 30.7 (6.8-137.3) 
24 21.1 (4.9-89.9) 
23 28.0 (5.4-144.4) 
Brandt 1988 31 692.3 (26.7 – 17976.4) 
Dal Forno 2006 31 21.5 (4.8 – 96.4)  
28 33.2 (11.4 – 96.8) 
Desmond 1994 31 13.0 (0.7 – 240.1) 
28 17.6 (1.0 – 324.6) 
25 62.7 (3.3 – 1193.6) 
23 10.0 (1.6 – 61.5) 
Go 1997 33 16.3 (1.6 – 163.4) 
31 9.0 (1.6 – 50.7) 
29 13.3 (2.2 – 81.2) 
25 39.5 (2.0 – 787.7) 
Johnston 2011 31 12.0 (1.2 – 118.9) 
Kempen 2007 29 47.1 (5.3 – 416.6) 
28 21.8 (4.0 – 117.8) 
27 23.5 (4.8 – 114.7) 
26 11.5 (2.7 – 48.8) 
25 15.1 (3.1 -73.8) 
24 15.1 (3.1 – 73.8) 
Lipton 2003 29 13.9 (5.3 – 36.0) 
28 17.7 (7.0 – 44.6) 
24 13.9 (4.7 – 41.3) 
Seo 2011 25 60.5 (22.2 – 165.5) 





Figure 4-6 Meta-regression of TICS threshold score against (A) overall accuracy (diagnostic 
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This systematic review identified 34 studies describing 15 differing telephone-
based CSIs. The best available test accuracy evidence was for the TICS and TICS-
m. The pattern of test properties, with high sensitivity and lower specificity at 
conventional thresholds, suggest that these tools could be used as an initial 
screen for potential dementia. In the identification of MCI however, TICS-m was 
more specific, than sensitive. Subgroup analyses suggested that telephone-based 
cognitive assessments (T-MoCA) were useful in stroke patients, but the small 
number of studies limits recommendations. 
The literature on telephone assessments was characterised by substantial 
heterogeneity. Heterogeneity was evident even within the publications 
describing a single test. For example, TICS was the test with the greatest 
supporting test accuracy literature. Within the TICS label, there was the original 
TICS (most often used to identify dementia), and its modified version (with the 
additional delayed recall component), often described as preferable for MCI 
identification. However, other modified TICS versions were found in the 
literature. This illustrates a situation seen in other areas of dementia research 
where we should not assume the content of a test based on the name given by 
researchers (232). Tests are often altered to be country or culture specific, but 
there were also examples of modification to scoring or content where the 
rationale for the change was unclear. In future studies, researchers should 
specify the specific cognitive test components and scoring systems that they 
have used and avoid altering these aspects of published tests unless fully 
justified. 
The threshold scores used to define a person as ‘test positive’ varied even where 
the same screening test was used. Taking TICS as an example, most of the 
included studies did not use the original recommended threshold score of 31. 
Indeed, most did not report a pre-specified threshold score at all, but rather 
reported accuracy across a range of different potential cut-off scores. This can 
over-estimate the accuracy of the test, as researchers may preferentially report 
the threshold that performs best in their data. Meta-regression suggested that by 
altering the threshold of the test, one test property (sensitivity or specificity) 
can be favoured over the other.  
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Considering both the target condition and the choice of comparator group are 
very important when interpreting accuracy data, and especially in the decision-
making for data synthesis. For example, two studies may both be targeting 
dementia, but one may want the test to discriminate from MCI, and the other to 
discriminate from healthy cognition. Studies poorly defining the target condition 
(e.g., cognitive impairment), are unhelpful as we are unable to ascertain what 
severity of impairment the authors are referring to and results can be 
misinterpreted. Agreement on MCI diagnosis can also be challenging due to the 
numerous definitions and diagnostic criteria (233). The MCI studies that we 
included targeted different types of MCI (amnestic only, single, multi-domain), 
therefore there is argument that even these should not be combined. Our review 
highlights the importance of standardisation in definitions, and on which 
diagnostic criteria are used for diagnosis. 
4.4.1 Research in context 
Faced with a choice of methods for administering cognitive tests, clinicians may 
wonder whether the accuracy of telephone-based assessment is comparable to 
that of traditional face-to-face assessments. Comparing the summary estimates 
for accuracy of TICS, TICS-m, T-MoCA against recent reviews of MMSE and MoCA 
(192, 234, 235) would suggest that there is no substantial decrement in accuracy 
when using the telephone. To definitively assess comparative accuracy would 
require comparison of telephone and in-person assessment in the same 
population against the same gold standard. I found no studies using this 
approach and so our indirect comparisons are the best available evidence at 
present. 
4.4.2 Strengths and limitations  
This is the first systematic review to include meta-analyses to investigate the 
accuracy of telephone-based cognitive assessments. Strengths of this work 
include a comprehensive search strategy informed by an information specialist 
and following best practice guidance for the conduct of test accuracy reviews 
(including multiple data sets; ensuring two researchers carried out screening and 
data extraction independently and offering systematic consideration of bias for 
each of the included studies). 
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Limitations of the included studies should be considered when interpreting our 
findings. Problematic design issues were frequent, such as the use of case-
control methodology. Like other test accuracy reviews, we highlight issues to be 
considered in the design and reporting of future cognitive test accuracy studies, 
for example, the need for standardised reporting of the content and application 
of cognitive tests. 
The pooled analyses were limited (few studies for each outcome) due to 
variation in the telephone-based tests used, different threshold scores 
employed, and different diagnostic criteria for dementia and MCI. The limited 
number of studies also precluded the incorporation of quality assessment into 
the summary data.  
4.4.3 Implications for clinical practice and research  
There are no set values of sensitivity or specificity in which recommendations 
can be made for all settings. As these metrics are inversely proportional, 
comparison of different tests is dependent on the context of how the test will be 
used. TICS and TICS-m appear to be sensitive tests for the identification of 
dementia when using the original test thresholds (31 and 28 respectively). This 
means they could be useful for first-line screening, eliminating those unlikely to 
have dementia and selecting a group who require further testing.  This however 
comes at the cost of a high number of false positives. Unqualified accuracy 
metrics can often seem abstract and illustrating test properties using a 
theoretical example can aid understanding. Based on the data for TICS: in a 
theoretical population of 1000 community dwelling older adults, including 80 
people living with dementia; 74 of these would be correctly classified using TICS 
with the conventional threshold. However, 267 people without dementia would 
also screen positive and may, as a result, receive additional unnecessary 
investigations. 
A different pattern of accuracy was demonstrated in the identification of MCI so 
this context of use should be considered separately. The STIDA is unique to other 
telephone-based screens, including sections on medical history, patient-reported 
cognitive and functional abilities, and informant-based questions, in addition to 
the formal cognitive screening questions. This is worth highlighting since 
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independence in activities of daily living (ADLs) is a key differentiation between 
MCI and dementia and it is rare that questions evaluating the impact of cognitive 
impairment on ADLs are included within cognitive screens (in-person or 
otherwise). Data regarding functional ability are often obtained using an 
informant-based questionnaire, for example, the IQCODE (236). While the STIDA 
(222) was the only scale to incorporate a proxy section, published informant-
based questionnaires were found amongst other included studies. These were 
administered over the telephone with a family member, following completion of 
the cognitive screen with the patient. We only extracted accuracy data from the 
patient section of the STIDA, to be consistent with the other included screening 
tests, however the study reported that accuracy was higher when used in 
combination with the informant section. 
Although these results are encouraging, telephone-based screens have inherent 
limitations and face-to-face assessment should not be abandoned or replaced. A 
main limitation of this mode of screening is that it prevents the evaluation of 
visuospatial functions. The purpose of using the screening test is therefore 
central to this discussion. If used in a clinical setting, as part of the pathway to 
reach a dementia diagnosis, then just like face-to-face screens, they should be 
followed up with a comprehensive physical and neuropsychological examination 
before a diagnosis is reached. However, the purpose of cognitive screening in 
some settings is not necessarily to detect dementia. Many neurological 
conditions have visuospatial sequela e.g. spatial neglect following a stroke (237), 
which would not be detected by telephone-based screens. This means that if the 
clinical or research purpose is to identify any level of cognitive deficit, they will 
be less useful in conditions where these abilities are frequently impaired (e.g. 
posterior cortical atrophy (PCA) and PD (238)). The vast majority of studies 
included in this review were targeting AD type dementia and although 
examination of visuospatial abilities provides valuable information (239), 
memory impairment is the predominant early and central feature of AD (240). 
Therefore, as telephone-based cognitive screening tools major on memory, they 
would be suitable for first-line screening.   
As telephone evaluation does not allow for lip reading or non-verbal cues, 
people living with hearing impairment may be further disadvantaged. This is 
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especially a concern since there is evidence that hearing loss negatively impacts 
test scores in healthy, older adults when assessed in-person (241). Since the 
included studies did not address the impact of hearing impairment on test 
accuracy, I cannot provide conclusions regarding this. However, experience of 
using telephone-based cognitive screens within my research group has confirmed 
that screening participants with hearing impairment or even where participants 
have different accents is challenging. Tasks most at risk are those which have 
strict instructions regarding repetition, for example reading out words for 
memory tasks as participants may be unable to hear test stimuli, whereas other 
items which can be repeated (e.g., asking someone their age) are less 
problematic. This emphasises the importance of reminding patients to wear 
hearing aids and the importance of practical aspects such as having a good 
phone connection. Previous work completed in-person has shown that a headset 
with an amplifier has helped those with hearing impairment to complete a 
cognitive assessment (103). Telephone technologies allow for amplification and 
headsets could be provided to patients. The studies conducted in a stroke 
setting also did not provide information on whether participants had aphasia. 
Future research should provide data on whether samples include participants 
with hearing impairment or aphasia; and should explore whether accuracy is 
impacted within these groups.  
With these limitations in mind, the data suggest that telephone-based screening 
may have a particular role when in-person assessments are not feasible (e.g., for 
those who cannot attend clinic appointments) and in large trials, cohorts or 
registries that require a cognitive outcome measure at scale. Greater use of 
screening via videoconferencing (VC) is anticipated, which offers the 
convenience of telephone with some of the advantages of in-person testing. 
Through this format, minimal modifications to the original measures would need 
to be made and visuospatial abilities can be assessed. However, this represents a 
new approach to testing and so should be subject to the same scrutiny of test 
properties as any other novel assessment. A recent systematic review comparing 
neuropsychological assessment delivered face-to-face or via VC found that scores 
dropped for some tasks, whilst others were unchanged (242). Some preliminary 
supporting evidence also exists in community-based stroke survivors from a 
recent study comparing face-to-face and VC administrations of the MoCA using a 
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randomised crossover design (243). A review considering the diagnostic accuracy 
of VC is needed, where clinical diagnosis is used as the comparator. Although 
there was no clearly superior telephone screening test, this does not imply that 
new tests should be developed. There were many telephone assessments 
included in the review, yet the number of telephone cognitive assessments 
available are greater still, since a number did not meet our inclusion criteria. 
Further research should therefore be done evaluating the psychometric 
properties of available tests so summary estimates can be more reliable in the 
future. There is also an argument for selecting one or two tests as the preferred 
measures and ensuring that researchers and clinicians are trained in application 
and scoring. This is aligned with and moves towards core outcome sets in other 
aspects of neurology and dementia. 
To conclude, this review found the TICS and TICS-m to have high sensitivity in 
the identification of dementia in non-specialist settings. Telephone-based 
cognitive screens should be considered as an alternative screening method when 
face-to-face assessment is not viable. 
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5 Assessing Post-Stroke Psychology Longitudinal 
Evaluation (APPLE) study methods 
Chapter 1 detailed our current understanding and evidence gaps in research 
concerning post-stroke cognitive assessment. Few acute stroke studies report 
data using brief cognitive screens or stroke-specific cognitive screens. Chapter 2 
demonstrated that around a quarter of participants do not fully complete brief 
cognitive screens, due to a range of reasons, and very few CSIs provide scoring 
where participants are untestable. Chapter 3 demonstrated that some shortened 
forms of the MoCA have similar sensitivity and specificity to that of the full 
scale. Building on this work, the study detailed in this Chapter, aims to provide 
data on some of these research gaps. This Chapter describes the study methods 
and Chapters 6 and 7 provide the results.  
5.1 Overview of the study 
Assessing Post-Stroke Psychology Longitudinal Evaluation (APPLE) is a 
multicentre, observational cohort study. The broad aims of the study are to 
understand the neuropsychological consequences of stroke, at both the acute 
stage and longer-term. The study is funded by the Stroke Association and Chief 
Scientist Office of Scotland; funding reference: PPA 2015/01_CSO. The protocol 
is registered on research registry (ID: 1018) and available in Appendix 9. 
This longitudinal study follows participants over a period of 18 months but for 
the purpose of my thesis I am using the data collected up to the 6-month follow-
up. In this chapter I describe the COAs and CSIs used for the two chapters that 
follow; I do not describe any of the other measures used in the APPLE study 
which are not relevant to my work; these are described in two other PhD theses.  
5.1.1 Ethical Approval 
Ethics committee and local Research and Development approval was obtained 
for all sites (REC number 16/SS/0105) (Appendix 11). 
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5.1.2 Study Aims  
The overall aim is to examine psychometric properties of eight generic, brief 
CSIs and a stroke-specific CSI: The Oxford Cognitive Screen (OCS).  
My specific research aims using the APPLE data set are detailed below. 
Chapter 6 aims (using generic, brief CSIs): 
• Completion rates. 
• Longitudinal comparison of participants classified as cognitively impaired 
(screen positive) using different brief CSIs. 
• Floor/ceiling effects across the CSIs. 
• Accuracy of brief CSIs in detecting pre-stroke cognitive impairment when 
compared to clinical diagnosis. 
• Accuracy of brief CSIs in detecting cognitive impairment on the OCS. 
Chapter 7 aims (using the OCS): 
• Completion rates and floor/ceiling effects. 
• To examine whether impairments in individual OCS cognitive domains or a 
global OCS score are associated with later functional, mood and quality of 
life outcomes at six months. 
Chapter 6 aims are detailed in the APPLE protocol in Appendix 9. Chapter 7 was 
designed by myself, after the APPLE study had commenced.  
5.2 Patient and public involvement 
People living with stroke have been involved in all stages of the study. Over-
burdening the patient is a concern in studies involving cognitive testing and 
multiple scales/questionnaires. At the planning and design stages, my supervisor 
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and the APPLE team gained feedback on the proposed tests from stroke 
survivors. This helped refine the final scales which would be considered 
acceptable and subsequently included. A patient advisory group was also set up 
as part of the study to comment on both the design and progress of the study. 
The group consists of stroke survivors and healthcare professionals.  
5.3 Inclusion & Exclusion criteria 
Participants were generally recruited through acute stroke units, with a minority 
recruited through a TIA clinic. In the attempt to include a representative cohort, 
all participants admitted with suspected stroke due to any aetiology 
(ischaemic/haemorrhagic) or TIA were considered eligible. We sought to include 
participants that are often excluded from research, for example those with 
known cognitive impairment/dementia or aphasia. The inclusion and exclusion 
criteria which were set are detailed in Table 5-1.  
Table 5-1 Inclusion & Exclusion criteria 
 
Inclusion Criteria Exclusion Criteria 
1. Clinical diagnosis of stroke or 
TIA at time of assessment. 
2. Age greater than 18 years. 
3. Clinical team happy that 
patient is suitable for some 
form of psychological testing. 
1. No spoken English prior to 
stroke. 
 
5.4 Informed consent  
Participants were required to have the patient information sheet (PIS) for at 
least 24 hours prior to providing written informed consent. For participants 
deemed to lack mental capacity, consent was sought from their nearest 
relative/guardian. Mental capacity was determined by the researcher, with input 
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from the clinical multidisciplinary team, where required. According to the 
mental capacity act, a person needs to be able to understand the information 
relevant to the decision, retain that information and use or weigh up that 
information. Therefore, if there was a concern that any of these criteria were 
not met, a relative signed the consent form. Where available, relatives were 
separately recruited into the study in order to complete the informant-based 
assessments. The PIS can be found in Appendix 10. 
5.5 Schedule of events 
Longitudinal data were collected across five timepoints in the study, in order to 
capture any potential changes in cognition. In this thesis I have used data from 
the first three timepoints: baseline, one month and six months. 
5.5.1 Baseline 
The baseline visit was completed as soon as possible following the participant’s 
admission to the stroke unit. After eligibility criteria were checked, written 
informed consent was obtained. Clinical and demographic information for each 
participant were collected from their medical notes. This included documenting 
any history of MCI or dementia recorded in the medical record and capturing 
years of education, hearing/visual impairment from the participant directly. 
Visual impairment captured those who were partially sighted or blind but did not 
include those who wear glasses/contact lenses. Stroke severity was measured 
using the National Institutes for Health Stroke Scale (NIHSS) (244) score 
completed on hospital admission or shortly afterwards. A full description of this 
scale can be found in Chapter 2. The Confusion Assessment Method for the 
intensive care unit (CAM-ICU) (245) was used to screen for delirium.  
A range of COAs were completed to capture the patient’s pre-morbid functional 
abilities: 
• Global disability was assessed using the modified Rankin Scale (mRS) 
(246): scores range from 0 (no disability) to 6 (death). Full description of 
the measure is covered in Chapter 2.  
144 
 
• Independence in basic activities of daily living was measured by the 
Barthel index (BI) (247). The BI covers 10 areas (feeding, bathing, 
grooming, dressing, bowels, bladder, toilet use, transfers, mobility, 
stairs) and is scored from 0-100 (with higher scores indicating greater 
independence) and covers feeding, bathing, grooming, dressing, bowels, 
bladder, toilet use, transfer, mobility, and stairs.  
• Independence in instrumental activities of daily living scale (IADL) was 
measured using a variation of Lawton’s IADL scale(248), scored 0-14 (with 
higher scores indicating greater independence). The scale covers 
telephone use, getting to places outside of walking distance, shopping for 
groceries/clothes, preparing meals, housework, taking medicine and 
handling money. Each of the seven areas is scored either 0 (completely 
unable), 1 (with some help) or 2 (without help).  
5.5.1.1 Baseline Cognitive Assessment 
Our baseline assessment, referred to throughout as ‘AMT-plus’, has additional 
questions to the 10-point Abbreviated Mental Test. As many brief CSIs share 
common questions, I scored eight different CSIs from one set of questions: CDT, 
Abbreviated MoCA, 4AT, Cog-4, 6-CIT, NINDS-CSN 5-min MoCA, AMT-4 and AMT-
10. The tasks in these tests largely assess learning and memory, with only a few 
other tasks covering other DSM-5 cognitive domains (Table 5-3). 
It is important to note that through taking this approach some changes to the 
original scales have been made. Delayed recall in our assessment includes the 
five words used in the MoCA (face, velvet, church, daisy, red). This is different 
to the delayed recall component in the 6-CIT which includes a 5-part name and 
address, and the AMT-10 includes a 3-part address. Most of the cognitive 
assessment data were collected prospectively with the exception of a few 
patients who were untestable, but the AMT-4 had already been completed by 
the clinical team and was documented in the medical notes and the Cog-4 which 
was scored from the admission NIHSS score.  
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Content or scoring 
in this study 
6-CIT Delayed recall 
5 components: John, 
Smith, High St, 
Bedford 
5 words In MoCA 
NINDS-CSN Total score 12 
11 (day of the 
week not asked) 
AMT-10 Delayed recall 
2 components: 42 
West Street 
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It is acknowledged that it is debatable as to which domains some tasks fall under. In some cases, 




Clock drawing test (CDT) 
The CDT is traditionally used to assess visuo-spatial and constructive abilities, 
but errors can also be due to memory or attentional dysfunction. It is included 
within numerous cognitive screening tests and occasionally used as a standalone 
test. It has proven to be useful in screening for dementia (249, 250), detecting 
cognitive impairment such as spatial neglect and has been validated in various 
settings. It is considered less useful for detecting milder forms of cognitive 
impairment (251). 
There are different methods to administer the task, for example some CSIs 
include a pre-drawn circle and different times can be used. Scoring methods can 
vary substantially in terms of complexity and can be quantitative or qualitative. 
In the APPLE study this task is administered and scored according to the MoCA 
guidelines which score the task out of three (Figure 5-1). Some other tests which 
include the CDT state that the hand length is not scored e.g., the Mini-Cog (63), 
therefore I was unable to derive this test. 
 




One point is allocated for each of the following three criteria:  
• Contour (1 point): the clock face must be a circle with only 
minor distortion acceptable (e.g., slight imperfection on 
closing the circle);  
• Numbers (1 point): all clock numbers must be present with no 
additional numbers; numbers must be in the correct order and 
placed in the approximate quadrants on the clock face; Roman 
numerals are acceptable; numbers can be placed outside the 
circle contour;  
• Hands (1 point): there must be two hands jointly indicating the 
correct time; the hour hand must be clearly shorter than the 
minute hand; hands must be centred within the clock face with 
their junction close to the clock centre. A point is not assigned 
for a given element if any of the above criteria are not met. 
148 
 
Abbreviated MoCA (147) 
This is the shortest of the SF-MoCA versions described in Chapter 3. The tasks 
retained from the Czech version of the original MoCA are clock-draw and delayed 
recall and the total score is eight. The validation paper included individuals aged 
60 or over, without known cognitive impairment. 
Cog-4 (252) 
The Cog-4 uses the following four items taken from the NIHSS: level of 
consciousness which measures orientation (month & age), ability to follow 
commands, language, and extinction & inattention. It is a cognitive measure 
that is easy to obtain since the NIHSS is routinely completed. The Cog-4’s 
limitations however have been documented by previous studies: poor accuracy 
when compared to the MoCA (253), significant floor effects and scores are 
dependent on side of stroke (254). 
Six-Item Cognitive Impairment Test (6-CIT) (255)   
The 6-CIT, previously known as the ‘short Blessed test’ or the ‘six-item 
orientation-memory-concentration test’, was created as a shortened version of 
the Mental Status Test (MST)(256). It is scored out of 28 but unlike most tests, 
higher scores indicate worse cognition. The items include current year and 
month, immediate recall of five components (unscored), current time, count 
backwards from 20, months of the year backwards, delayed recall of five 
components. The following score categories can be used: 0-7 normal, 8-9 mild 
cognitive impairment, 10-28 significant cognitive impairment. The 6-CIT has 
been used in both primary and secondary care, yet there are few validation 
studies available(257). 
10-point Abbreviated Mental Test Score (10-AMT) (61) and 4-point AMT (4-AMT) 
(149) 
The 10-AMT was designed from a list of 26 questions, and initially validated in 
hospital inpatients aged 65 or above (61). The items include age, current time, 
immediate recall of two components (unscored), current year and location, 
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recognising two people, DOB, year of WW1, name current president/prime 
minister, and count backwards from 20. A shortened 4-point AMT (4-AMT) was 
later introduced retaining four items: age, date of birth, place and year. It was 
initially validated against the 10-AMT in an outpatient population (149). Both 
tests have been widely used within hospitals in the UK and validated in acute 
medical settings (258). 
The 4 ‘A’s Test (4AT) (www.the4AT.com) 
The 4AT is a four-item screening test mainly designed and used in delirium 
detection. Score thresholds however are also provided for possible cognitive 
impairment. The test consists of an observational assessment of alertness, the 
AMT-4, months of the year backwards and the final item asks whether there is 
evidence of acute change or fluctuation in mental status arising over the last 2 
weeks and still evident over the past day. A score of 0 indicates that delirium or 
cognitive impairment is unlikely, 1-3 indicates possible cognitive impairment, ≥4 
indicates possible delirium and cognitive impairment.  
NINDS-CSN 5-min protocol (110) 
As discussed in the introduction, the National Institute of Neurological Disorders 
and Stroke-Canadian Stroke Network (NINDS-CSN) recommended a 5-minute 
assessment which could be administered both in person and over the telephone. 
It is also one of the shortened forms of the MoCA detailed in Chapter 3, 
consisting of a five-part delayed recall, orientation (date, month, year, day of 
the week, place, city) and verbal fluency (total score 12). In the APPLE study we 
have data for all items apart from day of the week, therefore the total score in 
this study is 11. 
5.5.2 One Month follow-up   
The one-month follow-up was completed either at the hospital’s clinical 
research facility, the patient’s home or in hospital if the participant was still an 
inpatient. We repeated the same cognitive assessments as described at baseline 
(AMT-plus). In addition, the Oxford Cognitive Screen (OCS) was attempted with 
the participant. The OCS has been designed for the acute stroke setting and 
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creates a cognitive profile of strengths and weaknesses, rather than an overall 
score or global categorisation. A full description of the test can be found in 
Chapter 1. A copy of the OCS is provided in Appendix 13. 
5.5.3 Six Month follow-up 
At the six-month follow-up, we used one of three versions: a full-length version 
incorporating all assessments and scales, a shortened version or a telephone-
based version. In-person assessments were prioritised and carried out at a 
clinical research facility or at the participant’s home. The full-length version 
was also prioritised and used with the majority of participants. The shortened 
version was used in scenarios such as where participants had severe aphasia, 
hearing impairment, dementia or struggled at the last follow-up. Each case was 
considered separately and no a priori rules were set. We attended follow-ups 
with both versions available to use if required. Participants were reassured in all 
versions of assessment that they could stop at any time. 
The telephone-based assessment was mainly used for participants who could not 
attend due to mobility issues or geographical barriers but was also convenient to 
obtain follow-up data for those participants with time constraints (e.g., those 
who work full-time). 
5.5.3.1 Full length assessment  
The full-length assessment took approximately 45 minutes – 1 hour to 
administer, consisting of a neuropsychological battery of tests followed by a 
range of questionnaires. Cognition was first assessed using the ‘AMT-plus’ again, 
followed by the NINDS-CSN 30-minute neuropsychological protocol.  
Functional, mood and quality of life outcomes 
For global disability and basic activities of daily living, the mRS and the Barthel 
were completed again. The 3-level version of the EQ-5D (259, 260) was used to 
assess health-related quality of life (HRQoL). There are two components to the 
scale: the EQ-5D-3L descriptive system and the EQ visual analogue scale (VAS). 
The first part asks the participant to rate whether they have no problems, some 
problems, or extreme problems across five areas (mobility, self-care, usual 
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activities, pain/discomfort, and depression/anxiety). This generates a 5-digit 
number reflecting responses for each question, for example 11111 would reflect 
no problems across the five areas. This 5-digit number was then transformed 
into a single summary utility index score, using the published UK time trade-off 
(TTO) validation (261). The VAS instructs the participant to rate how good their 
health is at the present moment, in their own opinion, on a scale from 0 (worst 
imaginable health state) to 100 (best imaginable health state).  
The Center for Epidemiologic studies Depression Scale Revised (CESD-R) (262) 
contains 20 items covering nine symptom areas: sadness, loss of interest, 
appetite, sleep, concentration, guilt, fatigue, agitation, and suicidal ideation. 
The participant is asked how often they have experienced each symptom using 
five response options. The score range for the measure is 0 to 60, with higher 
scores indicating more frequent depressive symptoms. The symptoms reflect 
DSM-V criteria for a major depressive episode. 
5.5.3.2 Short version  
The shortened version took approximately 20 minutes to administer. Cognition 
was assessed using the ‘AMT-plus’, followed by the Montreal Cognitive 
Assessment (MoCA). The MoCA is scored out of 30, with higher scores reflecting 
better performance. Full description of the MoCA can be found in Chapter 1. The 
CESD-R, mRS, EQ-5D are also completed. 
5.5.3.3 Telephone version 
The telephone version took approximately 20 minutes to administer. For the 
cognitive assessment we used the TICS-m (101). A full description of the TICS-m 
and other telephonic CSIs are available in Chapter 4. 
We also include the items from the ‘AMT-plus’ that can be delivered over the 
telephone: Time, Place, Date of Birth, Year of World War 1, News item, Months 
of the year backwards, Fluency (letter F). Only one of the brief CSIs (AMT-4) 
could be scored from the included questions. 
The following scales were also completed over the telephone: mRS, CESD-R and 




Patients were recruited into the study across 11 UK hospital sites (8 NHS trusts): 
the Glasgow Royal Infirmary (GRI), Queen Elizabeth University Hospital (QEUH), 
Royal Alexandra Hospital, University Hospital Monklands, University Hospital 
Hairmyres, Aberdeen Royal Infirmary, Victoria Hospital (Fife), Forth Valley Royal 
Hospital, Perth Royal Infirmary, Charing Cross Hospital and Swansea (Figure 5-2).  
 
Figure 5-2 Map of APPLE recruitment sites 
 
Recruitment commenced straight after ethical approval was obtained. The first 
participant was recruited into the study in November 2016 and the final in 
February 2019. We recruited 354 stroke participants and 151 informants in total. 
Full breakdown of recruitment per site is given in Table 5-4. 
5.7 Case report forms 
I collected and recorded anonymised participant data on paper case report forms 
along with two other PhD students and the research nurses involved at each 
hospital site. All files are securely filed in a locked room at each hospital, with 
another copy held securely at the Robertson centre for Biostatistics (RCB), 
University of Glasgow. The RCB managed the APPLE database for all sites, 
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including generating queries and dealing with database locks. All data was 
collected and handled according to International Conference on Harmonisation 




Table 5-4 Recruitment (stroke participants) across each NHS trust 
 
NHS Health board and hospital Number of participants recruited (N) 















NHS Grampian 30 
Imperial College Healthcare NHS trust 12 
NHS Forth Valley 7 
NHS Tayside 3 





6 Use of Brief Cognitive Screening Instruments 
post stroke: a longitudinal study 
6.1 Introduction 
For cognitive screening instruments (CSIs) to be implemented in acute medical 
settings, they need to be simple to deliver, since administration time is 
considered a key determinant of usage (153, 263). As discussed in Chapter 2, 
feasibility, and acceptability of administering a CSI in acute stroke is 
multifaceted; a range of factors relating to the participant, the HCP delivering 
the screen and the hospital setting itself should be acknowledged. 
In addition to administration time, a CSI that can be used by any HCP, with 
minimal training, is also preferred. The SSNAP 2019 acute organisational audit 
report highlighted that only 7% of stroke units have access to a qualified clinical 
psychologist working full time 
(https://www.strokeaudit.org/results/Organisational/National-
Organisational.aspx). The assessment paradigm recommended is the use of brief 
CSIs during the hyperacute period for initial triage, followed up with more 
detailed testing at later time-points (264). For this reason, sensitivity of tests is 
often favoured over specificity.  
As described in Chapter 1, brief CSIs in this thesis refer to those CSIs that can be 
administered in under 5 minutes. In Chapter 3, various SF-MoCAs demonstrated 
high sensitivity for detecting cognitive impairment in the stroke validation 
sample. In addition to brief tests derived from the MoCA, there are many other 
brief CSIs available, for example those designed for primary care, yet many of 
these have not been validated in a stroke population. A previous systematic 
review examining test accuracy of CSIs for detection of multi-domain cognitive 
impairment or dementia in stroke concluded that there was no evidence that 
CSIs with longer administrations perform better in terms of accuracy (120). 
However only three studies with data on brief CSIs were found and included, 
providing data on the three cities test (265), CDT (266), Cog-4, AMT (10- and 4- 
point versions) and 4AT in stroke (267). Two of these studies used either the 
MoCA or MMSE as the reference standard, both of which have limitations, as 
discussed in Chapter 1. Although this systematic review did not address the 
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accuracy of CSIs to detect milder levels of cognitive impairment, there is 
evidence that being impaired in a single cognitive domain can have significant 
impact on functioning (268, 269).  
The primary aims of this study were to calculate the rates of participants 
classified as ‘test positive’ according to eight different brief CSIs across three 
timepoints and to determine the accuracy of them using different reference 
standards: pre-stroke cognitive impairment (against clinical diagnosis) and post-
stroke cognitive impairment (against the OCS). Secondary aims were to report on 
completion rates and floor/ceiling effects of each CSI across three timepoints. 
6.2 Methods 
6.2.1 Study design 
This is a prospective, observational, longitudinal study using data from the 
APPLE study. Details regarding ethical approval, eligibility criteria, informed 
consent, and study conduct are available in the previous chapter. Most 
participants were recruited from hyper-acute/acute stroke units, with a minority 
recruited from a TIA clinic. The baseline visit was completed as soon as possible 
from recent stroke or TIA. The subsequent follow-ups were completed at 
approximately one and six months following the baseline visit, with a two-week 
window permitted either side of the follow-up date. 
I followed the Standards for Reporting Diagnostic Accuracy in dementia 
(STARDdem) checklist (270) for the conduct and reporting of the study. The 
checklist is available in Appendix 5. 
6.2.2 Index tests 
The CSIs were administered by researchers working on the APPLE study (PhD 
students, research nurses and investigators) across 11 UK hospital sites. All 
researchers received an instruction/training manual, detailing how to administer 
and score the CSIs used in the study. 
As detailed in the previous chapter, the questions included in the ‘AMT-plus’, 
along with sections from the CAM-ICU (245) and the NIHSS (244) were used to 
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score eight different CSIs: CDT, AMT-4 (149), AMT-10 (61), 6-CIT (255), 4AT 
(www.the4AT.com), Cog-4 (252), Abbreviated MoCA (147), NINDS-CSN 5-min 
MoCA (110). These CSIs were chosen as they shared a number of test items in 
common and have some supportive evidence in other settings (271-273). 
The relevant pages of the case report form (CRF) are available in Appendix 12. 
All index tests except the Cog-4 were completed at the same time-point. The 
Cog-4 was based on admission NIHSS and therefore from an earlier timepoint 
than the other CSIs. 
At the one-month visit, the AMT-plus and CAM-ICU were completed again but not 
the NIHSS, therefore all CSIs except the Cog-4 could be scored. At six months, 
the AMT-plus was completed in the face-to-face follow-up, and all tests except 
Cog-4 and 4AT could be scored. For those participants completing the 6-month 
follow-up via telephone, only the AMT-4 could be scored. 
Researchers were asked to document whether physical or verbal assistance was 
required to complete the cognitive assessment, for example if a participant had 
limb weakness, aphasia, hearing impairment, but these were not formally 
operationalised. Each CSI was administered and scored as close to the scale’s 
published guidelines as possible (deviations are detailed in the previous 
chapter). Published recommended threshold scores were used to classify a 
participant as cognitively impaired (Table 6-1). Some CSIs provide more than one 
threshold for different severities of cognitive impairment, for example the 6-CIT 
has a threshold for ‘MCI’ and another for ‘significant cognitive impairment’. In 
these cases, the threshold to detect the milder form of cognitive impairment 




Table 6-1 CSI threshold scores  
Test 





Clock-drawing test High score <3/3 
Abbreviated MoCA High score  <4/8 
Cog-4 Low score >0/9 
AMT-4 High score <4/4 
AMT-10 High score <7/10 
4AT Low score >0/12 
6-CIT Low score >7/28 







Abbreviations:  AMT, Abbreviated mental test; CDT, Clock drawing test; NINDS-CSN, National Institute of Neurological Disorders and Stroke-Canadian Stroke 
Network; 6-CIT, Six-item cognitive impairment test.





















































CDT x x x
Abbrev. 
MoCA
x x x x
AMT-4 x x x x
4AT x x x x x x x
6-CIT x x x x x x
10-AMT x x x x x x x x x x
NINDS-CSN 5-
min MoCA
x x x x x x x
Cog-4 x x x x
AMT-plus: NIHSS: CAM-ICU: 
CSI
Table 6-2 Scoring algorithm of each brief CSI 
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6.2.3 Reference standards  
The first reference standard I used was a diagnosis of pre-existing cognitive 
impairment. These data were obtained through the patient’s medical record and 
captured either a dementia or MCI diagnosis. Although the focus of this work is 
post-stroke impairment, it is important to also examine whether the CSIs 
identify pre-existing issues too. The same person collecting data from the 
medical record carried out the index tests and was therefore not blinded. 
I used the Oxford Cognitive Screen (OCS) as the post-stroke reference standard 
(completed at one month). There is no perfect choice of reference standard for 
the acute period following a stroke and clinical diagnosis of MCI/dementia is not 
recommended until at least six months post-stroke (264). Although the OCS is 
also a screening test, it is more comprehensive than all the index tests (greater 
coverage of cognitive domains) and designed specifically for a stroke population. 
When compared to the MoCA in previous research, the OCS had higher sensitivity 
(274). A full description of this CSI can be found in Chapter 1. 
Participants were scored on each of the 13 components of the OCS. Threshold 
scores are provided by the authors for each subtest and these were used to 
define impairment in a particular task (66) (Table 6-3). Each subtest sits within 
one of five OCS cognitive domains: attention, memory, language, praxis, and 
number processing. If a participant is impaired in a subtest, they are considered 
to be impaired within that domain (66). I used two categorisations of cognitive 
impairment: impaired in ≥1 domain (to capture single and multi-domain) and 
impaired in ≥2 domains (multi-domain only). All untestable data on the OCS 
were excluded to ensure that the categorisation of cognitive impairment was in 
fact related to cognition and not due to another reason, such as hemiparesis. 
Participants with a partially completed OCS were included and scored based on 
the tasks completed. Researchers carrying out the one-month assessment had 




Table 6-3 OCS tasks and threshold scores 
Domain Task Cut-off 
Memory Orientation <4/4 
Recall & recognition <3/4 
Episodic <3/4 
Language Picture naming <3/4 
Semantics <3/4 
Sentence reading <14/15 
Number Number writing <3/3 
Calculation <3/4 
Attention Broken hearts total <42 
Space asymmetry <-2 or >3 
Object asymmetry <-2 or >1 
Praxis Gesture imitation <8 
Executive functioning Executive score >4* 
*The executive score is calculated using the scores from three different trail tasks: circles, triangles 
and mixed  
6.2.4 Analysis 
At the time of writing this chapter, the database was not locked for the APPLE 
study as the host Clinical Trial Unit and biostatistics centre had not completed 
data queries and internal quality control checks following double data entry, 
therefore results may differ from subsequent publications.  
I summarised descriptive statistics for the demographic and clinical 
characteristics of the sample; variables with normally distributed data are 
summarised by mean and standard deviation, whereas skewed data were 
summarised by median and interquartile range (IQR). I used SPSS version 27 
(IBM, Armonk, NY, USA). 
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As discussed in the previous chapter, the APPLE database was managed by a 
biostatistics centre, and I had access to the data for the variables required for 
my PhD. To score each index test I created a scoring spreadsheet (Table 6-2; full 
version available in Appendix 14) for the biostatistics centre, detailing items and 
scoring for each CSI. I performed quality checks by independently scoring the 
CSIs for a subsample of participants to compare against the RCB derived scores. 
The subsample checked were chosen on a stratified basis, with a focus on 
checking the scoring of those with partially and fully untestable CSI data. Any 
issues found were resolved through discussion with the biostatistics centre and 
scoring was re-calculated again where necessary. 
I made some assumptions for scoring the CSIs. For three questions (months of the 
year backwards, count backwards from 20 and 5-word delayed recall), I required 
the number of errors made by the participant. In the CRF, researchers were 
asked to document the number of errors made by the participant, as well as 
indicate ‘yes’ or ‘no’ according to certain rules: yes for delayed recall = ≥4 
words correct; yes for count backwards = all correct; yes for months of the year 
backwards = ≥7 months correct). For months of the year backwards, count 
backwards from 20 and 5-word delayed recall, if yes was ticked, and number of 
mistakes missing, I assumed these cases were 0 mistakes. Where no was ticked 
and number of errors missing, I considered their possible score range, for 
example a ‘no’ for delayed recall could mean the participant scored between 0-
3 correct. If this score range would alter their categorisation of being impaired 
the participant was excluded.  
To address the multiple research objectives the following analyses were carried 
out for each CSI, which are detailed in the following subsections: 
• Percentages of participants falling below the threshold score and 
classified as test positive; 
• Test accuracy of baseline CSI compared to a pre-stroke diagnosis of 
MCI/dementia; 
• Prognostic accuracy of baseline CSI compared to one-month OCS; 
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• Test accuracy of one month CSI compared to one-month OCS; 
• Completion rates and reasons for incompletion; 
• Floor/ceiling effects. 
6.2.4.1 Dealing with incomplete and untestable data 
To build on the work completed in Chapter 2, I anticipated data to be missing 
for varying reasons. In the CRF, a range of pre-specified untestable reasons were 
provided for researchers to choose where assessment could not be fully 
completed: aphasia, limb weakness, confused, drowsy/reduced consciousness, 
deaf, motor problem, visual problem, unwell, refused, other (specify). 
For two CSIs (4AT and Cog-4), there are ways for dealing with untestable data 
built into the scoring. For the other CSIs, methods for missing data were planned 
a priori. For this particular study, I considered data to be missing under the 
following conditions: missing CRF, participants declined individual questions or 
the full test; participants were discharged; a task could not be completed due to 
positioning of the participant; a task was not completed due to a researcher 
error (e.g., missed); missing data with reason unknown.  
Participants who could not be tested for other reasons, for example aphasia, 
limb weakness, confusion, reduced consciousness were classified as impaired for 
that item (and assigned the corresponding impaired score). This approach 
mirrors that taken in the 4AT and is supported by previous research (275) as it 
reduces the number of type two errors (false negatives).  
6.2.4.2 CSI results and test accuracy  
At all three time-points (baseline, one and six months), I calculated the 
percentage of participants categorised as ‘test positive’ on each of the eight 
CSIs using recommended thresholds. 
To estimate sample sizes required in test accuracy studies, simple nomograms 
can be used (276). There are four elements to the nomogram (prevalence, 
sensitivity/specificity, confidence intervals and number of patients) and if a 
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researcher knows any three, the fourth can be calculated. In the APPLE 
protocol, an estimate of 400 participants was made, based on a prevalence of 
40% cognitive impairment at one month (a=0.05). 
The results of each CSI were evaluated against the two reference standard 
assessments. When the baseline brief CSIs were compared to the OCS at one 
month, I refer to this as prognostic test accuracy, since the index test and 
reference standard were completed at different timepoints, whereas when the 
one-month brief CSI results were compared to the OCS I refer to this as test 
accuracy (completed at same timepoint).  
Sensitivity, specificity, positive and negative predictive values (PPV/NPV) and 
area under the receiver operating characteristic curve (AUC) were calculated 
using the Delong et al. (1988) method (277). An AUC value of 0.5 indicates the 
test is no better than chance at detecting the desired outcome. Values of 0.7-
0.8 are considered acceptable, 0.8-0.9 excellent and 0.9-1.00 outstanding (278). 
Based on the reasons discussed in the introduction, CSIs with a high sensitivity 
(>0.7) were required to be recommended, rather than those with high 
specificity. The optimal threshold score, determined by the Youden index 
method, was also determined. The Youden index however gives equal weight to 
sensitivity and specificity. I used MedCalc version 19.5.3 (MedCalc Software Ltd, 
Ostend, Belgium) for these analyses.  
For the primary analyses, participants who were untestable were included. I 
then ran sensitivity analyses excluding these participants to examine if accuracy 
altered. This was done for all CSIs apart from the 4AT and Cog-4, which already 
incorporate scoring for these scenarios. 
6.2.4.3 Completion rates, floor/ceiling effects, errors 
The number of participants with a complete data set (no missing or untestable 
data) for each CSI was recorded. Floor and ceiling effects were calculated for 
both the individual items of the AMT-plus and of the eight named CSIs, through 
calculating the percentage of participants scoring zero (floor effect) or full 
marks (ceiling effect) on each item/CSI. Three of the CSIs have the opposite 
scoring structure, in that a high score indicates poorer cognition (4AT, Cog-4 and 
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6-CIT), so for these instruments a score of zero was captured as the ceiling 
effect. A criterion of >15% was applied to determine if floor/ceiling effects were 
present (116).  
I also recorded the types of errors made by researchers in administrating/scoring 
the AMT-plus items. Throughout the APPLE study, CRFs from other hospital sites 
were sent to me and the rest of the team at the host clinical site. We checked 
the scoring of tasks which could be scored retrospectively (e.g., clock draw). 
6.3 Results 
There were 354 participants recruited into the APPLE study (97% recruited from 
a HASU). Follow-up data were available for 268 participants at one month and 
220 participants at six months. The participants at each timepoint are detailed 



















Missing AMT-plus data: 
full test (N=5), partially 
incomplete (N=22) 
One month (N=268) 
CDT (N=254) 
AMT-4 (N=262) 







6 months (N=220) 
Full version (N=144) 
Short version (N=18) 
Telephone version (N=58) 
 
Missing AMT-plus data: 
full test (N=1), partially 
incomplete (N=4) 
Declined, withdrew or lost to f/u: N=86  
Declined, withdrew or lost to f/u: N=45 
Died N=3  
Missing AMT-plus data: 
full test (N=5), partially 
incomplete (N=22) 
Missing OCS data: full 






Table 6-4 Characteristics of the sample (N=354) 
 
Abbreviations: HASU, hyper acute stroke unit; ICH, Intracerebral haemorrhage; IS, Ischaemic 
stroke; IQR, Interquartile range; LACS, lacunar stroke; NIHSS, National Institute of Health Stroke 
Scale; PACS, Partial anterior circulation stroke; POCS, posterior circulation stroke; TACS, Total 
anterior circulation stroke; TIA, Transient ischaemic attack 
Variable Summary statistic 
Age: Mean (SD) 69.1 (12.8) 
Sex: N Male (%) 197 (56%) 
Stroke Classification (includes IS & 
ICH) 
 
Missing data = 2 
TACS: 33 (9%) 
PACS: 118 (34%) 
LACS: 85 (24%) 
POCS: 68 (20%) 
TIA: 47 (13%) 
Side of brain affected by index 
stroke 
(includes TACS/PACS/LACS/TIA) 
Missing data = 2 
Right: 146 (41%) 
Left: 131 (37%) 
Bilateral: 5 (1%) 
NIHSS: Median (IQR) 
Missing data = 2 
2 (1-4) 
Pre-morbid mRS: Median (IQR)  
 
Missing data = 3 
0 (0-2) 
Capacity to consent themselves: N 
(%) 
332 (93%) 
Previous stroke: N (%) 87 (25%) 
Years in education: Mean (SD) 
 
Missing data = 31 
12.0 (3.4) 
Pre-stroke dementia or MCI: N (%) 26 (7%) 
Presence of aphasia on admission 
NIHSS Q.9 (>0): N (%) 
48 (14%) 
Limb weakness on admission  
NIHSS Q.5 (>0): N (%) 
Right: 60 (17%) 
Left: 90 (26%) 
Hearing impairment: N (%) 
 
Missing data = 2 
63 (18%) 
Visual impairment: N (%) 
 
Missing data = 2 
96 (27%) 




The baseline assessment took place at a median of 6 days (IQR 4-9) post stroke 
and a median of 4 days (IQR 3-7) post admission to the stroke unit or TIA clinic. 
Five participants were CAM-ICU positive, indicating a potential presence of 
delirium. 
6.3.1.1 AMT-plus completion rates  
Five participants were fully untestable on the AMT-plus (did not complete any 
questions) due to aphasia, confusion, and reduced consciousness. There were 22 
participants with partially completed AMT-plus; 10 of these participants were 
classified partially untestable due to motor problems, aphasia, deafness, visual 
impairment, confusion and 12 participants had incomplete assessments but were 
not classified as untestable, with the following reasons: discharged, declined, 
taken from medical records, completed via telephone, and missing with 
unknown reason. For completion of the AMT-plus: 11 participants required 
physical assistance to complete the AMT-plus and 46 required verbal assistance. 
6.3.1.2 CSI results and accuracy  
At baseline, the percentage of participants classified as impaired across the 8 
CSIs ranged 12% (AMT-10) to 69% (CDT), using recommended thresholds. 
Sensitivity of each CSI when comparing the results of the CSIs to a pre-stroke 
cognitive impairment syndrome ranged 0.46 (Cog-4) to 0.84 (NINDS-CSN 5-min 
MoCA). Specificity ranged 0.32 (CDT) to 0.89 (AMT-4). AUC ranged 0.63-0.81 and 
was highest for AMT-10 and 6-CIT. In sensitivity analyses, where untestable 
participants were removed, sensitivity decreased/specificity increased slightly 
across all CSIs (Table 6-5).  
When comparing the accuracy of each CSI to detect any level of cognitive 
impairment (single and multi-domain) at 1 month, sensitivity ranged 0.14 (AMT-
10) to 0.76 (CDT). Specificity ranged 0.45 (CDT) to 0.96 (AMT-4). AUC ranged 
0.56-0.70 and was highest for the NINDS-CSN 5-min MoCA. In sensitivity analyses, 
where untestable participants were removed, sensitivity decreased/specificity 




When comparing the accuracy of each CSI to detect multi-domain cognitive 
impairment at 1 month, sensitivity ranged 0.25 (AMT-10) to 0.87 (CDT). 
Specificity ranged 0.45 (CDT) to 0.96 (AMT-4). AUC ranged 0.62-0.77 and was 
highest for the NINDS-CSN 5-min MoCA. In sensitivity analyses, where untestable 
participants were removed, sensitivity decreased/specificity increased slightly 
or stayed the same across all CSIs (Table 6-7).
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Table 6-5 Accuracy of each CSI at baseline to identify pre-stroke diagnosis of dementia or MCI 
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>0       
*<4 in sensitivity analysis. Abbreviations: AMT, Abbreviated mental test; AUC, Area under curve; CDT, Clock drawing test; MoCA, Montreal Cognitive Assessment; 
NINDS-CSN, National Institute of Neurological Disorders and Stroke-Canadian Stroke Network; NPV, Negative predictive value; PPV, Positive predictive value; 4AT, 4 
A’s test; 6-CIT, Six-item cognitive impairment test. 
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Table 6-6 Prognostic accuracy of each CSI at baseline to identify post-stroke cognitive impairment (single and multi-domain) 
 
 Main analyses (including untestable) Sensitivity analyses 
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Abbreviations AMT, Abbreviated mental test; AUC, Area under curve; CDT, Clock drawing test; MoCA, Montreal Cognitive Assessment; NINDS-CSN, National Institute 
of Neurological Disorders and Stroke-Canadian Stroke Network; NPV, Negative predictive value; PPV, Positive predictive value; 4AT, 4 A’s test; 6-CIT, Six-item 
cognitive impairment test. 
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Table 6-7 Prognostic accuracy of each CSI at baseline to identify post-stroke cognitive impairment (multi-domain) 
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Abbreviations: AMT, Abbreviated mental test; AUC, Area under curve; CDT, Clock drawing test; MoCA, Montreal Cognitive Assessment; NINDS-CSN, National 
Institute of Neurological Disorders and Stroke-Canadian Stroke Network; NPV, Negative predictive value; PPV, Positive predictive value; 4AT, 4 A’s test; 6-CIT, Six-
item cognitive impairment test. 
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6.3.2 One Month  
The one-month assessment took place at a mean of 42.3 days (SD 19.5) post-
stroke. Between the baseline and one-month assessment, three participants had 
a further stroke.  
6.3.2.1 AMT-plus completion rates 
Five participants were fully untestable on the AMT-plus (did not complete any 
questions) due to aphasia, unwell, reduced consciousness, confusion. This 
included two participants who had been previously deemed testable at baseline. 
There were 12 participants with partially completed AMT-plus; 10 of these 
classified partially untestable due to motor problems, aphasia, deafness, visual 
impairment, confusion, language barrier and two participants had incomplete 
assessments due to declining the assessment but were not classified as 
untestable. For completion of the AMT-plus: 9 participants required physical 
assistance and 35 required verbal assistance. 
6.3.2.2 CSI results and accuracy  
At one month the percentage of participants classified as impaired across the 
CSIs ranged 8% (AMT-10) to 64% (CDT). Sensitivity to detect any level of cognitive 
impairment (as detected by the OCS) ranged 0.17 (AMT-4) to 0.75 (CDT). 
Specificity ranged 0.54 (CDT) to 1.00 (AMT-10, Abbreviated MoCA). AUC ranged 
0.58-0.70 and was highest for the CDT and Abbreviated MoCA (Table 6-8). In the 
sensitivity analyses, where untestable participants were removed, sensitivity 
decreased/specificity increased slightly across all CSIs (Table 6-8).  
When comparing the accuracy of each CSI to detect multi-domain cognitive 
impairment, sensitivity ranged 0.18 (AMT-10) to 0.86 (CDT). Specificity ranged 
0.45 (CDT) to 0.99 (AMT-10). AUC ranged 0.63-0.72 and was highest for the 
NINDS-CSN 5-min MoCA. In sensitivity analyses, where untestable participants 
were removed, sensitivity decreased/specificity increased slightly or stayed the 
same across all CSIs. 
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Table 6-8 Test accuracy of each CSI to identify post-stroke cognitive impairment (single and multi-domain) 
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Abbreviations: AMT, Abbreviated mental test; AUC, Area under curve; CDT, Clock drawing test; MoCA, Montreal Cognitive Assessment; NINDS-CSN, National 
Institute of Neurological Disorders and Stroke-Canadian Stroke Network; NPV, Negative predictive value; PPV, Positive predictive value; 4AT, 4 A’s test; 6-CIT, Six-
item cognitive impairment test. 
175 
 
Table 6-9 Test accuracy metrics of each CSI against the OCS (multi-domain CI) 
 
 Main analyses (including untestable) Sensitivity analyses 
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Abbreviations: AMT, Abbreviated mental test; AUC, Area under curve; CDT, Clock drawing test; MoCA, Montreal Cognitive Assessment; NINDS-CSN, National 
Institute of Neurological Disorders and Stroke-Canadian Stroke Network; NPV, Negative predictive value; PPV, Positive predictive value; 4AT, 4 A’s test; 6-CIT, Six-
item cognitive impairment test. 
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6.3.3 Six months  
The six-month assessment took place at a mean of 195.7 days (SD 21.3) post-
stroke. 144 participants completed the full follow-up, 18 completed the 
shortened version, and 58 completed the telephone-based version.  
6.3.3.1 AMT-plus completion rates 
One participant was fully untestable on the AMT-plus (did not complete any 
questions) due to aphasia. This participant was also untestable at the previous 
timepoints. There were four participants with partially completed AMT-plus; 3 of 
these classified partially untestable due to motor problems and one participant 
had an incomplete assessment without a documented reason so were not 
classified as untestable. For completion of the AMT-plus: 6 participants required 
physical assistance to complete the AMT-plus and 23 required verbal assistance.  
6.3.3.2 CSI results 
The percentage of participants classified as impaired ranged 7% (AMT-10) to 64% 
(CDT). 
6.3.4 All timepoints 
6.3.4.1 CSI results 
Figure 6-2 illustrates the percentage of participants classified as impaired across 
the three timepoints. In this sample of participants, across all timepoints, the 
CDT resulted in the greatest number of participants classified as cognitively 
impaired and the AMT-10 resulted in the least. Between the first and second 
timepoints, the percentage of participants classified as impaired decreased 
across all CSIs. Between the second and third timepoints, the percentage of 
those classified as impaired decreased or plateaued for all but one test: the 5-
min MoCA recommended by NINDS-CSN which increased from 54-59%. The largest 





Figure 6-2 Percentage of participants scoring below the threshold for each test (classified 
as cognitively impaired) at each time-point using each CSI  
 
6.3.4.2 Completion rates, floor/ceiling effects, errors 
Completion of the different test items included in the AMT-plus ranged 94-98% at 
baseline, 95-98% at one month, and 98-100% at six months. Across all timepoints, 
the clock-draw had the lowest completion rate. The percentage of items correct 
ranged 39-99% at baseline, 44-99% at one month, and 43-100% at 6 months. At 
baseline and one month, the date of birth (DOB) item had the highest 
percentage correct and clock draw hands had the lowest percentage correct. At 
6 months, all participants got the two-person recognition item correct and 
verbal fluency had the lowest percentage correct (Table 6-11). 
Across the eight CSIs at baseline, the Cog-4 had the highest completion rate 
(99%) and the Abbreviated MoCA had the lowest (93%). All CSIs demonstrated 
ceiling effects (>15%) but effects were highest for the Cog-4 (99%), 4AT (98%) 
and AMT-4 (87%). Across the seven CSIs at one month, the 4AT had the highest 
completion rate (100%) and the Abbreviated MoCA had the lowest (93%). All CSIs 
demonstrated ceiling effects, but effects were highest for the 4AT (78%) and 




































CDT AMT-4 AMT-10 Abbrev MoCA
6CIT NINDS-CSN 4AT Cog-4
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99%). Four out of six CSIs demonstrated ceiling effects: 6-CIT (25%), AMT-4 
(92%), AMT-10 (45%), CDT (37%) (Table 6-12). 
On reviewing the CRFs from other sites, some errors were identified for three of 
the AMT-plus items: verbal fluency, the CDT, and months of the year backwards 
(Table 6-10). In some cases, the task could be re-scored, whereas no action 
could be taken if it resulted from an administration error. For verbal fluency, it 
was decided that if the administrator did not specify that proper nouns/numbers 
were not permitted, it was unfair to penalise the participant. Additional training 
materials clarifying these items were provided to the sites (Appendix 15). 
Table 6-10 Errors identified in administration and scoring of AMT-plus 
AMT-plus item Error type Action 
Fluency Different letter to F used None 
Proper nouns or numbers 
scored as correct 
None 
Clock draw  Different time used to 
11:10 
None 
Scoring errors e.g. hands 
drawn as the same length 
marked as correct 
Re-scored 
Months of the 
year backwards 
Scoring and recording ≥7 
months as correct 























ness N (%) 
N (%) 
correct 
Age 346 (98%) 330 (95%) 262 (98%) 255 (97%) 162 (100%) 152 (94%) 
Time 346 (98%) 299 (86%) 261 (97%) 243 (93%) 162 (100%) 156 (96%) 
Date 346 (98%) 232 (67%) 261 (97%) 188 (72%) 162 (100%) 113 (70%) 
Month 346 (98%) 313 (90%) 262 (98%) 245 (94%) 161 (99%) 149 (93%) 
Year 343 (97%) 316 (92%) 262 (98%) 241 (92%) 161 (99%) 152 (94%) 
Place 346 (98%) 329 (95%) 262 (98%) 252 (96%) 162 (100%) 160 (99%) 
City 345 (97%) 331 (96%) 262 (98%) 255 (97%) 162 (100%) 161 (99%) 
Two-person 
recognition 
343 (97%) 316 (92%) 262 (98%) 252 (96%) 161 (99%) 161 (100%) 
Date of 
Birth 
345 (97%) 342 (99%) 262 (98%) 259 (99%) 162 (100%) 161 (99%) 
Date of 
WW1 








341 (96%) 309 (91%) 261 (97%) 243 (93%) 161 (99%) 147 (91%) 
5-word 
recallb 
342 (97%) 196 (57%) 260 (97%) 184 (71%) 161 (99%) 111 (69%) 
Clock-draw 
(face) 
331 (94%) 298 (90%) 254 (95%) 237 (93%) 158 (98%) 144 (91%) 
Clock-draw 
(Numbers) 
331 (94%) 214 (65%) 254 (95%) 186 (73%) 158 (98%) 120 (76%) 
Clock-draw 
(Hands) 
331 (94%) 128 (39%) 254 (95%) 111 (44%) 158 (98%) 73 (46%) 




341 (96%) 281 (82%) 261 (97%) 227 (87%) 162 (100%) 143 (88%) 
Letter F 
fluencyd 
343 (97%) 162 (47%) 260 (97%) 125 (48%) 162 (100%) 70 (43%) 
 
*Includes only those participants who completed the face-to-face follow-up. 
aCorrect = all numbers correct; bCorrect = ≥4 words correct; cCorrect = ≥7 
months correct; dCorrect = ≥11 words correct.
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Table 6-12 Floor and ceiling effects of each CSI across the three time-points (only those with full completion of each CSI included) 
 





Floor  Ceiling  
Fully 
completed 
Floor  Ceiling 
Fully 
completed 
Floor  Ceiling 
CDT 331 (94%) 25 (8%) 107 (32%) 254 (95%) 6 (2%) 97 (38%) 158 (98%) 5 (3%) 58 (37%) 
AMT-4 346 (98%) 0 (0%) 300 (87%) 262 (98%) 3 (1%) 235 (90%) 219 (99%)* 0 (0%) 201 (92%) 
AMT-10 342 (97%) 0 (0%) 121 (35%) 260 (97%) 0 (0%) 123 (46%) 161 (99%) 0 (0%) 72 (45%) 
6-CIT 336 (95%) 2 (1%) 91 (27%) 258 (96%) 89 (34%) 0 (0%) 161 (99%) 41 (25%) 0 (0%) 
Abb. MoCA 329 (93%) 4 (1%) 55 (17%) 249 (93%) 0 (0%) 50 (20%) 158 (98%) 1 (1%) 23 (15%) 
NINDS-CSN 341 (96%) 2 (1%) 59 (17%) 255 (95%) 0 (0%) 59 (23%) 159 (98%) 0 (0%) 20 (13%) 
4AT 348 (98%) 0 (0%) 257 (74%) 268 (100%) 210 (78%) 1 (<1%) - - - 
Cog-4 352 (99%) 2 (1%) 269 (76%) - - - - - - 





The absolute numbers of participants who screened positive for cognitive 
impairment varied widely at all three timepoints based on the CSI used. 
Consequently, test accuracy metrics of each CSI varied. To detect pre- and post-
stroke cognitive syndromes, brief CSIs had high specificity but low sensitivity. 
The two exceptions to this were the CDT and NINDS-CSN 5-min MoCA which had 
higher sensitivity than specificity. Generally, brief CSIs completed early after a 
stroke were more sensitive in detecting a pre-stroke diagnosis of MCI/dementia 
than detecting a post-stroke cognitive syndrome. Completion rates were good 
for all eight CSIs, but they all demonstrated ceiling effects (these were 
particularly high for the AMT-4, Cog-4 and 4AT). 
The accuracy of each CSI to detect post-stroke cognitive syndromes were similar 
when the index tests and reference standard were carried out at the same 
timepoint vs. when they were a month apart, with very slightly higher AUC when 
completed at the same timepoint. In sensitivity analyses, accuracy metrics were 
also similar when untestable patients were included and classified as impaired 
vs. excluded from analyses. The percentage of participants classified as 
impaired on each CSI did not decrease much over the three timepoints (largest 
percentage decrease was 9% for the NINDS-CSN 5-min MoCA between baseline 
and 6 months). This could be due to the brief CSIs having poor responsiveness to 
change, since they have a small number of test items. However, this comparison 
was based on those participants who had completed the follow-up at each 
timepoint rather than the exact same sample (different numbers of participants 
completed baseline, one month and six months). 
The NINDS-CSN and CDT had a different test accuracy profile to the other CSIs. 
Both test content and a high threshold score should be factored into the 
interpretation of this. Of the included CSIs, the NINDS-CSN 5-min MoCA was the 
only test to include a verbal fluency task. This could be considered one of the 
more difficult tasks, since only 47% of participants got this item correct (≥11 
words) at baseline, which dropped to 43% at 6 months. A high proportion of 
participants were also classified as impaired on the CDT. The scoring of this 
task, taken from the MoCA, is stricter than other CDT scoring methods in that it 
requires the hour hand to be clearly shorter than the minute hand. At baseline 
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only 39% participants got a point for the clock hands, rising to 46% at the 6-
month visit. Many clocks had to be re-scored since many researchers tended to 
score the hands as correct when they were the same length. While we did not 
calculate inter-rater reliability, it is likely for this component it would be low. 
Finally, verbal fluency and the CDT are also the only task components examining 
executive functioning, which could explain the higher sensitivity. 
To identify pre-stroke cognitive impairment, the 6-CIT and NINDS-CSN were the 
only CSIs to have both sensitivity and AUC ≥0.7. There were 26 participants with 
a pre-stroke diagnosis of MCI or dementia. Since the breakdown of dementia vs. 
MCI was not recorded in the CRF, I was unable to examine these groups 
separately. Using clinical diagnosis from the medical record as the choice of 
reference standard has limitations as it is not systematic; some individuals may 
not seek help and have undiagnosed cognitive impairment. 
The pattern of low sensitivity and high specificity found in this study mirrors 
previous research completed in stroke using the AMT-4, AMT-10, 4AT and CDT 
(267). The Cog-4 has previously been criticised due to having limited ability to 
detect cognitive impairment when compared to the MoCA (279). The Cog-4 had 
lower sensitivity in this study when compared to the OCS. Across other settings 
and purposes, the CSIs used in this chapter have a different test accuracy 
profile, for example the AMT-4, AMT-10 and 4AT have higher sensitivity to 
detect delirium (103), the 6-CIT, AMT-10 have higher sensitivity to identify 
dementia (271) and MCI (280). 
The rates of participants who were untestable were lower than Chapter 2. This 
is not surprising since participants entering research studies are often those with 
less disability compared to all patients admitted to a stroke unit. The rates of 
those untestable were similar across baseline and one month. As mentioned in 
Chapter 2, the 4AT is unique in the fact that it provides scoring for untestable 
patients, and for this reason has an advantage over other CSIs. The Cog-4 should 
in theory be similar, since it is scored from the NIHSS and there is guidance to 
score the NIHSS in patients with aphasia, comatose, intubated etc. 
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6.4.1 Strengths and Limitations  
Strengths of this work include a comparison of multiple CSIs and the use of a 
stroke specific CSI as reference standard. This study contributes to the limited 
literature of brief CSIs in a stroke population and is the first to provide 
psychometric data on the 6-CIT in stroke. This study is also unique to previous 
studies using brief CSIs as it provides longitudinal data across three timepoints. I 
followed best practice guidelines in the conduct and reporting of this study. 
In this study I used one set of questions to score the different CSIs, with the aim 
of reducing test burden for the participant. While this has a strength for 
feasibility in acute settings, it comes with limitations. As detailed in the 
previous chapter, there were some differences between the published version 
and the version used in this study for three CSIs: the 6-CIT, AMT-10 and NINDS-
CSN 5 min MoCA. The delayed recall component in two CSIs (name and address in 
6-CIT; address in AMT-10) was replaced by the 5 words used in the MoCA and it 
could be argued that the difficulty is not comparable. In addition, the NINDS-CSN 
5-min MoCA used in this study was 1-point lower as we did not ask participants 
the day of the week. 
No alternate versions of test items were used in this longitudinal study, so the 
same words were used for delayed recall at baseline, one and six months. I 
therefore should acknowledge the possibility of practice effects. There is no 
easy solution for this in longitudinal studies as while using alternate versions can 
attenuate practice effects, alternate forms may not be equivalent in difficulty 
(281). 
The research team took a pragmatic approach to assessment; however different 
assessors likely took different approaches if a patient had aphasia, limb 
weakness or hearing impairment, since the training materials did not provide 
specific instructions on how to approach assessment and scoring for those with 
impairments which would affect the assessment. With this being a multi-site 
study there were several different assessors. This is not necessarily a limitation 
since it mirrors clinical practice, but for future studies it is worth providing very 
specific examples for training purposes. To take the example of assessing a 
patient with severe hearing impairment, one may take the approach of other 
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studies and alter administration of items from verbal to visual (282) (e.g., 
presenting the words for delayed recall rather than reading them out), whereas 
another researcher may have recorded them as untestable. Both approaches are 
sensible, and the preferred approach should depend on the study objectives. 
Previous work has found that the modality of presentation of the MoCA (verbal 
vs. visual) does not affect overall performance but for the delayed recall item, 
those with visual presentation of the words scored higher (283). 
6.4.2 Implications 
Firstly, it is worth emphasising that the context of use for brief CSIs is routine, 
clinical use, rather than a clinical trial setting. All the CSIs demonstrated ceiling 
effects, meaning they are less sensitive to change and poorer at discriminating 
the milder end of the spectrum of cognitive impairment.   
The implications of these results for clinical practice depend on whether all 
patients testing ‘positive’ for cognitive impairment will be followed up, since 
the choice of CSI would therefore have an impact on resources. If CSIs are to be 
used as intended, for initial triaging, then those with high sensitivity are 
preferred. To detect pre-stroke cognitive impairment the NINDS-CSN 5-min MoCA 
and 6-CIT had some supportive evidence to be used for this purpose. For post-
stroke cognitive impairment, the NINDS-CSN 5-min MoCA and the CDT had 
supportive evidence to detect multi-domain CI (as detected by the OCS). When 
single domain cognitive impairment was included in the reference standard, 
performance was less optimal, so brief CSIs would not be recommended for this 
purpose. These results are based on the published recommended threshold 
scores, however in this sample, the thresholds recommended in the CSI 
development paper were not always the best threshold to optimise the AUC.  
In a CSI with high sensitivity, but lower specificity, a negative result can 
confidently rule out cognitive impairment. However, this comes at a cost of a 
greater number of false positives. Whereas CSIs with the opposite pattern, low 
sensitivity but high specificity, a positive result can confidently rule in cognitive 
impairment. This comes at a cost of a greater number of false negatives. 
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A way to illustrate this is to use a theoretical example. In a stroke unit admitting 
1000 patients, 260 would have persisting multi-domain cognitive impairment at 
one month (according to the OCS). Using the NINDS-CSN 5-min MoCA in the first 
week after a stroke (which has higher sensitivity than specificity), 224/260 
people would be correctly identified for having persisting impairment. However, 
392 people without persisting cognitive impairment would also screen positive 
and could receive additional unnecessary follow-up investigations. On the other 
hand, using the AMT-4, which has high specificity but low sensitivity, only 
42/260 would be correctly identified with cognitive impairment, but false 
positives would be reduced to 30.  
Another limitation to highlight regarding brief CSIs is that they do not adjust for 
years of education, however it has been argued that the 6-CIT is not sensitive to 
varying educational levels (284). 
6.4.3 Conclusion  
Using eight different CSIs resulted in varying proportions of participants being 
categorised as test positive for cognitive impairment. Most of these CSIs had low 
sensitivity, high specificity so would not be recommended for clinical use. The 
NINDS-CSN 5-min MoCA and the CDT however had some supportive data to detect 
both pre-stroke cognitive impairment and post-stroke multi-domain cognitive 
impairment. Considering accuracy in combination with completion rates, the 
NINDS-CSN 5-min MoCA had higher completion rates than the CDT, therefore out 
of the brief CSIs examined in this study, this would be the best option for the 




7 The Oxford Cognitive Screen (OCS): Feasibility, 
floor/ceiling effects and associations with later 
outcomes 
 
The previous chapters have focused on generic CSIs, however there is rationale 
to use a CSI which has been developed specifically for stroke, especially if the 
purpose is to detect cognitive impairments which are more common in this 
population, such as apraxia and visuospatial neglect. CSIs designed for other 
disease areas often do not account for physical or speech problems, therefore it 
is easy to lose points for these reasons and be classified as impaired. Chapter 2 
illustrated that limb weakness and speech impairment were the two main 
reasons for partially incomplete cognitive screens. Therefore, a CSI that takes 
these factors into account is favourable. 
In the previous chapter the brief CSIs demonstrated low sensitivity to identify 
cognitive impairment when compared to the OCS at one month. In this chapter I 
focus solely on the OCS and provide data on feasibility, floor/ceiling effects and 
prognostic ability. 
7.1 Introduction 
A running theme throughout this thesis is the purpose of post-stroke cognitive 
screening, bearing in mind that many CSIs were developed for different contexts 
of use. Results from screening can provide cross-sectional information but also 
potentially offer insight into a person’s future condition. If results can aid 
understanding of prognosis, clinicians can provide targeted support and better 
manage expectations for patients and their families. 
Thinking about prognosis, one should consider different timepoints after a stroke 
and the outcomes of interest. Prognosis of cognition itself is of interest since 
acute cognitive impairment after stroke can improve over time. Being able to 
differentiate between those who may not improve will help tailor/plan services 
accordingly. Beyond cognition, one may want to know whether results from early 
cognitive screening can predict other outcomes which are important to patients, 
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for example independence in activities of daily living (ADLs), mood and health 
related quality of life (HRQoL). 
It is well recognised that admission NIHSS is associated with later outcomes, with 
previous studies reporting associations with later morbidity, disability (285, 286) 
and function (287). The NIHSS however poorly represents cognition and therefore 
does not address the impact of early cognitive impairment. There has been 
increasing interest in examining whether early cognitive screening predicts later 
activities and participation. This topic was addressed in a systematic review 
which found  14 eligible studies (288). The CSIs varied between studies; a 
mixture of global dementia screens (MoCA, MMSE) and domain-specific tests 
(e.g., trail making test, line bisection test) were used within 6 weeks of stroke. 
A range of outcome measures were used, including the Barthel index (BI), 
Frenchay Activity Index (FAI), mRS and Functional Independence Measure (FIM) 
at 6-12 months. The authors concluded that the relationship of acute cognitive 
impairment and later functional impairment was more consistent when domain-
specific tests were used. One reason for this could be that CSIs like MoCA and 
MMSE, have poorer sensitivity to stroke specific impairments (68). Domain-
specific results found impairments in visuospatial abilities, visual memory, visual 
neglect and executive functioning independently associated with activities, but 
there were no high-quality studies addressing participation. This review 
highlighted gaps in the literature to be addressed in future research, such as use 
of a stroke-specific CSI, and controlling for important confounders, such as 
education, to reduce risk of bias. Additional studies have also been published on 
this topic more recently, with varying timepoints for baseline completion and 
later follow-up, for example one study completed the MoCA at 36-48hrs after 
stroke and found the results to be associated with functional dependence at 3 
months, defined by the mRS dichotomised at <3 (289). 
Although global CSIs have also demonstrated ability to predict later outcomes, 
without carrying out domain-specific tests, one is unable to determine which 
specific areas of cognition contribute towards later functioning and whether 
domains are differentially associated, since there are no normative data or 
threshold scores provided for individual tasks. No study to date has examined 
early assessment using the OCS or another stroke specific CSI to address later 
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functional, mood and QoL outcomes. Studies either have studied cognitive 
impairment as a unitary concept or focused on one specific impairment such as 
aphasia, neglect with later outcomes.  
As described in previous chapters, the OCS is becoming a popular choice for 
clinical use (53), yet it is yet to be used as an endpoint in an interventional 
clinical trial. Traditionally, cognitive screening has only given an aggregate total 
score. The OCS however does not take this approach; it was purposefully 
designed to avoid an overall pass/fail, with threshold scores provided for each 
task. Researchers and trial methodologists would therefore benefit from 
guidance on ways to best utilise the data from this screen and have data to 
justify analysis plans. I will compare domain-specific results vs. a single global 
score to assess the utility of this approach.  
The primary aim was to examine associations between OCS individual cognitive 
domains and OCS global score at one-month post-stroke with cognitive, 
functional, mood and QoL outcomes at 6 months. Secondary aims were to 
provide details on completion rates and floor/ceiling effects of the OCS. 
7.2 Methods 
This study used data from the APPLE study: an observational, longitudinal cohort 
study described in Chapter 5. For this study I used data collected in the study at 
baseline, one month and six-month time-points. 
7.2.1 Cognition 
At the one-month follow-up in the APPLE study, the OCS (66) was completed 
face-to-face. A two-week window either side of the one-month date was 
permitted, so data were collected up to 6 weeks following study entry. Study 
entry however was not the same as stroke onset.  
The OCS provides domain-specific data across five broad cognitive domains: 
memory, attention, language, number processing and praxis. Within each 
domain are subtests which have individual threshold scores to determine 
impairment (66) (thresholds provided in the previous chapter). Based on this a 
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visual snapshot of the patient’s strengths and weaknesses can be provided 
(Figure 7-1). A full description of the scale is given in Chapter 1. 
I split the attention domain into its two subdomains (spatial attention and 
executive functioning) based on previous literature addressing these domains 
separately. I categorised participants as impaired across each of the six 
cognitive domains, if they scored below the recommended threshold score in any 
of the 12 subtests detailed in the inner circle in Figure 7-1. A global OCS score 
was also calculated for all participants who had completed at least 1 subtest, 
based on the number of domains impaired (range 0-6). While the OCS was not 
designed to make an overall ‘global’ categorisation of impairment, the scale’s 
authors have used a global score in previous publications (290) and advise on 
their website that being impaired in at least one task would be outside of the 
population norm. 
 
7.2.2 Six-month outcome measures 
At six months, outcomes were chosen to reflect different aspects of stroke 
recovery. These data were collected either face-to-face or over the telephone. 
A generic HRQoL measure was used: the EQ-5D 3-level (259). The index scores 
range from -0.594 to 1 (higher scores reflecting better QoL).  
Figure 7-1 OCS domains and tasks 
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The Center for Epidemiologic Studies Depression Scale Revised (CESD-R) (262) 
was used to measure symptoms of depression (score range 0-80; higher scores 
indicate more depressive symptoms). The Barthel index (BI) (247) was used to 
measure independence in basic ADLs (score range 0-20; higher scores indicate 
greater independence). The Lawton scale was used to measure independence in 
instrumental ADLs (score range 0-14; higher scores indicate greater 
independence). The mRS was used to measure global disability (score range 0-6; 
higher scores indicate greater disability).  
The BI, Lawton, and CESD-R scales were usually completed directly by the 
participant, whereas the mRS and OCS were administered and scored by the 
researcher. The BI, Lawton and EQ-5D were also completed by a family 
member/informant, where available, and these data were used in this study 
where patient self-report data were not available. All outcome measures, apart 
from the mRS, were not developed for the stroke setting (they are disease-
generic scales). Full descriptions of all measures are available in Chapter 5.  
For participants where the 6-month follow-up was not completed but had died 
by the time of the 12-month follow-up, a score of 5 was assigned for the mRS to 
reflect deteriorating health. No other assumptions were made.  
7.2.3 Analysis 
As detailed in the previous chapter, at the time of writing this chapter, the 
database was not locked for the APPLE study, therefore results may differ from 
subsequent publications.  
7.2.3.1  Completion rates, floor/ceiling effects, errors 
Consistent with previous chapters, I examined the rates of item-level and scale-
level missing data (completion rates) across the full data set and recorded the 
reasons for incompletion or untestable. 
I calculated the percentage of participants scoring the lowest score (0) or full 
marks (floor and ceiling effects) for each OCS item. The OCS does not have one 
overall total score range, so scale level floor/ceiling effects were calculated by 
the number of participants scoring the lowest/highest possible score across all 
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12 tasks. A criterion of >15% was applied to determine if floor/ceiling effects 
were present (116).  
I checked the case report forms from other hospital sites and checked the 
scoring of tasks which could be scored retrospectively (e.g., broken hearts, 
trails). In addition, I recorded other errors in OCS administration/scoring which 
were identified based on queries from the research nurses.  
7.2.3.2  Associations with 6-month outcomes  
Dealing with untestable data and time since stroke 
For models including each of the six cognitive domains, all missing (incomplete 
and untestable) data were excluded, since this would prevent interpretation of 
specific cognitive impairments. For models including a global OCS score, 
participants who were partially untestable were included (score reflected tasks 
completed); those who were fully untestable were excluded. Any data collected 
more than 7 weeks post stroke were excluded from regression analyses, to 
ensure that the heterogeneity in time from stroke to OCS assessment was 
minimised. A time window of 6 weeks is often used in the literature (288). In this 
study the choice of 7 weeks was a compromise between minimising 
heterogeneity but maximising the participants that could be included in the 
analysis. Due to a small sample size, I could not restrict the time window 
further. 
I summarised descriptive statistics for the demographic and clinical 
characteristics of the sample; variables with normally distributed data are 
summarised by mean and standard deviation, whereas skewed data were 
summarised by median and interquartile range (IQR). 
I compared the participants with 6-month follow-up data to those without on a 
range of demographic and clinical variables. Group comparisons were made 
using Pearson’s chi2 (categorical data), independent t test (continuous variables) 




Based on previous literature (7, 288, 291, 292) I identified variables that could 
act as confounders: Age at time of study entry; Sex; Years in education; Stroke 
severity measured using the NIHSS on admission (score range 0-42); Pre-stroke 
disability measured using the mRS (score range 0-5; 0 indicating no symptoms 
and 5 indicating severe disability). Full description of the NIHSS and mRS can be 
found in Chapter 2.  
The NIHSS scores had a positive skew so were placed into five categories, as 
defined by the following score ranges: 0, 1-4, 5-15, 16-20, 21-42 and treated as 
ordinal. This is an approach used in other studies (293). Years in education had a 
positive skew and was transformed with a natural log transform (‘LN’). Pre-
morbid mRS had a positive skew and was dichotomised using >1 to define 
disability (294).  
Outcomes 
I conducted a series of regression models to investigate the associations of 
impairments in memory, language, praxis, number processing, spatial attention, 
executive functioning, or a global OCS score, with a range of stroke outcomes 
(each cognitive domain or global score were examined in a separate model).  
For the 6-month outcome variables, the mRS, EQ-5D TTO and CESD-R data were 
treated as continuous. The CESD-R data were positively skewed and transformed 
with a natural log transformation. As 0 is a possible score on the CESD-R, I 
preceded the transformation by adding a value of 1 to all participant’s scores. 
The BI and Lawton scores were negatively skewed, and the normal probability 
plots indicated that the residuals were not normally distributed (an assumption 
of linear regression). Data transformations did not improve the distributions, so 
the BI and Lawton IADL were dichotomised at <20 and <14, respectively. These 
threshold scores were chosen to capture any level of disability in ADLs. 
Linear regression was therefore used for three outcomes (mRS, EQ-5D, CESD-R) 
and logistic regression for two outcomes (BI and Lawton ADL). I first ran 
univariate/unadjusted models which did not control for any potential 
confounders. I then ran multivariate/adjusted models including the five 
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covariates mentioned above. For linear regression I checked normality of 
residuals (normal probability plots are provided in Appendix 16) and 
multicollinearity of continuous variables (lack of multicollinearity indicated by 
variance inflation factor <2). To describe the associations with the mRS, EQ-5D, 
CESD-R I used standardised betas. For associations with the BI and Lawton, I 
reported odds ratios (ORs). 
Sample size calculation 
I used G-Power, version 3.1 to inform a sample size calculation for multiple 
linear regression. This calculation was performed after the APPLE study had 
started but before this sub-study data analysis was performed. Based on 
inclusion of 6 independent variables, a moderate effect size of F2= 0.15, power 
of 0.95 and a statistical significance level of 0.05, I required a sample size of 146 
participants. For logistic regression sample size, I used the rule of 10 outcome 
events per covariate. To include 6 covariates, I therefore required 60 cases. 
I conducted all statistical analyses using IBM SPSS version 26 (NY: IMB Corp). For 
primary analyses, I used a significance level of 5%. As a sensitivity analysis, I 
applied a Bonferroni correction, to account for multiple testing and the 
increased risk of a Type 1 error, accepting differences as significant at p<0.007.  
7.3 Results  
Administration of the OCS was attempted in 268 participants at a mean of 42.3 
(SD 19.5) days post-stroke. Of those that had completed one-month, six-month 
follow-up data for at least one outcome variable were available for N=202. For 
those participants without follow-up data, 66 (25%) were either lost to follow-up 




Figure 7-2 Consort flow diagram 
 
7.3.1 Completion rates, floor/ceiling effects, errors 
A breakdown of data completeness, floor and ceiling effects for each task are 
provided in Table 7-1. Data completeness was good for all items (>90%). The 
heart cancellation test had the lowest completion (93%) and orientation, picture 
naming and semantics had the highest completion (96%). On an item level, floor 
effects were low across all tasks (all ≤2%). Ceiling effects were lowest for broken 
hearts (17%) and highest for the semantic task (98%). On a scale level there was 
no evidence of a floor or ceiling effect.   
OCS attempted (N=268) 
• Completed >49 days 
post-stroke (N=49) 
• Fully untestable 
(N=10) 





6-month short or 





Table 7-1 Completeness, floor/ceiling effects of OCS tasks (N=268) 








Orientation (0-4) 258 (96%) 1 (<1%) 240 (93%) 
Recall & 
recognition (0-3) 
255 (95%) 1 (<1%) 185 (73%) 
Episodic 
recognition (0-4) 





258 (96%) 2 (1%) 173 (67%) 
Semantics (0-4) 258 (96%) 1 (<1%) 253 (98%) 
Sentence reading 
(0-15) 
257 (96%) 2 (1%) 195 (76%) 
Number Number writing 
(0-3) 
256 (96%) 5 (2%) 217 (85%) 





248 (93%) 0 (0%) 42 (17%) 
Praxis Gesture imitation 
(0-12) 





251 (94%) 5 (2%) 207 (82%) 
Trails (triangles) 
(0-6) 
251 (94%) 2 (1%) 216 (86%) 
Trails (mixed) (0-
13) 
251 (94%) 5 (2%) 139 (55%) 
Full test - 245 (91%) 0 (0%) 15 (6%) 
 
Overall, there were missing OCS data (partially and fully) for 23 (9%) participants 
(Table 7-2). Ten participants (4%) were fully untestable; 9 (3%) were untestable 
on the full test due to stroke-related impairments or reduced consciousness, and 
one (<1%) declined the full test. Thirteen participants (5%) were partially 
untestable; 8 (3%) due to stroke-related impairments, 2 (1%) declined certain 
items and 3 (1%) participants had incomplete data due to positioning of the 




Table 7-2 Incomplete OCS tasks with reasons (N=23) 
Participant OCS task Reason given by researcher for 
missing data 
1 Heart Cancellation Motor problem 
2 Full test Aphasia 
3 Heart Cancellation Unable to understand tasks 
Trails 
4 Full test Confused 
5 Sentence reading Aphasia and poor understanding 
 
Writing numbers & calculation 
Heart Cancellation 
Recall & recognition, episodic 
recognition 
Trails 
6 Heart cancellation Language barrier – could not 
understand Recall & recognition, episodic 
recognition 
Mixed trails 
7 Trails Confused 
8 Full test Aphasia 
9 Heart cancellation Visual problem 
10 Heart cancellation Too tired to complete test 
Gesture imitation 
Recall & recognition, episodic 
recognition 
Trails 
11 Full test Medically unwell 
12 Trails Declined, said it was too difficult 
13 Heart cancellation Lying flat 
Trails 
14 Full test Drowsy 




16 Full test Mix of aphasia, tired and motor 
problems 
17 Full test Pre-existing cognitive 
impairment and at limit 
18 Trails (circles and triangle) Missed by researcher 
19 Full test Medically unwell 
20 Full test Medically unwell 
21 Heart Cancellation Page printing error* 
22 Full test Declined 
23 Number Declined 
Heart cancellation 
* heart cancellation page did not print out landscape 
In addition to missing data, there were cases of administration/scoring errors 
where data were available. Items were re-scored for tasks which could be scored 
retrospectively. Other errors in administration which were identified but not 
linked to a specific patient are also documented in Table 7-3. Additional training 
materials clarifying these items were provided to the sites (Appendix 15).  
Table 7-3 Errors identified in administration and scoring of OCS 
OCS item Error or query type Action 
Orientation Not showing multiple choice 
options following an incorrect 
response 
None 
Gesture imitation Scoring of finger positions  None 
Trails  Scoring errors Re-scored 
Mixed task - started at circle 
rather than triangle 
None 
Broken hearts Grid lines drawn onto paper None 
Page printed smaller None 
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Incorrect totals Re-scored 
Delayed recall Scoring of free recall and 
recognition combined – scored 
out of 8 rather than 4 
Re-scored 
 
Across the domains assessed by the OCS, impairments in spatial attention were 
most common (N=65/248; 26%), while impairments in praxis were least common 
(N=20/257; 8%). The percentages of those classified impaired in each domain 
(both excluding untestable participants and including them as impaired) are 
provided in Figure 7-3. 
 
Figure 7-3 Percentage of patients impaired in each cognitive domain   
 
There were 140 (54%) participants who were impaired in at least one cognitive 
domain. There were 65 participants (26%) with multi-domain cognitive 























Figure 7-4 Percentage of participants with each global OCS score (excluding untestable 
participants) (N=258) 
 
7.3.2 Associations with 6-month outcomes 
Restricting OCS assessment to within seven weeks of stroke onset excluded 49 
participants from analysis. In total, there were 164 participants that received an 
OCS assessment within this timeframe (mean: 37.8 days, SD 5.6, range 18-49 
days), and had data for at least one 6-month outcome, which were included in 
regression analyses. 
The 55 participants without 6-month follow-up data did not differ from those 
with follow-up data with regards to age, sex, NIHSS, years in education, pre-
morbid mRS, previous stroke, impairment in executive functioning, spatial 
attention, and praxis. However, a greater proportion of those without follow-up 
data had a history of dementia/cognitive impairment and were impaired across 
the domains of memory, language, and number processing (Table 7-4). Using a 
threshold score of <20 on the BI, 41 participants were classified as impaired in 
basic ADLs. Using a threshold score of <14 on the Lawton, 62 participants were 
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Abbreviations: IQR, interquartile range; MCI, mild cognitive impairment; mRS, modified Rankin 




HRQoL (EQ-5D TTO) 
In unadjusted models, impairments in spatial attention, executive functioning 
and global OCS score were significantly associated with lower EQ-5D scores 
(Table 7-5). In adjusted models, executive dysfunction was the only type of 
cognitive impairment that was independently associated with lower EQ-5D 
(standardised beta = -0.21 (95% CI: -0.41 to 0.07); this was significant at p<0.007 
(Table 7-6). 
Depressive symptoms (log CESD-R) 
In unadjusted models, praxis impairment was significantly associated with lower 
scores on the CESD-R (Table 7-5). In adjusted models, no cognitive data were 
independently associated with symptoms of depression (Table 7-6). 
Global disability (mRS) 
In unadjusted models, impairments in number processing, language and global 
OCS score were significantly associated with higher 6-month mRS (Table 7-5). In 
adjusted models, impairment in number processing was the only type of 
cognitive impairment that was independently associated with a higher 6-month 
mRS (standardised beta = 0.15 (95% CI: 0.03 to 1.25); this was significant at 
p<0.05 but not at p<0.007 (Table 7-6). 
Independence in Basic ADLs (BI) 
In unadjusted models, impairments in spatial attention, executive functioning, 
number processing and global OCS were significantly associated with impairment 
on the BI (Table 7-5). In adjusted models, no cognitive data were independently 
associated (Table 7-6). 
Independence in instrumental ADLs (Lawton) 
In unadjusted and adjusted models, no cognitive domains were significantly 
associated with impairment on the Lawton (Tables 7-5 and 7-6).   
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Table 7-5 Unadjusted models: Associations between cognitive domains and six-month 
outcomes 
 Six-month outcomes 
Log CESD-R EQ-5D mRS Barthel Lawton 
Standardised beta (95% CI) Odds ratio (95% CI) 


















































N=149 N=155 N=161 N=112 N=112 










N=149 N=155 N=161 N=112 N=112 










N=149 N=155 N=160 N=112 N=112 










N=149 N=155 N=161 N=112 N=112 
*p<0.05; **p<0.007. Abbreviations: CESD-R, Center for Epidemiologic Studies Depression 




Table 7-6 Adjusted models: Associations between cognitive domains and six-month outcomes 
 Six-month outcomes 
Log CESD-R EQ-5D mRS Barthel Lawton 






























































































N=134 N=139 N=144 N=104 N=104 
All models included age (years), sex, NIHSS , pre-morbid mRS (dichotomised) and years 





There were 12 participants with executive functioning impairment included in 
regression analyses. The executive function score is calculated using three trails 
tasks: two simple (circles, triangles) and one complex (mixed). In these 12 
participants, the median scores on the first two trails tasks were 6/6 (range 5-6 
on circles, 4-6 on triangles), and on the mixed task 3/13 (range 0-7). The median 
executive score was 8.5 (range 5-12). 
There were 15 participants with number processing impairment included in 
regression analyses. There are two tasks in this domain: number writing and 
calculations. All participants were impaired on the number writing task. There 
were different types of errors for this task (Figure 7-5). The main error type 
(73%) was adding extra zeros, for example ‘1500200’ instead of ‘15,200’. One 
participant was impaired on the calculation task. 
 
Figure 7-5 Number encoding errors of participants with 6-month f/u (N=15) 
 
7.4 Discussion 
The OCS had good completion rates and no scale level floor/ceiling effects. Most 
OCS domains were associated with at least one outcome at six months in 
unadjusted models, but only two domains remained significant when controlling 
for potential confounders; number processing impairment was associated with 








Number separated into two
"700 and 8 instead of 708"
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reduced QoL on the EQ-5D. However, the magnitude of association was modest 
and only executive dysfunction remained significant when adjusting for multiple 
testing. No independent associations were found using the OCS global score. 
Early executive dysfunction has previously been found to be independently 
associated with various later outcomes, including HR-QoL as found in this study 
(288). In one study executive functioning was evaluated using six different tests 
as part of a NPB within the first three weeks post-stroke, followed up with a 
stroke specific QoL scale (14). In another study, an independent association was 
found between the trail making test (TMT) part B at 72 days post-stroke and QoL 
at 10 months, as assessed by the sickness impact profile (295). I used the EQ-5D, 
which covers the following areas: walking, self-care, usual activities, 
pain/discomfort, anxiety/depression. It therefore covers a wide range of 
concepts, some of which may be more affected by impairments in executive 
functioning than others. Previous research has also found associations of 
executive dysfunction with the Barthel index (7) and depression (14) which were 
not replicated in this study, although the EQ-5D captures both functional and 
mood aspects. 
While previous research has found associations with other types of cognitive 
impairment with later outcomes, number processing impairments have not been 
amongst these findings. This impairment was found to be associated with greater 
disability as measured by the mRS. To explore this result, I examined the types 
of errors made by participants. Transcoding zeros were the most common 
number processing error for this task, as previously reported in another study 
(296). In this study the researchers hypothesised that zero takes a special role in 
the process of number transcoding, which requires a higher cognitive load and 
attentional demand. This could therefore reflect an impairment in complex 
attention, consistent with previous findings of attentional disorders being 
associated with later function and participation (13, 288, 297). Since cognitive 
screening tasks involve a number of processes, there is an argument that domain 
‘purity’ does not exist, which can mean that some apparently different results 
could in fact involve the same processes. This association however could also 
have been due to a type 1 error since it was not significant when a Bonferroni 
correction was applied. 
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Over half of the sample (54%) were impaired in at least one OCS domain which is 
lower than the incidence found in previous studies using the OCS; one study 
reported 86% (274) and another 92% (91). Across the different OCS cognitive 
domains, spatial neglect was the most common type of cognitive impairment in 
this sample. Previous research has also found the OCS attention domain to be 
commonly impaired (274, 290). The number of tasks within each domain in the 
OCS differs, for example there are three subtests for language and only one for 
praxis, therefore it could be argued that it is easier to be classified as impaired 
in a domain which has a greater number of tasks. This matches my data, since 
only 8% were impaired on praxis. 
Most OCS domains at one-month post-stroke were not independently associated 
with the range of outcomes selected in this study. This analysis was of a 
predictive nature rather than cross-sectional. Results should therefore not be 
interpreted to mean that cognitive impairment does not affect these areas of 
one’s life. These results may illustrate that domain-specific impairments had 
improved by the time of the 6-month follow-up. 
Considering these results in context with previous findings raises the following 
areas of discussion in terms of reproducibility of findings: which cognitive 
screens and outcome measures are used, the timing of assessment post-stroke 
and differing ways of data management/analysis. Different studies have included 
both different CSIs and outcome measures and therefore may not be 
comparable. Results are likely to be specific to the measures used, therefore, 
although evidence was not found for impairments in certain domains, this does 
not mean that they are not associated with later functional abilities. In terms of 
previous studies which found associations of impaired MoCA/MMSE with later 
outcomes (289, 298, 299), there is evidence that patients with aphasia (274, 
300) and limb weakness can perform poorer on these tests, so it may not 
necessarily be cognitive impairment driving these associations. 
Previous studies use the term ‘early’ cognitive impairment, but how early is 
early? While I restricted analyses to data collected within seven weeks, this is 
still a considerably wide range, considering that the prevalence of cognitive 
impairment will be highest early on after a stroke (7, 20, 301). My sample size 
however prevented me restricting this time window further. Some previous 
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studies completed the CSI within the first few days after stroke (302) which 
could reflect the differences in findings. To compare this with research 
concerning the NIHSS predicting later outcomes (285, 286, 303), data is usually 
taken from admission, when the score is at its highest. 
Finally, differing results across the literature may be due to differing methods of 
analysing data. Different studies treat the same outcomes as continuous, 
ordinal, or binary and results could differ because of this. Dichotomising 
continuous data is not recommended, however this is usually only applied when 
dealing with a skewed distribution, such as in this study.   
7.4.1 Strengths and weaknesses 
Strengths of this work include using a stroke-specific CSI and controlling for 
important confounding variables recommended by previous work (288). Having 
informants participate in the study enabled us to obtain outcome data for 
participants who were unwell. 
Limitations of this work include a limited sample size and not having follow-up 
data for all patients. The data available for the two outcomes (BI and Lawton) 
were particularly underpowered as reflected in the wide CI’s. Lost to follow-up 
or declining follow-up could be due to various reasons, for example it could 
reflect greater disability, or it could reflect no disability as participants are back 
at work/too busy to take part. I had knowledge that some participants without 
6-month follow-up data had poor health outcomes, including being admitted to a 
care home, significant health deterioration or hospitalised. However, with this 
information alone, I was unable to infer scores on outcome measures. 
Participants without follow-up data also included a greater number of people 
who were impaired across three cognitive domains.  
Finally, although APPLE was an all-inclusive study, the sample included in this 
chapter generally consisted of participants with mild strokes and I also included 
those with a TIA diagnosis, therefore these results are not necessarily 
representative of patients with severe strokes and functional impairment. When 




Results.aspx), the median NIHSS was two points lower. Results may differ if 
future samples include participants with severe strokes, since they are at a 
heightened risk of cognitive impairment. However, as demonstrated in chapter 
2, participants with a higher NIHSS are also more likely to be untestable on CSIs. 
7.4.2 Implications 
There was insufficient evidence of results from the OCS at one month being 
associated with a range of patient outcomes at six months, but some evidence 
that executive dysfunction was independently associated with reduced QoL. 
Further studies are necessary to understand the prognostic ability of the OCS. 
The OCS had strengths when compared to the other CSIs covered in this thesis. 
The OCS firstly did not demonstrate floor/ceiling effects. Another strength of 
using a domain-specific CSI rather than a global one is that data from partially 
incomplete assessments, can be included rather than excluding the participant 
entirely, since there are cut-off scores for individual questions. 
Weaknesses of the OCS are that more resources and training are required. In 
terms of materials needed to administer, each participant requires a 14-page 
document, along with a 30-page test booklet which can be re-used. More 
administration/scoring error types were observed for this screen, in comparison 
to the brief CSIs and completion rates were no better than the brief CSIs 
described in the previous chapter. 
7.4.3 Conclusion  
The OCS performed well in terms of completion rates and floor/ceiling effects. 
When completed one-month post-stroke it had limited prognostic utility for a 
range of functional and mood outcomes at six months, when controlling for 
confounders and adjusting for multiple testing; only executive dysfunction was 
associated with reduced QoL. Further studies are required to understand the 




8.1 General overview 
Cognitive screening after a stroke is recommended by clinical guidelines, 
specialist societies and as part of national audit programs. However, due to 
vague recommendations, different cognitive syndromes and differing opinions 
regarding CSI choice and timing, a range of CSIs are being used in clinical 
practice and research. For clinical use, the decision is left to the individual 
clinical team and with hundreds of CSIs available, stroke-specific and generic, 
there can be uncertainty in deciding which CSI is fit for purpose. 
In this thesis I undertook a series of studies to provide empirical data to 
contribute to our understanding of the performance of CSIs at varying timepoints 
after stroke. I focused on feasibility, accuracy, floor/ceiling effects and 
prognostic ability of a range of different CSIs. 
Understanding psychometric properties of CSIs is essential to provide the 
foundation for many other areas of research into cognition. Without knowing 
these properties, results cannot be fully interpreted and their ability to work as 
clinical outcome assessments (COAs) is limited. These methodological 
considerations are important since limitations with CSIs can result in misleading 
or incorrect conclusions. For example, in clinical practice, cases of cognitive 
impairment may be missed and in research an interventional clinical trial could 
fail to meet its endpoint based on the CSI chosen, rather than lack of treatment 
efficacy, or a longitudinal study may find limited change over time due to the 
CSI lacking responsiveness. 
8.2 Summary of key findings 
A summary of the thesis objectives and key findings are provided in Table 8-1. 
Chapter 2 provided valuable insight into completion rates of CSIs in a real-world 
setting, with a quarter of patients being untestable for varying reasons. Across 
the individual items, the CDT had the lowest completion rate, whereas age had 
the highest. Across the different named CSIs, the Abbreviated MoCA, Mini-Cog 
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and GP-COG had the lowest completion, whereas there was no missing data for 
the 4AT, due to scoring options for those who are untestable. In the context of 
acute stroke, incomplete assessments and missing data are common, although 
the reasons are not always reported in research studies, since these participants 
are often excluded. In addition to stroke related impairments, older adults can 
have other comorbidities or hearing/visual impairments which can impact 
administration and interpretation of a CSI. 
In Chapter 3, through undertaking a systematic review, I identified 13 shortened 
versions of the MoCA. I reviewed the accuracy of the SF-MoCAs in the published 
literature to identify varying cognitive syndromes and then validated the SF-
MoCA versions in two independent data sets. Across the published literature and 
in the external validation, the performance of the short forms varied but 
demonstrated high sensitivity to detect multi-domain cognitive impairment, 
according to different reference standards. 
In Chapter 4, I carried out another test accuracy systematic review; this time 
focusing on multi-domain telephone-based CSIs to identify MCI or dementia. 
Across 34 studies, I identified 15 CSIs, but only four of these CSIs were used in 
participants post-stroke (TICS, TICS-m, T-MoCA, T-MoCA short). Of the limited 
data available in stroke, the telephone CSIs demonstrated high sensitivity to 
detect multi-domain cognitive impairment, but more work should be undertaken 
before they can be recommended for clinical use. In non-stroke settings, the 
TICS and TICS-m had the greatest supportive evidence base to screen for 
dementia. 
In Chapter 5, I described the methods and conduct of a prospective multi-centre 
post-stroke cohort study of cognition: APPLE. This study had a more inclusive 
inclusion criteria than other stroke cohorts, with the intention to include groups 
often excluded from research (e.g., those with aphasia and pre-existing 
cognitive impairment). The methods outlined in this chapter relate to Chapters 6 
and 7. 
In Chapter 6, I evaluated the use of brief CSIs in stroke. I examined completion 
rates, floor/ceiling effects and accuracy to detect both pre- and post-stroke 
cognitive impairment. Completion rates were higher than Chapter 2 (all >90%). 
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Three tests (AMT-4, Cog-4, 4AT) exhibited high ceiling effects. The pattern of 
accuracy for pre- and post-stroke cognitive syndromes was generally high 
specificity, low sensitivity, apart from the CDT and NINDS-CSN 5-min MoCA which 
had the opposite pattern. The two SF-MoCAs used in this chapter demonstrated 
lower sensitivity than the work completed in Chapter 3, likely due to the choice 
of reference standard (OCS). 
In Chapter 7, I investigated whether domain-specific results from the OCS 
completed at one month after stroke admission were associated with patient 
outcomes at six months. I also provided data on OCS completion rates, and 
floor/ceiling effects. In unadjusted models, all domains apart from memory 
were significantly associated with at least one outcome. However, when 
controlling for confounding variables (such as age, education, pre-stroke 
disability and stroke severity), and adjusting for multiple testing, only one 
domain remained significant with one outcome: executive dysfunction had a 
modest association with reduced quality of life (EQ-5D). The OCS had good 
completion rates, but fewer participants fully completed it in comparison to the 
brief CSIs and there were more types of administrator errors. There were no 
issues of floor/ceiling effects. 
8.3 Limitations 
Limitations of each chapter have been discussed throughout the thesis. In 
addition to those already detailed, there are some broader limitations to take 
into account. 
Across all chapters with prospective data collection (chapters 2, 6 and 7), most 
of the participants were recruited from Glasgow. Therefore, it is important to 
take into account that the samples included in these studies are not necessarily 
representative of all patients post-stroke, for example with regards to 
socioeconomic status (304). 
Another important limitation and broader discussion point concerns the choice of 
reference standard in diagnostic test accuracy of CSIs, seeing as there is no 
consensus on a gold standard for assessing cognition. For example, if dementia is 
the cognitive syndrome of interest, clinical diagnosis would be considered the 
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gold standard. However, there are different diagnostic criteria available, which 
may result in different outcomes (305, 306). 
8.4 Implications for clinical practice and research 
8.4.1 Choice of CSI 
First and foremost, purpose must drive CSI choice and there are various purposes 
of post-stroke cognitive screening. There is no perfect CSI; each have different 
strengths and limitations. These trade-offs need to be weighed up within the 
specific context of use before recommendations are made. To choose 
appropriately, one should define the specific purpose of screening at a particular 
point of time, including the cognitive syndrome of interest and what action will 
be taken based on the results. Differences in opinion regarding CSI choice are 
generally down to viewing the purpose of screening, especially at an early-stage 
post-stroke, through different paradigms, e.g., triaging for those at risk of 
dementia vs. wanting to detect milder cognitive impairment that reveal more 
about a person at that particular point in time. 
Screening should not be undertaken purely to satisfy guidelines/local protocols, 
without any plans to act on the results. In the absence of evidence-based 
treatments for post stroke cognitive issues, other actions could include 
communicating the results back to the patient and MDT, informing other 
rehabilitation areas (physiotherapy, speech and language therapy, occupational 
therapy) and making plans for follow-up and relevant support. I recognise that 
recommendations for CSI choice need to be pragmatic, bearing in mind that 
resources are quite different across hospitals; CSI recommendation cannot be 
universal for all hospitals and all patients. Results from all CSIs applied in acute 
stroke settings should be interpreted in the context of potential pre-stroke 
cognitive impairment, delirium, depression, and aphasia. 
Based on the work completed in this thesis, completion rates vary across 
different CSIs. If you were choosing a CSI based on this aspect alone, you would 
choose one which incorporates a scoring option for being untestable, such as the 
4AT. Stroke-specific CSIs do not necessarily result in higher completion in 
comparison to brief generic CSIs; at the one-month follow-up in the APPLE study, 
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all CSIs had good full completion rates, but the OCS had the lowest (91%) and the 
4AT had the highest (100%). However, it should be noted that the OCS was 
administered after the AMT-plus. A strength of having cut-off scores for each 
task (like in the OCS) is that in the scenario of a partially incomplete 
assessment, you can score and interpret the other complete tasks. This is unlike 
most other CSIs which use sum scores, and normative data is not available for 
subtasks. As the reasons vary widely for incompletion (stroke related and non-
stroke factors), you may choose a CSI to address one aspect of non-completion 
(e.g., use of non-verbal tasks for those with aphasia) but it may not address 
other areas (e.g., writing tasks for those with limb weakness). Of note in this 
thesis, drawing tasks such as the CDT, trails, broken hearts, had lower 
completion rates and there were cases of examiner errors in scoring, therefore 
they can be problematic for both patients and those administering the CSI. 
Test completion is just one aspect to consider with regards to CSI choice. 
Another important aspect is validity. If MCI or dementia are present prior to the 
index stroke, the NINDS-CSN 5-min MoCA, CDT and 6-CIT carried out after the 
stroke had the highest sensitivity to identify it. Many of the brief CSIs examined 
in this thesis could not be recommended for clinical practice for the purpose of 
identifying post-stroke single or multi-domain cognitive impairment (as defined 
by the OCS) due to low sensitivity. High sensitivity is preferred in acute 
screening, as tests are often used to identify those patients who require more 
detailed assessment and a CSI with low sensitivity will miss many patients who 
have cognitive impairment. The NINDS-CSN 5-min MoCA and the CDT were the 
only two CSIs to have high sensitivity (above 0.8); these could be used as an 
initial screen for multi-domain cognitive impairment and followed up with a 
more detailed assessment at a later timepoint. Many of the brief CSIs exhibited 
high ceiling effects, which indicates they would have poor responsiveness if 
serial assessment is planned. 
CSI choice would differ for other screening purposes. To identify delirium post-
stroke, the 4AT has a different pattern of accuracy (very high sensitivity) (307), 
which is not surprising, since this is the syndrome it was developed for. Likewise, 
to detect milder single-domain impairments, CSI choice would differ. Stroke-
specific instruments, such as the OCS, are particularly advantageous to identify 
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cognitive syndromes more prevalent in this population, for example neglect and 
apraxia. For clinical use, there are a number of benefits of having more detailed 
domain-specific information as opposed to CSIs which provide one overall score. 
I would argue the results are more beneficial to the therapy team (as opposed to 
medical) to ascertain the nature of cognitive impairment, to consider the impact 
of the specific cognitive profile on various aspects of one’s life and to provide 
targeted rehabilitation. If we do not identify and recognise specific types of 
cognitive impairment, we cannot manage them. Domain-specific measures are 
also valuable to examine at trajectories since impairments in different domains 
can progress differently (301). In terms of prognostic ability beyond cognition, 
the results from Chapter 7 suggested that when completed at one month, results 
from the OCS provided limited prognostic information for later functional 
abilities/disability, when variables such as age, education, stroke severity and 
previous disability were controlled for. 
In light of the recent pandemic, CSIs which can be administered remotely are 
required. Based on the review I undertook in Chapter 4, telephone-based CSIs, 
such as T-MoCA and TICS, are an alternative to screen for multi-domain cognitive 
impairment but would not be appropriate to identify single-domain or milder 
forms of cognitive impairment. They have limitations as visuospatial abilities 
cannot be assessed and they are likely an inappropriate format for those with 
aphasia. Video-based options may address some of these limitations, but more 
research is needed so we understand the feasibility and validity of this 
approach. 
Finally, there are additional aspects not covered in this thesis that also 
contribute to the choice of CSI. These include cost/copyright restrictions, 
availability of alternate versions and cross-cultural translations. Digital CSIs are 
also alternatives to traditional pencil and paper CSIs. Automated scoring and 
reporting will likely improve acceptability for clinicians and improve 
standardisation (308), since we know that there can be subjectivity with scoring 
and they also allow for results to be available in real time. Having a record of 




CSIs are carried out by healthcare professionals and researchers from different 
specialities, with differing training and experience. While instruction materials 
exist for CSIs, administration and scoring errors occur frequently. Training is 
essential for use of CSIs and should not be underestimated or overlooked. In the 
scenario where CSIs are not regularly used, refresher training should be 
undertaken. Recent studies carried out with OTs working in stroke services, also 
highlighted the importance of training in this area (53, 309). 
In APPLE we had unique insight into how research teams are completing CSIs. 
Case report forms and the anonymised OCS patient pack were sent directly to 
the host clinical site for quality checking before being sent to the biostatistics 
centre for data input. While having an independent biostatistics centre has many 
strengths, it is important to remember that they will not identify scoring errors, 
unless they happen to be out of range. In non-commercial, observational studies, 
data monitoring (including source data verification) rarely happens. In the APPLE 
study, if the case report forms had been sent directly to the biostatistics centre, 
a number of errors would have gone unnoticed as without seeing the source data 
and knowing the assessments, you are blind to these issues. This process had 
time implications and is likely not practical for large clinical studies. It could be 
argued that quality may be further compromised when using electronic case 
report forms, since there are often no spaces for the researcher to record notes 
or explanations. Electronic forms do, however, have other strengths. 
While I documented the types of errors identified in cognitive screening 
throughout the APPLE study, I did not record the incidence of them. Only some 
items can be checked and re-scored. Therefore, there are likely many more 
errors being made in administrating/scoring CSIs than we are aware of, without 
being present at the time of screening. It is fair to say that of the brief CSIs and 
the OCS used in the APPLE study, more training and support were needed for the 
OCS, since there were more types of administration and scoring errors. 
CSI errors are not often recorded or mentioned in published studies, although 
they are likely to be prevalent. One study using routine clinical data from 
community older adult’s mental health teams, reported that 78% of assessments 
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using the Addenbrooke’s cognitive evaluation (ACE-III) had scoring or 
arithmetical errors (310). Another study completed in primary care also 
highlighted issues with scoring and reporting of results from CSIs (311). Test 
scores were ambiguous, incorrect or incomplete in 26% of cases using the 6-CIT 
and in 32% of cases using the GPCOG. I believe that errors reveal that training 
has been insufficient, but also a possibility that the CSI may be poorly 
acceptable to all clinicians. CSIs which have numerous different scoring 
guidelines, for example the CDT, are especially problematic and likely to be at a 
higher risk of scoring errors. 
CSI authors need to provide greater guidance, including examples of common 
errors, so there is less subjectivity surrounding cognitive screening. Different 
formats of training are available for different CSIs. In addition to written 
instructions, some CSIs provide instructional videos. However, it is rare to 
finding training materials demonstrating the different incorrect ways in which a 
participant could respond, with the corresponding scoring.  
Research teams can often have high turnover of staff, so it is important to check 
in with sites and ensure that new staff are trained appropriately. Based on the 
experience in this the APPLE study, I would recommend checking scoring of CSIs 
for a sample of participants from each site at an early stage of the study so any 
issues can be rectified. All participant responses on CSI items should be recorded 
so scoring can be checked later (for example record the responses for months of 
the year backwards and all words mentioned in a fluency task). 
The authors of the MoCA have moved towards a mandatory paid 1-hour training 
and certification. Their justification for introducing this is to ensure consistency 
and accuracy. Dr. Nasreddine states some common mistakes made on the MoCA 
in an email advertising the training; Informing patients of the words they missed, 
missing the 2nd learning trial of words for immediate recall, scoring the clock 
incorrectly and over explaining tasks. While I support mandatory training, it 
should not incur a cost. Free training materials should be available for all 
clinicians and researchers using them. I would also support the requirement of a 
certification exam for usage. 
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8.4.3 Recommendations for future studies in cognition 
Carrying out work for this thesis has highlighted a number of areas of 
improvement for the conduct of studies using CSIs. The first topic concerns 
providing sufficient details about the CSI and the threshold score used. While 
undertaking the two systematic reviews, some studies poorly described these 
aspects in the methods. This is particularly a concern where shortened versions 
of tests are used and the test items are not specified, for example ‘mini-MoCA’ 
is not an informative title. It also should not be assumed that shortened versions 
will perform as well as the full scale. Scales should not be altered, shortened, or 
combined to create a new COA, without appropriate supportive validation work. 
Researchers should also clearly describe the threshold score used to define 
impairment, for example stating a threshold score of 10, could be interpreted by 
different people as <10 or ≤10. 
I recommend to always rely on the original development paper for a copy of the 
scale, and instructions for administration/scoring. While this may sound obvious, 
CSIs and other COAs can be altered by third parties, and then incorrect versions 
can be carried forward or important details lost. An example of this was the 
GPCOG, where one resource online 
(https://www.alz.org/media/documents/gpcog-screening-test-english.pdf) does 
not specify details for scoring the hands of the clock, whereas the development 
paper details that the hand length is not important. 
Finally, studies should specify the profession of the person administering the CSI 
in the study, as well as detailing any training they have received. It is important 
to know this as acceptability/feasibility from the point of view of the assessor 
may be different across professions. Many of these aspects are captured in 
STARDdem but reporting guidance for CSIs could be created for use in any type 
of study into cognition (outside of diagnostic accuracy studies). 
8.4.4 Missing or untestable data 
Missing CSI data in the context of stroke is not the same as missing data in PRO 
questionnaires. The data are rarely missing at random, as the participants who 
are untestable are often those who are at a high risk of dementia (123). There 
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are a range of reasons for incomplete CSIs and they should not always be 
grouped together. The reasons for missing data should be recorded so the data 
can be handled most appropriately and interpreted in a meaningful way. 
Statistical analysis plans should set a priori rules based on the specific objectives 
of the study. It would however be beneficial to have some evidence-based 
consensus and guidelines on how to deal with missing CSI data, with specific 
examples for researchers to refer to (e.g., if a participant declines a particular 
item). 
8.4.5 Future topics 
Completion rates were reported throughout this thesis, but other aspects of 
feasibility/acceptability should be explored in future work, including use of 
qualitative methods, to understand participant’s and clinician’s experience of 
cognitive screening post-stroke. The published literature in this area appears to 
be limited, even outside the context of stroke. Work in this area would move us 
towards a more person-centred approach to cognitive screening. I identified one 
non-stroke study investigating older adults’ attitudes towards cognitive 
screening through using a questionnaire (312). Some participants indicated 
preference to be assessed at home rather than a doctor’s office (35% vs. 10%), 
some indicated preference for a particular modality: computer/mobile device 
was preferred to paper and pencil (29% vs. 4%) and 63% indicated preference to 
complete the CSI without any company. Qualitative methodology could also be 
used to evaluate content validity of CSIs; Are CSIs measuring all aspects of 
cognition which are important to patients? Future work could also focus on 
understanding what constitutes meaningful change in each CSI. 
Since starting this PhD, a number of new stroke specific CSIs have been 
published, which are listed in Chapter 1. More work is needed to understand 
their performance beyond the original development paper and to examine how 
they perform against the OCS, which has now become the most popular stroke-
specific CSI. In this thesis I did not have a gold standard of which I could 
compare the OCS to. It would be beneficial to have accuracy data of the OCS 
compared to a recommended NPB, such as that recommended by NINDS-CSN. 
Future work from the APPLE study can compare one month OCS to NINDS-CSN 30- 
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and 60-minute protocols at 6/12/18 months for a measure of prognostic 
accuracy. 
Future work should produce data to provide recommendations concerning 
screening individuals with hearing or visual impairment and interpreting results 
in those with low education levels. I encourage future research to report on 
issues and errors arising using CSIs and to share experiences with the wider 
community, so issues can be recognised and addressed. Without action, there is 
a concern that the same mistakes are being repeated across studies. The number 
of errors made could also be used as a proxy measure of rater acceptability. 
Finally, this thesis included classical test theory (CTT) approaches to 
psychometrics. Future work would benefit from modern psychometric 
approaches (item response theory (IRT), Rasch measurement theory (RMT)) as 
these approaches provide additional valuable information, including information 
at an item-level. CTT assumptions are easy to meet, so many instruments can 
appear to perform well under this framework. 
8.5 Conclusion 
I have investigated feasibility, accuracy and prognostic ability of different CSIs 
used at varying time points post-stroke. Data from this thesis contribute to the 
growing literature concerning cognitive screening post-stroke and can be used to 
justify using (or not using) a particular CSI. Recommendations for CSI choice 
differ depending on the purpose of screening, including plans for following up 
those with identified cognitive impairment. 
I am keen to help improve the quality of both cognitive screening and research 
conduct in this area. Based on the work completed in this thesis, I have made a 
set of recommendations for those carrying out cognitive screening and for those 
designing and leading on studies into cognition. These include defining the 
purpose of screening, the training resources required, reporting guidance for 
studies using CSIs, and planning for participants being untestable. 
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Table 8-1 Summary of main findings 
Thesis aim Chapter Main findings 
To evaluate the feasibility (completion rates and 
reasons for missing data) of brief CSIs in acute stroke 
and to examine associations with being untestable. 
2 A quarter of participants were untestable on at least one test item. 
Across all individual items, the CDT had the lowest completion rate and 
age had the highest. Across the different named CSIs, the abbreviated 
MoCA, Mini-cog and GP-COG had the lowest completion rates, and the 
4AT had the highest due to scoring for untestable being incorporated. 
To identify the number of shortened versions of the 
MoCA in the literature, to review their accuracy and 
independently validate them in stroke and non-
stroke contexts. 
3 Thirteen SF-MoCAs were identified across the literature. Sensitivity was 
high across the context of stroke and non-stroke but based on varying 
reference standards. In the stroke validation, sensitivity was high 
against the MMSE. 
To identify telephone-based CSIs and to review their 
accuracy in stroke and non-stroke contexts. 
4 I identified 15 telephone-based CSIs, four of which were used in 
participants post-stroke (TICS, TICS-m, T-MoCA, T-MoCA short). Of the 
limited data available in stroke, the telephone CSIs demonstrated high 
sensitivity to detect multi-domain cognitive impairment. Outside of 
stroke the TICS and TICS-m had supportive evidence to screen for 
dementia. 
To examine the feasibility (completion rate and 
reasons for missing data) and floor/ceiling effects of 
brief CSIs across three timepoints. 
6 Completion rates were all above 90% at all three timepoints but there 
was fewer missing data at 6 months compared to baseline/one month. 
Ceiling effects were highest for the AMT-4, Cog-4 and 4AT. 
To examine the test accuracy of brief CSIs to identify 
pre-stroke MCI/dementia and post stroke cognitive 
impairment. 
6 The pattern of accuracy for pre- and post-stroke cognitive syndromes 
was generally high specificity, low sensitivity, apart from the CDT and 
NINDS-CSN 5-min MoCA which had the opposite pattern. 
To evaluate the feasibility (completion rate and 
reasons for missing data) and floor/ceiling effects of 
the OCS at one month. 
7 Full completion was 91%. Reasons for missing data included both 
participant factors and administrator errors. No floor/ceiling effects 
were observed. 
To examine whether the results from the OCS at one 
month are associated with patient outcomes at 6 
months. 
7 When controlling for variables known to impact functional and mood 
outcomes (such as age, education and stroke severity), and adjusting 
for multiple testing, impairment in only one domain (executive 
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Appendix 3: PRISMA checklist (SF-MoCA) 
Section/topic  # PRISMA-DTA Checklist Item  
Reported 
on page #  
TITLE / ABSTRACT  
Title  1 Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies. 81 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  81-82 
Clinical role of index 
test 
D1 State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, 
the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design). 
81 
Objectives  4 Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s). 82 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
82 
Eligibility criteria  6 Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study 
design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, 
giving rationale. 
83 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
83 
Search  8 Present full search strategies for all electronic databases and other sources searched, including any limits used, such that 
they could be repeated. 
Appendix 
4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included 






10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
83-84 
Definitions for data 
extraction 
11 Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) 
and other characteristics (e.g. study design, clinical setting). 
84 
Risk of bias and 
applicability 





13 State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment 
(e.g. per-patient, per-lesion). 
84 
Synthesis of results  14 Describe methods of handling data, combining results of studies and describing variability between studies. This could 
include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test 
positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing 
tests, f) handling of different reference standards 
84 
 
Page 1 of 2  
Section/topic  # PRISMA-DTA Checklist Item 
Reported 
on page #  
Meta-analysis D2 Report the statistical methods used for meta-analyses, if performed. N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if 
applicable) with reasons for exclusions at each stage, ideally with a flow diagram.  
87 
Study characteristics  18 For each included study provide citations and present key characteristics including: a) participant characteristics 
(presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference 
standard, g) sample size, h) funding sources 
94-96 
Risk of bias and 
applicability 
19 Present evaluation of risk of bias and concerns regarding applicability for each study. 97 
Results of individual 
studies  
20 For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 
2x2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver 




Synthesis of results  21 Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals. 92 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: 
failure rates, proportion of inconclusive results, adverse events). 
N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence. 106 
Limitations  25 Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review 
process (e.g. incomplete retrieval of identified research). 
107-108 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and 
clinical practice (e.g. the intended use and clinical role of the index test). 
108-110 
FUNDING   








Appendix 4: Chapter 3 SF-MoCA search strategy 
1.     Montreal Cognitive Assessment.ti,ab,kf  
2.     Montreal Cognitive*.ti,ab,kf  
3.     MoCA.ti,ab,kf  
4.     Mini adj3 Montreal Cognitive.ti,ab,kf  
5.     Mini adj3 MoCA.ti,ab,kf  
6.     Mini-MoCA.ti,ab,kf  
7.    miniMoCA.ti,ab,kf 
8.     Short adj3 Montreal Cognitive.ti,ab,kf  
9.     Short adj3 MoCA.ti,ab,kf  
10.     Montreal Cognitive adj3 5-minute protocol.ti,ab,kf  
11.   MoCA adj3 5-minute protocol.ti,ab,kf  
12.   1 OR 2 OR 3 OR 4 or 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 
13.   Short* form*.ti,ab,kf 
14.   Abbreviate*.ti,ab,kf  
15.   item reduction*.ti,ab,kf  
16.   minimum dataset. ti,ab,kf  
17.   Rasch*ti,ab,kf  
18.   Principal component analys*.ti,ab,kf  
19.   13 OR 14 OR 15 OR 16 OR 17 OR 18 
























Appendix 7: Chapter 4 Telephone CSIs search 
strategy 
Search syntax used across electronic databases: 
Key search terms:  telephone interview, telephone screening, cognitive screening and cognitive 
status. 
Concept 1 = “Dementia”    
1.  exp Dementia/ 




6. ("lewy bod*" or DLB or LBD).ti,ab. 
7. "cognit* impair*".ti,ab. 
8. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab. 
9. (memory adj3 (complain* or declin* or function*)).ti,ab. 
Concept 2 = “Cognition” 
1. (cognition or cognitive).ti,ab. 
2. Cognition/ 
3. Cognition Disorders/ 
4. Memory/ 
Concept 3 = “Telephone Assessment” 
1. telephon*.ti,ab. 
2. (tele* adj5 (screen* or interview* or study* or question* or assess*)). ti,ab. 
3. phone*.ti,ab.  
4. “telephone administered”.ti,ab. 
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5. “telephone-administered”. ti,ab. 
6. “testing by telephone” . ti,ab. 
7. “telephone test”. ti,ab. 
8. “telephone-test”. ti,ab. 
9. Concept 4= Specific Telephone Administered Cognitive Screening Tests 
10. “Telephone Interview for cognitive status”. ti,ab. 
11. TICS-m.ti,ab. 
12. “Telephone Interview for cognitive status- modified”.ti,ab. 
13. “The Brief Test of Adult Cognition by Telephone”.ti,ab. 
14. BTACT.ti,ab. 
15. “Telephone Dementia Questionnaire”.ti,ab. 
16. TDQ.ti,ab. 
17. “Brief Screen for Cognition Impairment”.ti,ab. 
18. “Memory and Ageing Telephone Screen”.ti,ab. 
19. “Telephone Cognitive Assessment Battery”.ti,ab. 
20. “Memory Impairment Screen- Telephone”.ti,ab. 
21. MIS-T.ti,ab. 
22. “Short Portable Mental Status Questionnaire”.ti,ab. 
23. SPMSQ.ti,ab. 
24. “Telephone Modified Mini- Mental state exam”.ti,ab.  
25. T3MS.ti,ab. 
26. “Telephone administered Minnesota Cognitive Acuity Screen”.ti,ab. 
27. MCAS.ti,ab. 




30. "Structured telephone interview for dementia assessment".ti,ab 
31. STIDA.ti,ab. 




1. TI ( (tele* N5 (screen* or interview* or study or question* or assess)) ) OR AB ( (tele* N5 
(screen* or interview* or study or question* or assess)) ) 
 
2. (MH "Telephone Consultation (Iowa NIC)") OR (MH "Telephone+") OR (MH 
"Telecommunications") OR (MH "Telehealth+") 
 
3. (MH "Remote Consultation")  
 
4. (MH "Delirium, Dementia, Amnestic, Cognitive Disorders") OR (MH "Amnesia+") OR (MH 
"Cognition Disorders+") OR (MH "Consciousness Disorders") OR (MH "Dementia+") 
 
5. TI dement* OR AB dement* 
 
6. TI cognit* OR AB cognit* 
 






1. TI ( (tele* N5 (screen* or interview* or study or question* or assess)) ) OR AB ( (tele* N5 
(screen* or interview* or study or question* or assess)) ) 
2. DE "Telemedicine" 
3. 2 or 3 
4. DE "Dementia" OR DE "AIDS Dementia Complex" OR DE "Dementia with Lewy Bodies" OR 
DE "Presenile Dementia" OR DE "Semantic Dementia" OR DE "Senile Dementia" OR DE 
"Vascular Dementia" OR DE "Alzheimer's Disease" OR DE "Cognitive Impairment" OR DE 
"Neurodegenerative Diseases" OR DE "Alzheimer's Disease" OR DE "Amyotrophic Lateral 
Sclerosis" OR DE "Corticobasal Degeneration" OR DE "Dementia with Lewy Bodies" OR DE 
"Multiple System Atrophy" OR DE "Parkinson's Disease" OR DE "Semantic Dementia" 
5. DE "Cognitive Impairment" OR DE "Cognition" OR DE "Animal Cognition" OR DE "Mental 
Lexicon" OR DE "Cognitive Ability" OR DE "Brain Training" OR DE "Mathematical Ability" OR 
DE "Reading Ability" OR DE "Spatial Ability" OR DE "Verbal Ability" OR DE "Memory 
Disorders" OR DE "Amnesia" 
6. TI dement* OR AB dement* 
7. TI cognit* OR AB cognit* 
8. TI memory AND AB memory 
9. 4 or 5 or 6 or 7 or 8 




Appendix 8: PRISMA checklist (telephone-based CSI)  
Section/topic  # PRISMA-DTA Checklist Item  
Reported 
on page #  
TITLE / ABSTRACT  
Title  1 Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies. 111 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  111-112 
Clinical role of index 
test 
D1 State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, 
the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design). 
111 
Objectives  4 Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s). 112 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
112 
Eligibility criteria  6 Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study 
design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, 
giving rationale. 
113 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
112-113 
Search  8 Present full search strategies for all electronic databases and other sources searched, including any limits used, such that 
they could be repeated. 
Appendix 
7 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included 






10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
112 
Definitions for data 
extraction 
11 Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) 
and other characteristics (e.g. study design, clinical setting). 
114 
Risk of bias and 
applicability 





13 State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment 
(e.g. per-patient, per-lesion). 
114 
Synthesis of results  14 Describe methods of handling data, combining results of studies and describing variability between studies. This could 
include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test 
positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing 
tests, f) handling of different reference standards 
114 
 
Page 1 of 2  
Section/topic  # PRISMA-DTA Checklist Item 
Reported 
on page #  
Meta-analysis D2 Report the statistical methods used for meta-analyses, if performed. 114 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
115 
RESULTS   
Study selection  17 Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if 
applicable) with reasons for exclusions at each stage, ideally with a flow diagram.  
116 
Study characteristics  18 For each included study provide citations and present key characteristics including: a) participant characteristics 
(presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference 
standard, g) sample size, h) funding sources 
122-123, 
126, 127 
Risk of bias and 
applicability 
19 Present evaluation of risk of bias and concerns regarding applicability for each study. 120 
Results of individual 
studies  
20 For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 
2x2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver 






Synthesis of results  21 Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals. 124, 128 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: 
failure rates, proportion of inconclusive results, adverse events). 
129, 131-
132 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence. 133 
Limitations  25 Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review 
process (e.g. incomplete retrieval of identified research). 
135 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and 
clinical practice (e.g. the intended use and clinical role of the index test). 
135-138 
FUNDING   
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Improving our assessment and understanding of the short, medium and  
longer term neuropsychological consequences of stroke 
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Longitudinal Evaluation (APPLE) 
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memory problems that can follow a stroke 
Protocol Version:    1.5 
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Protocol registration:  researchregistry1018 
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Amendment number Date Protocol version 
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AM02 22.05.17 1.4 (GN14NE496) 
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AD8 Ascertaining Dementia 8 Question Screener 
AE Adverse Event 
AMT Abbreviated Mental Testing  
ASU Acute Stroke Unit 
BI Barthel Index  
CAM Confusion Assessment Method 
CDR Clinical Dementia Rating  
CRF Case Report Form 
DISCS Depression Intensity Scale Circles 
DSM Diagnostic and Statistical Manual of Mental Disorders 
E-ADL Extended Activities of daily living  
EQ-5D Euro-QOL 5 Dimensions  
GAD-2 Generalised anxiety disorder (2 question screener) 
GCP Good Clinical Practice 
GDS Geriatric Depression Scale 
IQCODE Informant Questionnaire Cognitive Decline in the Elderly 
MCN Managed Clinical Network  
mRS Modified Rankin Scale 
NE-ADL Nottingham Extended Activities of Daily Living  
NIHSS National Institutes of Health Stroke Scale  
NPI-Q Neuropsychiatric Inventory Questionnaire  
OCS Oxford Cognitive Screen  
PHQ-2/SADS Patient Health Questionnaire (2 question screener) (structured assessment)  
PI Principal Investigator 
PIS Patient Information Sheet 
PRECiS Patient Reported Evaluation Cognitive Impairment Scale   
QEUH  Queen Elizabeth University Hospital  
RAH Royal Alexendra Hospital  
SADQ-10 Stroke Aphasia Depression Questionnaire  
SCID Structured Clinical Interview for DSM 
SF-SIS  Short Form Stroke Impact Scale  
SOP Standard Operating Procedure  
SRN Stroke Research Nurse 
SSRN Scottish Stroke Research Network  
STARD Strengthening Transparency and Reporting in Diagnostic Studies  
TIA Transient ischaemic attack 
VCI-H National Institute of Neurological Disorders and Stroke–Canadian Stroke Network 
Vascular Cognitive Impairment Harmonization Standards 




1 STUDY SYNOPSIS 
Title of Study: Improving our assessment and understanding of the 
short, medium and  
longer term neuropsychological consequences of stroke 
Study Centre: Glasgow Royal Infirmary and associated hospitals of the 
Managed Clinical Network for Stroke or Stroke Research 
Network. 
Duration of Study: 4 years 
Objectives: To establish a prospective inception cohort, recruited 
early after stroke and followed for up to 18 months with 
a focus on psychological outcomes.   
Primary Objective: There are three distinct work packages (WP). 
WP 1. To assess the prevalence of psychological 
problems that pre-date stroke. (A separate 
complementary study will describe test accuracy of short 
questionnaires for assessing pre-stroke psychological 
problems).  
WP 2.  To assess test accuracy and utility of brief 
cognitive and mood tests short for assessment of short 
and longer term psychological outcomes.  
WP 3.  To describe change in cognition and mood over 
time following a stroke, with assessments at one, six, 
twelve and eighteen months.   
Secondary Objectives: The secondary objective is to create a resource that can 
be used for future studies of psychological impact of 
stroke.  To this end we will ask participants if they wish 
to have blood taken for biobanking; if we can hold their 
anonymised data (clinical, laboratory and radiological) in 
a secure database and if we can access de-identified 
data from electronic health records. 
Main Study Endpoints Pre-stroke cognitive and physical function (based on 
CDR and SCID structured interviews). 
Change in cognition or mood symptoms based on 
repeated neuropsychological assessment (using VCI 
Harmonization Standard).  
Development of incident cognitive or mood disorder 
(consensus agreement based on collected materials).  
Rationale: National stroke guidance recommends early cognitive 
and mood screening but this policy lacks evidence-base. 
Building on previous work, we will create a programme 
of research designed to inform practice and policy. We 
will major on themes of “natural history” of 
neuropsychological problems; screening test 
accuracy/feasability; prognosis and user experience. 




Sample Size: 500 participants recruited to primary study, with plans 
for pooled analyses with other studies. Attrition is 
expected and we have based sample size on 200 
participants completing 18 month assessments. 
The pre-stroke assessment diagnostic study is based on 
a separate sample size calculation and requires 100 
informant interviews and diagnostic assessments. 
Screening Case note review of in-patient / outpatient attendees to 
the Acute Stroke Services by clinicians. A full log will be 
maintained. 
Inclusion Criteria 1. Clinical diagnosis of stroke or transient ischaemic 
attack (TIA) at time of assessment. 
2. Age greater than 18 years. 
3. Treating clinician happy that the patient would have 
some form of psychological assessment as part of usual 
care.  
Exclusion Criteria 1. Non-stroke diagnosis at time of assessment. 
2 Unable to consent and no suitable proxy available.  
4. No spoken English pre-stroke. 
4. Prisoners. 
Statistical Analysis  WP 1,2: Accuracy of screening tools will be described in 
terms of usual test accuracy metrics against a reference 
standard of semi-structured baseline clinical assessment 
(WP1) or prospective assessment with 
neuropsychological battery (WP2). We will employ an 
“intention to diagnose” approach. 
WP 3: Outcomes of interest are change in scores on 
neuropsychological battery and incident clinical mood 
disorder or cognitive impairment.  
We will use generalized linear models for prospective 
data to describe associations of baseline characteristics 
with change across repeated neuropsychological 
measures and use varying competing risk survival 
models. We will describe univariate and adjusted 
independent predictors of “outcomes” using odds-ratios 
for binary “outcomes” at chosen time-points. We will 
create prognostic models and if data allow predictive risk 
scores for outcomes, describing calibration; 











NB. All aspects of the study are optional, participants can chose to contribute to all or 
only one part of the study.  Some sites may not be able to offer biobanking.  
Key: Red boxes: short screening assessments; blue boxes: detailed screening 
assessments; green: structured psychology assessment with clinician input.  







NB. All aspects of the study are optional, participants can choose to contribute to all or 
only one part of the study.  Some sites may not be able to offer biobanking.  
Detailed Participant Schedule  
 
 










Review Eligibility √     
Consent √     
Blood / Urine for Biobanking  
(separate optional study) 
√ √ √ √ √ 
Patient assessment √     
Informant assessment √     
Structured clinical interview study 
(separate optional study) 
√    
Consent re-assessed  √    
Patient psychological screen  √    
Patient neuropsychological battery   √ √ √ 
Informant questionnaires   √ √ √ 
Clinical assessment 
(separate optional study) 
   √ 





We propose a programme of work designed to improve our understanding of 
neuropsychological effects of stroke. We will focus on themes of assessment, prognosis 
and natural history. Outputs will have immediate relevance and impact, providing an 
evidence base to policy and practice around early cognitive and mood screening and 
informing the design and conduct of future studies. The prospective cohort and 
biobank/big data resources created through this work will act as foundation for an 
ongoing portfolio, creating cross institutional research synergy; encouraging new 
researchers and providing the “substrate” for ongoing interdisciplinary work.  
 
People affected by stroke have consistently highlighted the importance of 
neuropsychological issues.[1] However, the field remains relatively under researched. 
Important evidence gaps collated at a Stroke Association convened priority setting 
workshop, were around the “natural history” of neuropsychological change after stroke; 
utility of early assessments and predicting who will require later specialist input.[2] Our 
proposed body of research is designed to address these priority areas.  Specifically, we 
will create a “real world” acute stroke inception cohort, offering prospective cognitive 
and mood testing to progress inter-related themes (Work Packages). We will also offer 
related complementary, optional studies looking at pre-stroke assessment and 
facilitating biobanking and ‘big data’ approaches.  
 
Despite the importance of psychological issues, memory, thinking and mood have not 
received as much attention in stroke research as other areas.[3,4] For this reason there 
are still fundamental questions that we don’t know the answer to. These include: 
● How do memory thinking and mood change after stroke? 
● What happens to memory, thinking and mood in the longer term after stroke? 
● Can we predict which people will have problems with memory, thinking and mood? 
● What is the best way to look for problems with memory, thinking and mood? 
● When should we perform tests of memory, thinking and mood? 
These are the questions we wish to answer with this programme of research. 
 
1.2 Pilot data to support the creation of a cohort  
The proposed programme of work builds on our previous systematic review and original 
research. Our national questionnaire and literature review has shown inconsistency in 
neuropsychological assessment strategies both in clinical practice and in research.[3,4] 
Subject responses from stroke units across Scotland suggest that clinical teams are 
looking for guidance around method and timing of neuropsychological assessment and 
around prognosis.   
Our systematic review work has highlighted a lack of data around cognitive and mood 
screening tools in acute care, albeit this is where the majority of initial assessment is 
performed.[5]   
With the Standards for Reporting of Diagnostic accuracy in Dementia 
(STARDdem)working group, we have creating guidance for conduct and reporting of 
diagnostic test accuracy studies and have used this to inform the proposed work.[6] 
Importantly, our pilot work has shown that studies of early neuropsychological 
assessment with prospective follow up can recruit rapidly and efficiently.[7,8] 
 
1.3 Involvement of stroke-survivors and others affected by stroke 
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This body of work has been created with input from stroke survivors and others 
affected by stroke. Input from stroke survivors and those affected by stroke will 
continue for the lifespan of the study. 
 
The researchers involved in this application were part of a national research priority 
setting group that collated feedback from various groups including strong 
representation from stroke survivors and care-givers. The number one research 
priority identified through this work was around problems with memory and thinking 
that can occur after stroke. This feedback was the inspiration behind this work.[1] 
 
The Stroke Association ran their own workshop around memory and mood problems, 
the lead applicant in this work was part of this group, that also included stroke 
survivors and representation from various professional groups. The conversations and 
experiences shared as part of this workshop and our daily clinical work in stroke units 
helped us create a body of work that we believe is relevant to stroke survivors and is 
in keeping with the issues that they feel are important.  The project was further 
reviewed by Stroke Association lay members as part of the grant review process. 
 
The research plan outlined in this application has been previously assessed by panel 
members of the UK Stroke Research Network CSG (acute and rehabilitation groups). 
This group includes clinicians from various disciplines and representation from those 
affected by stroke.  The insightful suggestions and comments we received, particularly 
around the conduct and reporting of the work, have improved the proposal 
considerably. 
 
In designing a study, researchers always need to balance their desire to collect 
detailed information with not over-burdening the person taking part in the study. With 
a stroke group based in Edinburgh we have shared the various tests of memory, 
thinking and mood that we propose to use. Feedback from the group helped us refine 
our set of tests to a selection that should be acceptable to stroke survivors while still 
giving us the necessary information we need to answer our research questions. 
 
As part of the study we will create an advisory group, who will meet once yearly. The 
advisory group will include two stroke survivors as well as representation from 
doctors, nurses and therapists. The group will act as a forum for stroke survivors and 
others to comment on the design of the study; the progress of the study; the 
“meaning” of the results obtained and how to share these results with the wider stroke 




1.4 Principal research questions 
This application is towards a programme of work supported by the Stroke Association 
and Chief Scientist Office Scotland. 
Within the programme are three distinct work packages (WP) designed to offer rich data 
that answer a number of important questions in stroke care. 
 
WP 1. The primary aim is to assess the prevalence of memory and thinking (cognitive) 
and mood problems that pre-date the stroke.  A complementary (optional) study seeks 
to describe the test accuracy of short questionnaires for assessing pre-stroke 
psychological problems.  
 
WP 2.  The primary aim is to assess how useful short tests are for detecting cognitive 
and mood problems immediately after a stroke and for detecting persisting cognitive 
and mood problems.  
 
WP 3.  The primary aim is to describe change in cognition and mood over time following 
a stroke, with assessments at around one month, six months, twelve months and 
eighteen months.   
 
A further important objective is to create a resource that can be used for future studies 
of psychological impact of stroke.  To this end we will ask participants if they wish to 
have blood taken for biobanking (optional); if we can hold their anonymised clinical, 
laboratory and imaging data in a secure database (optional) and if we can access de-
identified data from electronic health records (optional).  All these aspects are optional 






1.5  Summary of Risk Assessment 
We recognise the potential issues associated with this project; we have worked with 
patient groups, lay representatives and clinical study advisory groups to create a 
methodology that minimises issues while maintaining the research potential of the 
programme of research.  We have listed the potential issues and steps taken to minimise 
their impact.  
 
Test burden: The project involves cognitive and mood testing of patients and 
informants at various stages in the stroke journey.  We recognise the importance of 
minimising test burden.  Our pilot work suggests that patients struggle with standard, 
multidomain cognitive tests in the first days post stroke.  In this study we will 
concentrate on very brief tests.  As the brief tests share a number of questions, we can 
assess the performance of several tests at once by simply adding some questions to the 
short cognitive assessment that is used as standard in our clinical service.   
 
As part of our preparatory work we asked a stroke group based in Edinburgh to look at 
the tests we proposed for the acute study and they were happy that the tests were not 
overly burdensome.  Piloting the acute test battery with an Edinburgh research group 
suggests that completion should take around 20 minutes at most. Patients are not 
required to complete all the tests and they can ask to stop testing at any time.  Testing 
can be performed in two sessions or more depending on patient preference.  Feasibility 
of using brief tests is an important metric of this work and we will record how many 
patients attempt and complete tests.  If a participant becomes distressed or frustrated 
and it is clear that they are unable to complete testing, testing will be stopped. Any 
distress will be handled through reassurance and ending the assessment. 
 
Informants (family, friends, carers) will also be asked to complete paper based 
questionnaires.  We have chosen brief assessments that should take around 20 minutes 
and can be completed at a time that suits the participant.  
 
The prospective arm of the study will use a longer test battery.  Completing the study 
follow-up will involve four assessment visits over 18 months (one month; six months; 
twelve months; eighteen months).  We have chosen cognitive and mood tests 
recommended for stroke cohorts and which we use in clinical practice.  There is 
considerable experience of using these tests with stroke survivors.  The first session 
using these longer test batteries will not begin before six months post stroke to allow 
time for recovery.  Again testing can be performed in split sessions if the patient prefers.  
Completion of the tests is not mandatory and the patient can request to stop testing at 
any time. Where completion of the full assessment is not possible, we have specified a 
short form assessment protocols for use in person or over telephone. 
 
Opportunity cost: We recognise that while a patient is working on cognitive 
assessment they will not be able to work with ward staff / allied health professionals on 
other rehabilitation tasks. We will work with the ward team to minimise disruption. We 
will be performing an activity, cognitive and mood testing screen, that is a recommended 
part of routine care.  We will share the inpatient test results with ward staff on request 
and this should release their time for other activities. 
 
Disclosure of sensitive information: We will be assessing mood (emotions and 
feelings) we recognise that this can be a sensitive area.  If we detect probable 
depression, or other mood disorder we would advise the clinical team to refer to the 
Stroke Psychology service. In the event that suicidal thoughts/ideations are disclosed 
assessment will be stopped and a member of the treating clinical team will be informed 
immediately.  This action will also be documented in the patient's case notes.  The study 
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has input from the local Clinical Stroke Psychology service and they are happy to be 
contacted in the event of suicidal ideation or any other disclosures that may require 
clinical input. 
Patients may ask for their scores on the cognitive or mood tests.  We will share these 
data with the patient but we will also explain that these tests in and of themselves are 
not diagnostic of dementia / depression or other serious psychological problems. Rather 
they are part of an assessment that will be shared with the treating clinical team. If 
there is concern regarding a patients cognitive function or mood, the research team can 
access the stroke clinical psychology services and referrals can be made to Memory 
Clinic services. 
 
Informed consent: We want our study to produce results that reflect “real world” 
stroke care.  Previous studies of cognition and mood in stroke have limited themselves 
to consenting patients.  This gives a biased sample and produces results that lack 
external validity and clinical utility.  We propose a more generalizable approach, where 
we potentially include all patients with stroke unless the clinical team feel that any form 
of testing is inappropriate.  There will be a proportion of patients who may struggle to 
provide informed consent to research.  For a study with a cognitive focus, it is important 
that these patients are included.  In this instance we will seek consent from a suitable 
proxy (family, friend, carer).  For those patients who are included in the study with 
proxy consent; we will reassess capacity to consent and seek informed consent at one 
month follow-up visit.   
 
Test environment: For follow-up testing we will recommend that testing is performed 
within one of the clinical research facilities of the participating hospitals.  We have a 
budget to cover patient travel by taxi to allow this.  Some patients may be unable to 
attend the research facility or may for any reason choose to be assessed at home.  
Telephone based assessment is possible if required.  For home assessments, we will 
follow NHS GG&C and GU lone working procedures for safety.  
 
Use of participant data: Our cohort will provide a unique resource for understanding 
post-stroke psychological problems.  We wish to maximise the potential of the data 
collected, so that it can be used to answer clinically important questions beyond those 
outlined in the primary study.  Certain centres will invite participants to give a blood 
samples that will be stored for future analyses.  Participants can decline this biobanking 
aspect at any stage of the study and still help with other aspects.  The Robertson Centre 
for Biostatistics will hold anonymised patient data within a secure resource.  Our study 
follow-up is limited to eighteen months.  We will ask participants permission to link their 
study data to anonymised data from electronic health-records (clinical, laboratory, 
imaging).  This will allow future studies to look at longer term outcomes.  Again, 




2 STUDY OBJECTIVES AND PURPOSE  
We propose a study that has been designed to answer pressing clinical questions. 
National and international stroke guidelines recommend early cognitive and mood 
screening but this policy is based on expert opinion and lacks evidence-base. Building 
on our previous pilot work, we will create a programme of research designed to inform 
practice and policy. We will major on themes of “natural history” of neuropsychological 
problems following stroke; screening test accuracy/feasibility and prognosis. 
 
We anticipate that at study completion we will be able to offer:   
• Guidance on the optimal methods to assess for pre-stroke cognitive and mood 
problems.  
• Guidance on the optimal methods to assess for cognitive and mood problems in 
the acute stroke setting and in early follow-up. 
• Descriptions on the natural history of cognitive and mod symptoms following 
stroke.  
• An understanding of clinical, demographic features that predict poor and good 




This study will be performed according to the Research Governance Framework for 
Health and Community Care (Second edition, 2006) and WORLD MEDICAL 
ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research 
Involving Human Subjects 1964 (as amended). All investigators and key study 
personnel will undergo biennial GCP training. 
The study design is detailed below and is summarised in the flow chart and schedule. 
The programme of work is based on a prospective observational cohort, recruited at 
time of stroke and followed up with assessments focussing on neuropsychological 
aspects.  The cohort will allow for studies of test properties, studies of prognosis and 
epidemiology.  Inclusion of a biobank and consent to future electronic data linkage 
increases the research potential of the cohort. 
 
3.1 Study Population 
The study will involve participants aged over 18 years with clinical diagnosis of stroke 
or transient ischaemic attack (TIA) who meet the inclusion criteria and have none of the 
specified exclusion criteria. All will give full informed consent or have consent provided 
by appropriate proxy. 
Participants will be consecutive, stroke patients over 18 month recruitment. Primary 
sites will be Glasgow Royal Infirmary (GRI); Royal Alexandra Hospital (RAH) and Queen 
Elizabeth University Hospital (QEUH), with additional recruitment from other Scottish 
Stroke Research Network (SSRN) sites or research active stroke centres in other parts 
of the UK. To allow descriptions of generalizability and feasibility we will adopt an 
inclusive policy, offering testing to all adult (over 18 years) stroke survivors except 
where clinical team feel that any form of testing is inappropriate (for example end of 
life care). We will define stroke using World Health Organisation criteria. Our stroke 
rubric will include TIA and minor stroke and recruitment from outpatient clinics will be 
possible.  Co-recruitment with other observational or investigational trial will be 
possible. 
We will include patients with varying levels of communication problems. Our national 
ethics application will allow us to seek proxy consent for assessment and follow up where 
participant is unable to give direct consent at time of recruitment. The context is disease 
orientated and so will include new TIA/minor stroke seen at clinics as well as inpatients. 
Eligibility screening and recruitment will be performed by stroke research nurses or 
trained researchers. Initial assessment of capacity and willingness to be approached will 
be determined by the clinical team. 
 
3.2 Main Study Inclusion Criteria 
1. Clinical diagnosis of stroke or TIA at time of assessment 
2. Age greater than 18 years. 
3. Clinical team happy that patient is suitable for some form of psychological testing.  
Stroke will be diagnosed by a stroke specialist, defined as a focal neurological event of 
presumed vascular cause.  We will operate no time or imaging based inclusion criteria.  
3.3 Main Study Exclusion Criteria 
1. Non-stroke diagnosis at time of assessment. 
2. Unable to consent and no suitable proxy available.  
4. No spoken English pre-stroke. 
4. Prisoners.  
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3.4 Description of the work packages 
We propose a programme of work themed around improving cognitive and mood 
assessment. 
The portfolio is described as interlinked work-packages each with distinct aims and 
objectives.  In addition we offer optional, complementary studies.   
 
Work package one: Assessing pre-stroke psychological problems. 
• To describe prevalence of pre-stroke psychological problems (specifically, 
cognitive decline and depression) in an acute stroke cohort. 
• A separate (optional) study will assess the feasibility of using informant based 
screening tools for pre-stroke depression (GDS-informant scale; SADQ-10) and 
cognitive decline (IQCODE, AD-8) in an acute stroke setting. 
• A separate (optional) study will assess the accuracy of informant based screening 
tools for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) against a reference standard of semi-structured clinical assessment 
(using the Structured Clinical Interview [SCID] for DSM mood disorder and the clinical 
dementia rating [CDR] for cognitive assessment). 
 
Published research describing cognitive and mood problems following stroke assumes 
that the person had no problems prior to the stroke event.  This is overly reductionist 
approach fails to appreciate the complex relationship between psychological symptoms 
and cerebrovascular disease.  Stroke is predominantly a disease of older age and older 
people will show varying degrees of cognitive decline and mood problems.  These may 
be sufficient to warrant a diagnostic label, albeit often a diagnosis of dementia or mood 
disorder is not made in the community.[9]  Both cognitive decline and mood disorder 
seem to be associated with increased risk of stroke.[10]   
To understand the psychological picture seen after stroke we need robust methods of 
capturing the pre-stroke state.  A common approach is to conduct a questionnaire based 
interview with informants (family, friends, carers) and use the description of past 
cognitive and mood symptoms to assign a retrospective label.  Scales are available and 
are used in stroke care, for example the Informant Questionnaire for Cognitive Decline 
in the Elderly (IQCODE).  Our recent systematic review has shown that while test 
properties of informant scales are good in community dwelling older adults, no informant 
questionnaire has been validated in a stroke population.[11,12]   
We will use a classical test accuracy study design to describe the properties of informant 
tools in acute stroke. Stroke research nurses (SRN) or trained researchers will interview 
informants with short questionnaires looking to describe pre-stroke depression and 
cognition.  Within one month of this assessment, a trained member of the research team 
will conduct a semi-structured interview (based on standardised questionnaires of SCID 
and CDR (sum of boxes scoring https://www.alz.washington.edu/cdrnacc.html) with 
patient and family and formulate a clinical assessment of pre-stroke problems.  
Following discussion with a clinician, results will be operationalised as pre-stroke 
dementia or depression probable; possible; unlikely; unable to assess.  
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index test questionnaires will be 
compared against each other and against a reference standard of semi-structured 
clinical assessment. To describe feasibility we will collate numbers completing each test 
fully and partially; time and assistance required for completion. To incorporate feasibility 
into analyses, we will employ an “intention to diagnose” approach, including those 
unable to complete tests.[13] 
 
Work package two: Test accuracy and prognostic utility of brief screening tools 
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• To describe feasibility of using brief screening tools for diagnosis of cognitive and 
mood problems in acute stroke. 
• To describe accuracy of brief screening tools for diagnosis of cognitive and mood 
problems in acute stroke; comparing to each other and to a one month multi-domain 
assessment.  
• To describe prognostic accuracy of a one month multi-domain cognitive and 
mood assessments against detailed assessment at six, twelve, eighteen months.  
• To describe neuropsychological “case-mix” with reference to incident/prevalent 
delirium and impairments that may complicate cognitive and mood testing. 
 
The first step to management of neuropsychological problems is recognition and 
diagnosis. At present we have no agreed method on how or when to assess for these 
problems. Our pilot data suggests that standard multi-domain assessment tools are not 
feasible as a universal screen in the first days post stroke.[5,8] Thus, we suggest a 
neuropsychological assessment paradigm where brief assessments are used in the 
hyperacute period with increasingly detailed assessment at later time period.  
Various brief (less than five minutes) assessment tools for cognition and mood are 
available. Such tools are suited to acute settings and indeed are often used in the ASU, 
however data on test properties are limited.[5] Many of these brief assessments have 
shared items. We have created an instrument that combines elements from popular 
brief tests in a single assessment, allowing derivation of various scores while minimising 
test burden. Our brief mood testing includes a depression and anxiety questionnaire; 
pictorial assessment and single question. Tests for delirium are also included. We have 
not modified assessments for those with communication problems, as describing 
feasibility of tests across a range of stroke related impairment is an important outcome 
of our work. However, the tests used should be feasible for those with mild to moderate 
aphasia. At one month, a longer test battery will include multi-domain screening tool. 
(Assessments described in appendix). 
Our methodology is based on best practice in conduct and reporting guidance for 
dementia test accuracy studies (STARDdem).[6] Index test will be brief screening tools 
(acute assessment) and multi-domain screening tools (one month and beyond). Given 
the dynamic early changes in cognition and mood seen early after stroke, purpose of 
early testing should be to predict later problems. Thus our reference (gold) standard 
comparator will be mood disorder and multi-domain cognitive impairment as described 
by our neuropsychological battery at six, twelve and eighteen months with expert 
consensus diagnosis based on all collated materials at end of study. We recognise that 
these assessments are not diagnostic, rather they offer a suitable compromise between 
validity of assessment and suitability post stroke where formal diagnosis of dementia or 
mood disorder can be challenging. As an optional study, at 12/12 and 12/18 follow-up 
a random selection of participants, will be offered additional face to face clinical 
assessment with a senior stroke neuropsychologist or clinician blinded to other 
assessment scores.  At completion all 6,12,18 month study materials will be reviewed 
by the senior investigators (TQ, NB, JD, DJS) and a consensus diagnosis assigned for 
incident mood disorder and/or incident cognitive disorder, using descriptors of:probable, 
possible, unlikely.  
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index tests will be acute and one 
month assessments and will be compared against each other and reference standard of 
follow up assessment data. From the acute assessments, we will describe the accuracy 
of brief screening tests used in isolation and combined with Boolean operators of 
“OR”/”AND”. To describe feasibility we will collate numbers completing each test fully 
and partially; time and assistance required for completion. To incorporate feasibility into 





Work package three: Describing and predicting neuropsychological prognosis 
• To describe serial change in cognition/mood test scores and to describe 
prevalence of cognitive and mood diagnoses at time points of one month; six month; 
twelve months and eighteen months. 
• To describe univariate and adjusted independent predictors of both post stroke 
cognitive decline and post stroke mood disorder. 
• To develop, calibrate and validate predictive models for post stroke 
neuropsychological factors. 
• To estimate likely recruitment, “event rates” and loss to follow up for future 
cognitive/mood studies. 
Systematic reviews suggest substantial post stroke neuropsychological burden, however 
these data may have limited generalizability to acute settings.[14] Problems include 
selection bias; non-acute sampling and lack of data on important comorbidities such as 
delirium and prevalent dementia. Our pilot data describes a high incidence of 
cognitive/mood problems in first days post stroke with trajectories of improvement, 
stabilisation and decline.[8] We need “real world” data on baseline and natural history 
of neuropsychological change to inform practice, research and policy in this regard.  
Follow up will be at six, twelve and eighteen months, time-points chosen to reflect 
common clinical and study assessment times. Assessments will be face-to-face and 
performed in study centres or in participant’s home as required/requested. There will 
be opportunity for telephone assessment if required.  The six/twelve/eighteen month 
assessments will be performed by trained members of the research team. We make no 
assumptions around the pathology underlying post stroke cognitive change and so we 
have devised a battery of assessment that will allow derivation of scores for “vascular” 
dementia and Alzheimer’s Disease dementia.[15,16] While our principal mood interest 
is depression we have chosen a mood assessment that screens for various other 
disorders using structured clinical interview.[17] (see appendix for full details of all 
assessments)  After 12 and 18 month follow-up, a proportion of participants will be 
asked if they wish to take part in an optional  study, where they are assessed by a 
clinician and assigned a clinical label.  These results will be compared to our standard 
assessments. 
The work is modelled around the “fundamental” prognosis research paradigm as 
described by MRC PROGRESS prognosis research group.[18] Taking acute stroke as 
start-point, we will create an inception cohort, collecting clinical, demographic and 
neuropsychological “phenotyping” data at baseline and then prospectively following up 
with serial cognitive and mood assessments. 
For prospective follow up, outcomes of interest are change in scores on cognitive and 
mood screening tools and incident clinical mood disorder or multi-domain cognitive 
impairment. Multi-domain tools will be analysed as ordinal data and dichotomised at 
varying thresholds. Neuropsychological battery data will be transformed into z scores, 
with impairment defined as greater than 1.5 standard deviations below age and sex 
based norms. We will collect data on recurrent stroke, complications (falls, seizure, 
infection) hospitalisation/institutionalisation and death.  
We will explore repeated measures analyses adjusting for baseline covariates and 
describe temporal change in test scores. We will create prognostic models and if data 
allow predictive risk scores for the various cognitive and mood outcomes, describing 
calibration; discrimination and validation using bootstrapping.  
 
3.5 Identification of Participants and Consent 
Potential participants will be identified (by clinical or case note review by a member of 
the clinical team or attending Doctor) whilst in-patients or in a cerebrovascular out-
patient clinic. If the patient asks not to be approached no further action will be taken.  
The clinical team will make an assessment of capacity to consent to inclusion in the 
study. The principal criterion for entry into the study is that the treating team believe 
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an attempt at cognitive and mood assessment is appropriate.  We have used this 
approach in previous pilot studies and it has worked well.  
Following identification, potential participants will be approached in person and asked 
whether they would wish to consider taking part in the trial. Those who are willing to 
hear more will be given the participant information sheet (PIS) and a date (at least 24 
hours later) arranged for further discussion with a member of the research team. 
Eligibility will be confirmed by an investigator.  
At this second meeting, subjects will be asked if they have any questions and those who 
wish to participate will be asked to sign the consent form. Two copies will be signed 
(one each for the participant and the site file) and a copy of the signed consent form 
will be inserted into the casenotes. 
Consent will be taken by one of the investigators, research nurse or trained researcher. 
Consent will be staged to ensure that participation in the study is always voluntary and 
fully informed. At all points we will stress that taking part in the study is voluntary and 
if patients wish to terminate the cognitive testing early we will respect this wish which 
will not impact on the clinical care that they receive. 
For patients unable to provide informed consent, we will seek consent from a legal proxy 
or family, carer, friend.  We have outlined the details of this approach in the section on 
adults lacking capacity (see below). 
We offer additional complementary studies looking at informant assessment; blood 
taking for biobanking; prospective follow-up; clinical diagnostic study; data storage and 
linkage.  Participants will be given the option to consent to all aspects of the study or to 
limit their participation to certain aspects only.  In centres where biobanking is not 
possible this will not be included in consent form. 
We recognise that cognition can change over time.  Our pilot data suggests that 
immediately after stroke patients can have cognitive impairments that improve over the 
first weeks.[8]  At early follow-up (around 4 weeks post stroke) the participant’s 
capacity to consent will be reassessed.   
 
3.5.1 Including participants unable to provide informed consent  
We wish to include a representative sample of stroke survivors. For a study that is 
concerned with post stroke psychological problems we need to include a spectrum of 
cognitive abilities and impairments.  Previous work in this area has been limited by 
including non-representative populations and so results have lacked real world validity.   
To ensure our results have clinical utility, we will be maximally inclusive in our 
recruitment strategy.  
Patients may have cognitive problems, problems with communication/language or 
physical impairments. Some may have severe communication or cognitive difficulties.  
The assessment battery we propose, while not specific to aphasia, should be suitable 
for those with mild to moderate communication problems.    We will only assess those 
patients where the clinical team feel that an attempt at assessment of mood or cognition 
is appropriate. 
We do not wish to deny stroke survivors involvement in a study that might lead to 
benefit for those like them.  We believe the risk of participation in this observational 
study is minimal. 
Decisions on patient capacity to consent will be made by the Consultant/senior members 
of the Acute Stroke team at daily ward rounds or on first assessment. This is a standard 
part of usual clinical practice for stroke clinical teams. 
Where the ward clinical team determine a patient does not have capacity to consent, 
we would seek informed consent from a close relative/welfare guardian. We would still 
include the patient in decision making around the study as possible.  Choice of proxy 
will be made by the patient, either at the time of testing or based on previously 
expressed wishes.  
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We will involve the nearest relative/guardian/welfare attorney in the study, regardless 
of patient ability to consent as some of our measures require to be completed by an 
informant that knows the patient well. We have developed a specific information leaflet 
(PIS) for this purpose. 
Capacity to consent will be re-assessed at one month follow-up.  If a patient has been 
included using proxy consent but it is felt the patient now has capacity, consent will be 
rechecked at the follow-up visit.  In this scenario, if the participant does not give consent 
the participant would be withdrawn from the study. No further data or tissue would be 
collected or any other research procedures carried out on or in relation to the 
participant.  We would ask if those identifiable data or tissue already collected with 
consent could be retained and used in the study.  If the participant does not agree to 
this, the data and biobank samples will be removed from study registers.  
If the patient is felt to no longer have capacity to consent, the assessor will follow 
procedures outlined for including a patient that lacks capacity.  In this scenario, if a 
relevant proxy does not give consent the participant would be withdrawn from the study. 
Identifiable data or tissue already collected with consent would be retained and used in 
the study. No further data or tissue would be collected or any other research procedures 
carried out on or in relation to the participant. 
At subsequent follow-up visits, capacity to consent will not be formally reassessed but 
we will check that the participant is still happy to continue with the study and emphasise 
that the participant can withdraw at any time and not give a reason 
 
3.5.2  Withdrawal of subjects 
Participants will be told that they can withdraw their consent at any time without 
giving a reason and that this will not affect their care in any way.  Participants will be 
informed that they can participate in any or all of the follow up assessments. 
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3.6 Assessment Schedule 
The study will comprise a maximum of seven patient assessments.  A short baseline 
assessment; (optional) semi-structured clinical interview within first month; one month 
follow-up with short screening tests; then six, twelve, eighteen month follow-ups with 
multi-domain assessments with an optional clinical diagnostic assessment. Following the 
baseline assessments, each visit has a two week time window either side of the 
scheduled date during which it can be completed.  Other than baseline assessment, 
assessments will be preferentially performed in the Clinical Research Facility of the 
participating hospital.  There is the option for home assessment or for telephone 
assessment if required.  
 
3.6.1 Baseline assessment  
This will be completed as soon as possible following index stroke but not before 24 
hours to allow participants sufficient time to read study materials.  Initial assessment 
will confirm eligibility and consent.  Clinical and demographic details will be extracted 
from case-notes.  Clinical assessment will include National Institute of Health Stroke 
Scale (NIHSS) score, modified Rankin Scale (mRS); Barthel Index (BI): five question 
assessment for frailty (Fried), Lawton Extended Activities of Daily Living (E-ADL) a 
short questionnaire around physical activity (Brief Physical Activity Assessment [BPAA] 
and a measure of social inclusion (Medical Outcome Study Social Support 
Scale[MOSS-SSS] 4 item).   
The cognitive assessment (AMT-plus) will comprise the 10 point abbreviated mental 
test and clock drawing test, supplemented by a recall question, one letter fluency test 
and naming months of the year backwards.  This battery allows us to derive the score 
from 9 different screening tests without performing each test individually.  We will 
assess for delirium using Confusion Assessment Method (CAM-ICU).  We will assess 
for mood symptoms using Depression Intensity Scale Circles (DISCS) and the short 
forms of Patient Health Questionnaire PHQ-2/GAD-2.  If patient agrees and facility is 
available, bloods and urine will be taken for biobanking. 
Informants will be chosen by the stroke patient or ward staff if stroke patient unable 
to make this decision.  Informants will complete brief questionnaires describing the 
patient’s mood and cognition pre-stroke.  Questionnaires will comprise the Informant 
Questionnaire for Cognitive Decline in the Elderly (IQCODE); the Ascertain Dementia 
screener (AD-8).  The Geriatric Depression Scale informant version (GDS-i) and 
Stroke Aphasia Depression Questionnaire (SAD-Q).  Patients pre-stroke functional 
ability will be assessed using the BI, Fried and E-ADL.  The baseline visit will confirm a 
suitable time to organise the semi-structured clinical interview. 
 
3.6.1.1 Semi-structured clinical interview 
This optional study interview will be performed within one month of baseline 
assessment.  A trained member of the research team will interview the patient and 
informant.  Interview will cover diagnostic criteria necessary to assign a label of major 
neurocognitive disorder; delirium and major depression.  The content will be based on 
the operationalised structured clinical interview for DSM-5 (SCID) and the Clinical 
Dementia Rating (CDR – sum of boxes scoring 
https://www.alz.washington.edu/cdrnacc.html).  The interviewer will not have access 
to previous cognitive and mood screening assessment results.  Results of the interview 
will be discussed with the study team and a final consensus label will be 
operationalised as: probable cognitive/mood disorder pre-stroke; possible disorder; 
unlikely disorder; unable to assign a label.  We will emphasise that the assessments 
are not diagnostic but will share the information with the treating clinical team on 
request.   
3.6.2 One month assessment  
The one month assessment will be performed at a time convenient for the patient and 
informant.  One month assessments will comprise a repeat of the short patient cognitive 
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battery performed at baseline (AMT-plus, CAM-ICU), the Oxford Cognitive Screen (OCS) 
and the complete Patient Health Questionnaire (PHQ-SADS). We will collect information 
on post stroke complications (stroke, cardiac, seizure, infection, falls, fatigue [using 
brief fatigue inventory]) and any change in medication.  If the patient is agreeable and 
if available then further samples for biobanking will be taken.  
  
3.6.3 Six, twelve, eighteen month visit 
Assessments at six, twelve and eighteen months will be performed by researchers 
trained in the various assessments.  Patients will be assessed according to Vascular 
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network 
vascular cognitive impairment harmonization standards (VCI-H).[15,16]  Function will 
be assessed with mRS, BI, EADL and BPAA, MOSS-SSS at 12 and 18 month.  The patient 
will be asked about specific stroke complications of interest.  List of medication will be 
updated. 
At the six month assessment the assessor  will use the 30 minute version of the VCI-H  
If the patient struggles with this assessment, does not wish such a lengthy assessment 
or the assessment is not possible for any other reason, we have proposed a shorter 
assessment based on the VCI-H five minute battery.  For twelve and eighteen month 
assessments the patient will be offered the choice of full VCI-H (around 45 minutes) or 
shorter assessments. Choice of assessment used will be at the discretion of the 
researcher in discussion with participant and informant.   
In addition at the twelve and eighteen month visits the patient will complete generic 
and stroke specific quality of life measures: Euro-Qol 5 domains (EQ-5D); Short Form 
of the Stroke Impact Scale (SIS) and Patient Reported Evaluation of Cognitive Status 
(PRECiS). 
The informant will complete a caregiver burden scale (Zarit Caregiver Burden) and will 
complete the generic quality of life EQ-5D.  At 12 and 18 months the informant will 
complete the cognitive and mood questionnaires employed at baseline (IQCODE,Yes 
include  GDS-i) and will complete the neuropsychiatric inventory questionnaire (NPI-Q). 
Completion of the eighteen month visit marks the end of the study.  
 
3.7 Biobanking 
Urine and blood samples will be obtained as outlined in the appendix and then will be 
stored in the NHS GG&C biorepository; all aspects of collection and storage will be in 
line with NHS Greater Glasgow and Clyde policies.  Biobanking samples will be from 
GG&C participants only.  
Venepuncture will be performed from the antecubital fossa where possible (using a ~ 
19G (green needle) vacutainer (or similar) system). Three lavender top EDTA tube (or 
similar), a gold top clot activator (or similar) for serum chemistry measures and two 
grey tube (or similar) for glucose determination will be collected (ca 40 mls in total) 
 
3.8 Team Expertise and Project Management 
NHS Greater Glasgow and Clyde have agreed to act as sponsor. All protocols will be 
stored in publically accessible registers. Creation of case report forms (CRF), data 
management, archiving and analyses will be supported by Robertson Centre for 
Biostatistics. 
Terry Quinn (Glasgow) will lead the work and act as principal investigator (PI). He has 
particular expertise in stroke study methodology; test accuracy and cognitive/functional 
assessments. The core research team will include stroke research nurses at both sites; 
new researcher posts, designed to allow study towards PhD and dedicated statistical 
support. The multifaceted nature of the topic requires knowledge and skills in various 
areas and our collaborators bring this multidisciplinary expertise. Our experienced site 
leads have international reputations for excellent multicentre, prospective research: 
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Peter Langhorne (GRI); Kennedy Lees (QEUH). Ian Ford (Glasgow) will support all 
aspects of statistical analysis. Niall Broomfield (clinical lead for Glasgow stroke 
psychology services) will provide training for research nurses and doctoral students and 
will facilitate clinical assessments.  
We will form an advisory group who will provide oversight and guidance, the group will 
have representation from stroke survivors (x2); primary care; research networks 
(SSRN, SCDRN); neuropsychology (Jonathan Evans, Glasgow); the local stroke 
managed clinical network lead (Christine McAlpine) and an external expert on 
neuropsychological outcomes in stroke (Sarah Pendlebury, Oxford). 
4 Rater training  
We propose assessments using a battery of differing neuropsychological and functional 
tests.  We have extensive experience of training researchers in use of assessment 
scales.  Our previous work around outcomes assessments for large clinical trials has 
shown the importance of offering training, standardisation and quality control, even 
for those tests considered “routine” in stroke research.[19] 
 
We will use training materials produced for use with the assessments of interest.  
Online training resources will be available for functional outcomes (NIHSS, mRS. BI).  
For the neuropsychological tests we will offer face-to-face training.  Educational 
materials will be complemented by an investigator work book and Standard operating 
Procedures (SOPs) for all of the assessments required in the study.   To accompany 
the SOPs we will create study-specific case report forms to facilitate standardised 
assessment and scoring.  For PhD student assessors, the first three assessments will 
be supervised.  There is scope for further direct assessment and training as required. 
Contact details of the principal investigator and research team will be made available 





We propose an observational study with no intervention or change to usual care.  




6 STATISTICS AND DATA ANALYSIS 
6.1 Primary Outcomes 
We propose a programme of inter-related projects themed around improving cognitive 
and mood assessment.   
The portfolio is described as work-packages and optional studies each with distinct aims 
and objectives.  The outcomes and analysis plan for each will be described in turn.  
 
WP 1: Assessing pre-stroke psychological problems. 
• To describe prevalence (n, [%]) of pre-stroke psychological problems 
(specifically, cognitive decline and depression) in an acute stroke cohort. 
• As part of an optional, separate study, to assess the feasibility (n, [%] return 
rate, items complete, time for testing) of using informant based screening tools 
for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) in an acute stroke setting. 
• As part of an optional, separate study, to assess the accuracy (sensitivity, 
specificity, positive/negative predictive value) of informant based screening tools 
for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) against a reference standard of semi-structured clinical 
assessment. 
 
WP 2: Test accuracy and prognostic utility of brief screening tools 
• To describe feasibility (n, [%] items complete, time for testing) of using brief 
screening tools for diagnosis of cognitive and mood problems in acute stroke. 
• To describe accuracy (sensitivity, specificity, positive/negative predictive value) 
of brief screening tools for diagnosis of cognitive and mood problems in acute 
stroke; comparing to each other and to a one month multi-domain assessment.  
• To describe prognostic accuracy (sensitivity, specificity, positive/negative 
predictive value, ROC analyses) of a one month multi-domain cognitive and 
mood assessments against detailed assessment at six, twelve, eighteen months.  
• To describe neuropsychological “case-mix” with reference to (n, [%]) prevalence 
of pre-stroke cognitive decline; pre-stroke mood disorder (depression) and 
incident/prevalent delirium. 
 
Work package three: Describing and predicting neuropsychological prognosis 
• To describe the natural history (rates of outcomes; change over time) of post 
stroke neuropsychological problems at time points of one month; six month; 
twelve months and eighteen months. 
• To describe univariate and adjusted independent predictors of both post stroke 
cognitive decline and post stroke mood disorder (odds ratios, with corresponding 
95% confidence intervals). 
• To develop, calibrate and validate predictive models for post stroke 
neuropsychological factors. 




6.2 Statistical Analysis Plan 
The study will have a comprehensive Statistical Analysis Plan (SAP), which will govern 
all statistical aspects of the study, and will be authored by the Trial Statistician.  Full 
details of all statistical issues and planned statistical analyses will be specified in the 
SAP which will be agreed before analyses begin. 
 
6.3 Overview of statistical analysis  
 
6.3.1 WP1: Assessing pre-stroke psychological problems 
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index test questionnaires will be 
compared against each other and against a reference standard of semi-structured 
clinical assessment. From the acute assessments, we will describe the accuracy of 
brief screening tests used in isolation and combined with Boolean operators of 
“OR”/”AND”. To describe feasibility we will collate numbers completing each test fully 
and partially; time and assistance required for completion. To incorporate feasibility 
into analyses, we will employ an “intention to diagnose” approach, including those 
unable to complete tests. 
 
6.3.2 WP2: Test accuracy and prognostic utility of brief screening tools 
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index tests will be acute and one 
month assessments and will be compared against each other and reference standard 
of follow up assessment data. From the acute assessments, we will describe the 
accuracy of brief screening tests used in isolation and combined with Boolean 
operators of “OR”/”AND”. To describe feasibility we will collate numbers completing 
each test fully and partially; time and assistance required for completion. To 
incorporate feasibility into analyses, we will employ an “intention to diagnose” 
approach, including those unable to complete tests.  
 
6.3.3 Work Package three: Describing and predicting neuropsychological 
prognosis 
For prospective follow up, outcomes of interest are change in scores on cognitive and 
mood screening tools and incident clinical mood disorder or multi-domain cognitive 
impairment. Multi-domain tools will be analysed as ordinal data and dichotomised at 
varying thresholds. Neuropsychological battery data will be transformed into z scores, 
with impairment defined as greater than 1.5 standard deviations below age and sex 
based norms. We will collect data on recurrent stroke, complications (falls, seizure, 
infection) hospitalisation/institutionalisation and death.  All data from 6,12,18 month 
assessments will be assessed by a panel of the senior investigators and a consensus 
assessment for incident mood disorder and incident cognitive disorder made. 
 
We will use generalized linear models for prospective data to describe associations of 
baseline characteristics with change across repeated neuropsychological measures. 
With our statistician we will use varying competing risk survival models to account for 
events that may precede our neuropsychological outcomes of interest (mortality). 
We will describe univariate and adjusted independent predictors of “outcomes”. We 
will describe odds-ratios for binary “outcomes” at chosen time-points, using 
multivariate Poisson regression. 
We will explore repeated measures analyses adjusting for baseline covariates and 
describe temporal change in test scores. We will create prognostic models and if data 
allow predictive risk scores for the various cognitive and mood outcomes, describing 
calibration; discrimination and validation using bootstrapping.  
 
 
6.4 General Considerations 
In general we will apply parametric statistical methods; any variable not suitable for 
parametric analysis will be analysed using non-parametric methods. 
Descriptive statistics by study centre will be provided. A summary and listing of patients 
with protocol violations will be produced.  
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6.5 Software for Statistical Analysis 
All statistical analysis will be performed using SAS version 9.1 or later. 
 
6.6 Sample Size 
We anticipate recruiting n=500 participants across the three sites over 18 months 
recruitment.  We expect substantial attrition (death, loss to follow-up, development of 
cognitive problems that preclude further assessment) and anticipate n=400 one month; 
n=350 six month; n=300 twelve month and n=200 eighteen month follow up data. 
Data to allow sample size calculations for future studies is an intended output of this 
work. Recognising the uncertainty, we do not offer definitive “power” calculation per se, 
but our recruitment estimates suggest we will have sufficient patients to achieve our 
research aims.  
Scottish Stroke Care Audit reports over 1500 stroke discharges per annum across our 
three Glasgow sites. Our pilot data suggest that over 18 month recruitment, at a 
conservative estimate 500 will be suitable and agree to early assessment and follow up. 
Based on Information Services Division stroke data, we project estimates of n=400 one 
month; n=350 six month; n=300 twelve month and n=200 eighteen month follow up 
data. These numbers make our study equivalent to or larger than other international 
neuropsychological focused studies. By using research nurses for initial assessments 
and three full time PhD student assessors for follow up, daily maximum number of 
assessments per team member would be two. 
For the optional study describing accuracy of informant questionnaires we have a 
separate power calculation.  Using a nomogram approach [20] describing test properties 
of informant questionnaires, based on estimated prevalence of pre-stroke problems of 
20% and anticipated specificity of around 0.8, recruiting n=100 gives sufficient power 
to assess the scales. 
WP1 and WP2. Our recruitment is designed mindful of potential attrition.  For the test 
accuracy work, using a nomogram [20] based on prevalence of 40% cognitive 
impairment at one month, (α=0.05); our estimate of 400 participants would allow 
description of accuracy across a full range of plausible sensitivity/specificity. 
WP3. Based on published data on mood we would anticipate annual rates of outcomes 
at around 30% with n=125 “outcomes” in survivors at end of follow up (although our 
data suggests rates of cognitive/mood disorder may be considerably higher in 
unselected cohorts).  This gives sufficient power for the prospective models we have 
planned.   Based on our anticipated recruitment and retention, prognostic models will 
have power to describe multiple covariates.   
The optional subgroup study where results on neuropsychological assessment are 
compared to clinical assessment will be performed on n=25 in the first instance.  This 
is a pragmatic sample size.  Recruitment will be of sequential consenting participants 




6.7 Procedures for Accounting for Missing Data 
There will be no imputation of missing data for the primary or secondary endpoints in 
the first instance.  As part of the analyses we will explore the effects of various 
approaches to handling missing data. 
 
6.8 Procedures for Reporting Deviations from the Original Statistical Plan  
A detailed statistical analysis plan (SAP) will be agreed before analyses begin. Any 
deviations from this plan will be documented and justified in the final study report. 
 
6.9 Selection of Subjects to be Included in the Analyses 
We will run analyses including those with full test data and those with missing data, 
using intention to diagnose approaches.  
 
7 STUDY Closure / DEFINITION OF END OF STUDY 
The study will end when the last patient has their last study visit. 
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8 SOURCE DATA/DOCUMENTS 
8.1 Case Report Forms / Electronic Data Record 
Primary data collection will use paper based case report form (CRF).  Inpatient 
assessment scores will be shared with the hospital team on request. For out-
patient/community assessments, screening test summary results will not be shared with 
the General Practitioner (GP).  This approach was suggested by the Scotland A Research 
Ethics Committee and recognises that the screening tests are not diagnostic If 
assessment suggests a serious cognitive or mood disorder that requires urgent 
treatment results will be shared with the appropriate team.  
All participant data will be identified by the participant study identification number. CRF 
data will be securely transferred to the Robertson Centre for Biostatistics (RCB) for 
electronic entry. Data will be validated at the point of entry into and at regular intervals 
during the study.  Data discrepancies will be flagged to the study site by the statistician 
and any data changes will be recorded in order to maintain a complete audit trail (reason 
for change, date change made, who made change). 
 
8.1.1 Data Handling and Record Keeping 
 
All CRF data will be held in the RCB. The RCB manages all studies to the highest 
standards in accordance with its internal Standard Operating Procedures, ICH Good 
Clinical Practice, the European Union Clinical Trials Directive 2001/20/EC, the ICH 
Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9 and all other 
industry legal and regulatory guidelines. It has extensive experience of managing data 
in the context of privacy and data protection legislature, including the Data Protection 
Act 1998 and EU Data Protection Directive 95/46/EC. The Centre is certified for ISO 
9001:2008 for its quality systems, has TickIT accreditation for its software development 
and is BS7799 compliant.  
Only the study investigators will have access to participant identifiable data. We will 
permit trial-related monitoring, audits and regulatory inspections and will provide direct 
access to source data and documents. 
 
8.1.3 Data Security 
The RCB systems are fully validated in accordance with industry and regulatory 
standards, and incorporate controlled access security. High volume servers are firewall 
protected and preventative system maintenance policies are in place to ensure no loss 
of service. Web servers are secured by digital certificates. Data integrity is assured by 
strictly controlled procedures, including secure data transfer procedures. 
 
8.1.4 Database Software 
Data will be stored in MS SQL Server. 
 
8.1.5 Record Retention 
To enable evaluations and/or audits from regulatory authorities, the investigator agrees 
to keep records, including the identity of all participating subjects (sufficient information 
to link records), all original signed informed consent forms, source document in 
accordance with ICH GCP, local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer.  Data will be retained at the Data Centre for a minimum 





CRF data will be stored by the Robertson Centre for Biostatistics for 10 years after 
completion of the study.  
 
9 STUDY MANAGEMENT 
The trial management teams will be in place before recruitment begins.  
 
9.1 Routine Management of Study 
The study will be co-ordinated from the Glasgow Royal Infirmary, Glasgow by the PI. 
The study will be subject to review at any time by the West Glasgow Local Research 
Ethics Committee. 
 
9.2 Trial Management Committee (TMC) 
There will be no DSMC for this observational trial.  Independent oversite will be provided 
by the study advisory group.  
 
9.3 Data Safety Monitoring Committee (DSMC) 
There will be no DSMC for this observational trial.  
 
10 STUDY MONITORING AND AUDITING 
Study monitoring visits will be conducted according to a study-specific monitoring plan 
devised by NHS Greater Glasgow and Clyde and subsequent monitoring reports will be 
reviewed by NHS Greater Glasgow and Clyde. The Sponsor, NHS Greater Glasgow and 
Clyde, audit a randomly selected 10% of studies conducted under the Research 
Governance Framework per annum, as well as those identified using a risk assessment 
tool as specifically requiring assessment. Investigators and site staff will notified in 
advance of any audit and/or monitoring visits. 
 
11 PROTOCOL AMENDMENTS 
Any change in the study protocol will require an amendment. Any proposed protocol 
amendments will be initiated by the Chief Investigator and any required amendment 
forms will be submitted to the regulatory authority, ethics committee and sponsor. The 
Sponsor will determine whether an amendment is non-substantial or substantial. All 
amended versions of the protocol will be signed by the Chief Investigator and sponsor 
representative. Before the amended protocol can be implemented (or sent to other 
participating sites) favourable opinion/approval must be sought from the original 
reviewing REC and Greater Glasgow & Clyde Health Board Research and Development 
(R & D) office. The Chief Investigator will sign any amended versions of the protocol. 
All protocol versions and their amendments must be notified to the study team and to 
the data centre. 
 
12 ETHICAL CONSIDERATIONS 
12.1 Ethical Conduct of Study  
Study will be carried on accordance with the World Medical Association Declaration of 
Helsinki (1964) and it revisions (Tokyo (1975), Venice (1983), Hong Kong (1989), South 
Africa (1996), Edinburgh (2000), Seoul (2008) and Fortaleza (2013). 
There are no special ethical considerations pertaining to this study. Favourable ethical 
opinion will be sought before patients are entered into this study. The Chief Investigator 




12.2 Informed Consent 
The clinical team will assess study participant’s ability to provide informed consent.  
Where possible we will obtain written informed consent from both study patient and 
informant. 
Where a patient is unable to provide informed consent but clinical team are still happy 
for the person to participate in the study, informed consent will be sought from a suitable 
proxy.  Choice of proxy will be guided by patient preference expressed at time of 
assessment or expressed pre-stroke.  
The research nurse or trained member of the research team will explain the exact nature 
of the study in writing, provide patient and carer information sheets, and verbal 
information.  Study participants will be informed that they are free to withdraw their 
consent from the study or study treatment at any time.  
 
13 INSURANCE AND INDEMNITY 
The study is sponsored by NHS Greater Glasgow and Clyde. The sponsors will be liable 
for negligent harm caused by the design of the trial. NHS Indemnity is provided under 
the Clinical Negligence and Other Risks Indemnity Scheme (CNORIS). As the 
substantive employer of the CI, The University of Glasgow also has insurance with 
Newline. It will be confirmed prior to the study starting that insurance cover will be 
provided automatically under the current policy. The insurance cover will be subject to 
NHS indemnity being in place and Ethics Committee approval being obtained. 
The NHS has a duty of care to patients treated, whether or not the patient is taking 
part in a clinical trial, and the NHS remains liable for clinical negligence and other 
negligent harm to patients under this duty of care.  
As this is a clinician-led study there are no arrangements for no-fault compensation. 
 
14 FUNDING 
The study is funded by a Chief Scientist Office / Stroke Association Programme grant. 
 
15 ANNUAL REPORTS 
The funders mandate progress report and outputs to be submitted electronically via the 
Researchfish resource; these will be updated in real time and reviewed annually. Annual 
reports will be submitted to the ethics committee, regulatory authority and sponsor with 
the first submitted one year after the date that all trial related approvals are in place. 
 
16 Dissemination of Findings 
 
Study results will be submitted to an International Conference and will be submitted for 
publication in a peer review journal. No personal data will be used when publishing the 
results.  A lay summary and other material as appropriate will be offered to those 
participants who wish to receive it.  Participants will be asked at their last study visit if 
they are happy to be contacted and the preferred method for contact.  These data will 
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Appendix 10: APPLE Patient Information Sheet  
 
Assessing for memory, thinking & mood problems following a stroke 
Information sheet and consent form for potential participants 
 
Contact information: If you wish any further information about the study please contact  
Dr Terry Quinn,  Email:terry.quinn@glasgow.ac.uk, Tel:0141-201-8510 
 
Title of project: Improving our assessment and understanding of the short, medium and 
longer term neuropsychological consequences of stroke 
 
Assessing Post-stroke Psychology Longitudinal Evaluation – the APPLE study 
You are being invited to take part in a clinical research study.  The study will look at 
memory, thinking and mood changes that can happen after a stroke.  We are particularly 
interested in how well questionnaires and pencil and paper tests detect any problems.  You 
will be asked to complete some questionnaires and some pencil and paper tests looking at 
memory, thinking and mood.  If you agree, as an optional study, we will also ask someone 
that knows you well about any memory, thinking, mood problems that they may have 
noticed.  
Before you make a decision, it is important that you fully understand why the research is 
being done and what will be involved.  This study is part of a program of work supported 
by the Stroke Association.  This project is part of the PhD work for three students based at 
the University of Glasgow.   
This study is part of a program of work supported by the Stroke Association.  This project is 
part of the PhD work for three students based at the University of Glasgow.   
Please take time to read the following information carefully and discuss it with others if 
you wish.  Please ask me if there is anything that is not clear or if you would like more 
information.   
 
Thank you for taking the time to read and consider this. 
 
Summary  
The aim of the study is to describe changes in memory, thinking and mood that occur after 
a stroke.  We are not testing a new drug or method of assessment and there will be no 
change to the usual clinical care.  We provide a summary of the research in this section, 
with more detail later in this information sheet. 
 
Participants will be recruited at the time of their stroke.  The clinical team will identify 
suitable patients and if they agree, then we will approach them with details of the study.   
 
The study has a number of components and potential participants can choose to take part 
in all, some or none of these.  We will check that the person who has had a stroke and their 
family member/friend are both agreeable to the study and which parts they wish to assist 
with.  An optional part of the study involves asking a friend, family member or carer about 
their perception of the participant’s memory, thinking and mood.   
 
If you agree to take part you will be asked some brief questions looking at memory, thinking 
and mood.  If agreeable, your family member/friend will also be asked to complete 
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questionnaires on your mood and memory.  As an optional step a member of the research 
team will then interview you and your family member/friend together. They will use a 
structured questionnaire.  The purpose of this more detailed interview is to assess whether 
you had memory, thinking, mood problems before the stroke.   
 
At around one month later, a research nurse or member of the research team will assess 
you again.  They will use short questionnaires and pencil and paper tests to describe 
memory, thinking, mood and any complications from stroke that have happened.  At six, 
twelve and eighteen months you will be asked about their recovery, their quality of life and 
will be reassessed for memory, thinking and mood problems using a more detailed 
questionnaire.  Your family member/friend will be asked about your recovery, their 
perception of your memory, thinking and mood and whether they feel under strain as a 
carer.  
If the participant finds the assessments too long or tiring; a shorter assessment is available.  
If the participant prefers a telephone assessment rather than face to face interview is 
available. Completing all the study assessments is not mandatory.  You can choose to 
participate in all the assessments or chose to only help with some of them. 
 
The assessments performed at one, six, twelve and eighteen months are not diagnostic.  A 
proportion of participants will be asked if they can be assessed by a trained psychologist 
who will try and make a clinical assessment of whether the person has important cognitive 
or mood problems.  
 
If you agree, you will have some blood taken and will be asked to provide a urine sample 
at the first and subsequent assessments.  This step is not mandatory.   If you agree the 
information collected will be stored and used for future studies.  Some of these studies may 
involve linking the research information to other sources of information such as hospital 
records, x-ray files or national records of admissions.  All the information held will be 
anonymous. 
 
What is the purpose of study? 
After a stroke many people develop changes in their memory, thinking and mood.  Our 
study is looking at questionnaires and pencil and paper based tests of thinking.  We wish 
to see if these tests can be used to detect problems in patients who have had a stroke.  This 
is important as early detection of memory and thinking problems may allow treatment of 
these problems.  We also wish to describe how memory, thinking and mood change over 
time. 
 
Why have I been chosen? 
We wish to include a range of people who have had stroke.  We are particularly interested 
in whether certain pencil and paper or questionnaire tests are suitable for use in acute 
stroke units.  We are approaching patients with stroke if they wish to participate.  Your 
hospital consultant and team are aware of the study and have suggested that you may be 
suitable.  The final decision on participation is up to you. 
 
 
Do I have to take part? 
No.  It is up to you to decide whether or not you take part.  If you do decide to take part 
you will be given this information sheet to keep and will be asked to sign a consent form.  
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You are free to withdraw at any time and do not have to give a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care 
you will receive.  You can choose to participate in all aspects of the project or only part of 
the project. 
The researchers are not involved with your general care and will not be involved with 
treatment of any memory, thinking or mood problems.  The initial results of the tests of 
memory, thinking and mood can be shared with the hospital team looking after you.   
  
What will happen if I take part?  
The project involves different steps.  You can choose to participate in all aspects or to 
restrict your participation to certain areas only. 
 
Main study: A researcher will ask you to complete a series of pencil and paper tests of 
memory, thinking and mood.  We want to assess how easy it is for people with stroke to 
complete the tests, so it is fine if you are unable to complete all or any of the tests.  The 
tests should take around 20 minutes to complete and the researcher can help.  As part of 
the initial assessment the research team may access the clinical notes, laboratory reports 
or x-rays relating to your admission.  We will also ask a relative or someone who knows 
you well to comment on any memory, thinking or mood problems that they may have 
noticed.  
As an optional study, within one month of the first assessment, a psychology graduate 
studying for a PhD will chat to you and your relative about memory, thinking and mood.  
This interview will be at a time and date that suits you both.  The total interview should 
last no more than 60 minutes and can be in the hospital or at another place that suits 
you. 
The nurse or psychology student will arrange to see you both again at around four weeks, 
six months, twelve months and eighteen months after the first interview.  They will 
complete some other pencil and paper tests around memory, thinking and mood with 
you and your relative.  These assessments should last less than 60 minutes.  Assessments 
will be at a date and time that suits you and can be in the hospital (we will pay for 
transport), in your house or over the telephone.  You can choose to help with all of these 
assessments or only a selection.  
 
Additional study A: After this study is complete, we wish to keep the results of the 
(anonymised) questionnaires and pencil and paper tests so that we can use these, with 
other researchers, to answer new questions on memory, thinking and mood problems 
after stroke.  We will use your hospital identifier (CHI number) to link the research results 
to other electronic databases, for example the other hospital records, the national record 
of hospital admissions or national record of drug prescribing.  Any matching of 
information between databases will be performed in such a way that participants’ data 
will be kept anonymous.  The information will be held securely in the Robertson Centre 
for Biostatistics, Glasgow.  As we wish to look at how problems now influence future 
health, we have set no time limit on how long we will keep the information for.   
 
Additional study B: While in the acute stroke unit, and at each study visit, a research 
nurse will ask if a blood and/or urine sample can be taken.  This will involve one needle 
for the blood sample at each visit.  This step is optional and at any visit you can decline 
the blood sample.  We will store the blood and urine to allow for future studies looking at 
ill-health in stroke.  Storage will be in the secure facilities of the NHS Greater Glasgow and 
Clyde biobank.  The samples will allow us to look at blood cells and other molecules in 
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blood and proteins in urine.  We may use the materials to look at genetic factors.  The 
genetic studies may involve looking at genes associated with certain disease or looking at 
all the genes.  We would not use samples for stem cell work. 
 
What do I have to do? 
If you agree to participate you will be asked to sign a consent form.  We are also interested 
in the thoughts and assessment of a family member/friend on your memory, thinking and 
mood.  If you agree, we would also like them to complete some short questionnaires.  There 
is a separate information sheet and consent form describing this study.  You will have at 
least a day to decide if you want to participate.   
 
What are the possible benefits to me from taking part? 
There are no direct benefits to you or your family member/friend from taking part.  
Participants in the study will get a detailed assessment that can be shared with the clinical 
team.  By taking part you will help us decide on the best way to test for memory, thinking 
and mood problems after stroke.  The study will also help us understand how memory, 
thinking and mood change over time. 
 
What are the possible disadvantages and risks from part? 
From being part of the study you will get more detailed, and longer, assessments of 
memory, thinking and mood than would happen in standard care.   
 
What if something goes wrong? 
If you have a concern about any aspect of this study please contact the research team 
(details at end of leaflet) who will do their best to answer your questions. 
 
You have the right to withdraw from assessment at any time without providing a reason 
and with no impact to the care you receive.  If you are unhappy about any aspect of the 
study and wish to make a formal complaint the normal NHS complaints mechanism is also 
available to you. 
 
What happens when the study is finished? 
We will collate all the information from participants and look to see which tests are best 
at picking up memory, thinking and mood problems and how these issues change over 
time.  The information collected will be securely stored for an indefinite time.  Other 
researchers may access anonymised information to answer new research questions.  The 
blood samples taken will be stored securely in the NHS Greater Glasgow & Clyde Biobank 
facility for ten years.  At the end of the study, if you agree, we will send you the results of 
the various research projects.   
 
What will happen to the results of the study? 
The results of the tests may be shared with the clinical team working within the stroke unit 
and with your GP.  We hope to publish the final results of our study in a scientific journal 
and discuss the results at professional meetings.  Personal details will not be available in 
any of these materials.  If you are interested in the results when the study is complete, 
details can be sent to you.   
 
Who will see my information? (confidentiality)  
All the information we collect during the course of the research will be kept confidential 
and there are strict laws which safeguard the privacy of the patient at every stage.  Initial 
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scores on the questionnaires and pencil and paper tests may be shared you’re your hospital 
stroke team.  If during testing we detect any new diagnoses, we will share this with your 
hospital team.  All information collected by the research team will be anonymised and 
stored in a secure way. The information will be held securely in the Robertson Centre for 
Biostatistics, Glasgow. If you agree we will keep the results of the anonymised 
questionnaires to allow us and other researchers to use them in future projects.  The 
information collected as part of the study may be looked at by representatives of the study 
Sponsor, NHS GG&C, for audit purposes. 
Part of our questions on mood includes asking about low mood (depression).  If we suspect 
severe depression or suicidal thoughts, questioning will be stopped and the treating 
physician contacted immediately.  In this case you may also be referred to appropriate 
specialised help.  
 
Some additional information on how we use your information 
NHS Greater Glasgow and Clyde is the sponsor for this study based in UK. We will be using 
information from and/or your medical records in order to undertake this study and will act 
as the data controller for this study. This means that we are responsible for looking after 
your information and using it properly. NHS Greater Glasgow and Clyde will keep 
identifiable information about you for 10 years after the study has finished. 
 
Your rights to access, change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If 
you withdraw from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible. 
 
The NHS hospitals taking part in the study will collect information from you and/or your 
medical records for this research study in accordance with our instructions.  The NHS 
hospitals will use your name and contact details to contact you about the research study, 
and make sure that relevant information about the study is recorded for your care, and to 
oversee the quality of the study. Individuals from NHS Greater Glasgow and Clyde and 
regulatory organisations may look at your medical and research records to check the 
accuracy of the research study. The participating NHS hospitals will pass these details to 
NHS Greater Glasgow and Clyde/University of Glasgow along with the information 
collected from you and/or your medical records. The only people in NHS Greater Glasgow 
and Clyde/University of Glasgow who will have access to information that identifies you 
will be people who need to contact you about research or audit the data collection process. 
The people who analyse the information will not be able to identify you and will not be able 
to find out your name or contact details.  The participating NHS hospitals will keep 
identifiable information about you from this study for 10 years after the study has finished. 
 
When you agree to take part in a research study, the information about your health and 
care may be provided to researchers running other research studies in this organisation 
and in other organisations. These organisations may be universities, NHS organisations or 
companies involved in health and care research in this country or abroad. Your information 
will only be used by organisations and researchers to conduct research in accordance with 




Your information could be used for research in any aspect of health or care, and could be 
combined with information about you from other sources held by researchers, the NHS or 
government.  
 
Where this information could identify you, the information will be held securely with strict 
arrangements about who can access the information. The information will only be used for 
the purpose of health and care research, or to contact you about future opportunities to 
participate in research. It will not be used to make decisions about future services available 
to you, such as insurance. 
 
Where there is a risk that you can be identified your data will only be used in research that 
has been independently reviewed by an ethics committee. 
 
You can find out more about how we use your information by contacting the Principal 
Investigator: terry.quinn@glasgow.ac.uk 
 
Who is organising and funding the study? 
This study is being organised by the Institute of Cardiovascular and Medical Sciences, 
University of Glasgow.  The study is funded by the Stroke Association.  The researchers will 
receive no remuneration for including you in the study.    
 
Who has reviewed this study? 
This study has been reviewed and approved by Scotland A Research Ethics Committee.  All 
research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee.  A favourable ethical opinion has been obtained from Scotland A REC.  
NHS management approval has also been obtained. 
 
SUMMARY  
If you agree to participate you will be asked to complete some tests assessing memory, 
thinking skills and mood.  Tests will be performed during this admission and at four future 
visits.   
 
Name of Lead Researcher  
Dr Terry Quinn, Senior Clinical Lecturer, University of Glasgow. 
 
Name of sponsor      Name of Funder 








     Chairman Dr Ian Zealley 
     Vice-Chairman Dr Colin Selby 
Scotland A Research Ethics Committee Research Ethics Service 
2nd Floor Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 










28 July 2016 
 
Dr Terence J Quinn 
Room 2.44 New Lister Building 
Institute of Cardiovascular and Medical Sciences 
Glasgow Royal Infirmary, Alexandra Parade 
G4 0SF 
 
Dear Dr Quinn  
 
                  Scotland A REC 
2nd Floor Waverley Gate 
              2 - 4 Waterloo Place 
              Edinburgh 
              EH1 3EG 
             Tel: 0131-465-5679 
Study title: Improving our assessment and understanding of the short, 
medium and longer term neuropsychological consequences 
of stroke 
REC reference: 16/SS/0105 
Protocol number: GN14NE496 
IRAS project ID: 199099 
 
Thank you for your letter, responding to the Committee’s request for further information on the above 
research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, together with 
your contact details. Publication will be no earlier than three months from the date of this opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to make a 
request to postpone publication, please contact the REC Manager, Miss Manx Neill, 
manx.neill@nhslothian.scot.nhs.uk.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on 
the basis described in the application form, protocol and supporting documentation as revised, subject to the 
conditions specified below. 
 
Adults with Incapacity (Scotland) Act 2000 
 
I confirm that the Committee has approved this research project for the purposes of the Adults with 





     Chairman Dr Ian Zealley 
     Vice-Chairman Dr Colin Selby 
Scotland A Research Ethics Committee Research Ethics Service 
2nd Floor Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
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                    2
nd
 Floor Waverley Gate 
                                       2 - 4 Waterloo Place 
                                                       Edinburgh 
                                                        EH1 3EG 
                                         Tel: 0131 465 5678
26 July 2017 
 
Dr Terence J Quinn 
Room 2.44 New Lister Building 
Institute of Cardiovascular and Medical Sciences 
Glasgow Royal Infirmary, Alexandra Parade 
Glasgow, G4 0SF 
 
Dear Dr Quinn, 
 
Study title: Improving our assessment and understanding of the short, 
medium and longer term neuropsychological consequences of 
stroke 
REC reference: 16/SS/0105 
Protocol number: GN14NE496 
Amendment number: AM02 (REC Ref 16/SS/0105/AM02) 
Amendment date: 09 June 2017 
IRAS project ID: 199099 
 




The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment 
on the basis described in the notice of amendment form and supporting documentation. 
 




The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
Notice of Substantial Amendment (non-CTIMP)    09 June 2017  
Other [Bogna Drozdowska Curriculum Vitae]      
Other [Emma Elliot Curriculum Vitae]      










Telephone Number: 0141 232 1813 
E-Mail: Maureen.Travers@ggc.scot.nhs.uk 
website www.nhsggc.org.uk/r&d 
Clinical Research & Development 
West Glasgow ACH 
Dalnair Street 






Dr Terence Quinn 
University of Glasgow 
Institute of Cardiovascular and Medical Sciences 
New Lister Building  
Glasgow Royal Infirmary  
Glasgow 




NHS GG&C Board Approval 
Dear Dr Terence Quinn 
 
Study Title:  Improving our assessment and understanding of the short, medium and longer term 
neuropsychological consequences of stroke 
Principal Investigator:   Dr Terence Quinn 
GG&C HB site Glasgow Royal Infirmary 
Sponsor NHS Greater Glasgow and Clyde 
R&D reference: GN14NE496 
REC reference:  
Protocol no: 
(including version and 
date) 
version 1.2 (05.07.2016) 
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant Approval for the above study. 
 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004 
a. During the life span of the study GGHB requires the following information relating to this site 
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections. 
 
It is your responsibility to ensure that all staff involved in the study at this site have the appropriate GCP training according 
to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such training to be filed in the 
site file. 
 
2. For all studies the following information is required during their lifespan. 
a. Recruitment Numbers on a quarterly basis 
b. Any change of staff named on the original SSI form 
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Appendix 12: Case report form pages 
 
Produced by Robertson Centre for Biostatistics, University of Glasgow
APPLE Study
Protocol Version 1.5
Version 4.0 (26 Feb 2018)
Initials Date of Visit







Page 1 of 14
Untestable - Reason
(enter appropriate number from table on page 13)
Time taken to complete1.
Verbal assistance required to complete 212. Yes No































UN If other (9), specify:
19
N/A








Give recall items at this point: face, velvet, church, daisy, red 




























If other (9), specify:
3432

























If other (9), specify:
5048






























































Appendix 14: Brief CSIs scoring algorithm 
   





















































Clock-drawing test x x x
Total: 3 /1 /1 /1
Abbreviated MoCA x x x x
Total: 8 /5 /1 /1 /1
AMT-4 x x x x
Total: 4 /1 /1 /1 /1
4AT x x x x x x x
 Total: 12
0 points if ≥7 
correct, 1 point 
if <7 OR refusal, 
2 points if 
untestable 
4 points If 
yes, 0 if no
4 points if yes, 
0 if no

























10-AMT x x x x x x x x x x
Total: 10 1 1 /1 /1 /1 /1 /1 /1 /1







x x x x x x x
Total: 11 1 1 /1 /1 /1 /5 /1
Cog-4 x x x x
Total: 9 /2 /2 /3 /2
AMT-plus: NIHSS: CAM-ICU: 
if AMT-4 is 4/4 = 0 points. If AMT is 3/4 = 1 point, if there are 
≥2 errors or if they are untestable = 2 points
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Appendix 15: Guidance document sent to APPLE sites 
CLARIFICATION OF AMBIGUOUS TEST ITEMS – ADMINISTRATION AND SCORING 
 
Oxford Cognitive Screen  
Question  Clarification 
3. Orientation 
If the patient doesn’t get any of these questions right by free recall, show them the multiple-choice answers 
5. Sentence 
reading 
The patient must correctly pronounce each word to get full marks (e.g. quay needs to read as ‘key’). Self-correction 
is allowed. Don’t penalise for dysarthria. 
6. Number 
writing  The patient needs to write out the number numerically (708), not ‘seven hundred and eight’ 
7. Broken Hearts  
• The maximum time for this task is 3 minutes. Please stop the task after this time.  
• Keep the page centred with the triangle in the patient’s midline. The page should not be turned or 
moved from this position.  
• Please do not draw lines across the heart cancellation page (like how the scoring template has) 
• Space asymmetry “total in boxes 7,8,9,10 minus total correct in 1,2,3,4” – this means only add up the 
full hearts which have been cancelled out in these boxes, don’t include any that have cancelled out 
which have gaps 
8. Meaningless 
gesture imitation  
If the patient correctly copies the 2 gestures after 1 demonstration they receive the full 3 points and you don’t need 
to repeat them a second time.  
 
Scoring: 
 On the two gestures: 
3 if both correct first time 
2 if both correct on second go 
1 if one correct on second go 




For the single finger positioning: 
3 if correct first time 
2 if correct second time 
1 if incorrect but recognisable second time (e.g orientation error – this means it is the correct shape but not the 
mirror image) 
0 if completely wrong (not recognizable) 
9. Delayed recall 
and recognition  
Verbal memory - If the patient gets all 4 words correct by free recall then you do not need to show them the 




If an error is made at some point, but subsequent performance is correct, the correct connections are 
acknowledged. Self-correction is allowed. 
 
AMT 
Question  Clarification 
3. Date In the current CRF version this item is split into 3 subpoints. The “Day” item relates to the day of the month e.g. 
“16th”, not the day of the week e.g. “Tuesday”. If the patient says the day of the week, prompt them for the exact 
date. 
10. Recall The patient must correctly recall a minimum of 4 words (in any order) to pass. “Number of mistakes” in the last 
column refers to the number of recall items not mentioned by the patient. For example, if a patient says “church, 
daisy, face“, “number of mistakes” should be 2. If a patient says “face, rose, church, silk, arm, purple”, the number 
of mistakes is 3. 
11. Clock draw  Please ask the patient to set the time to 11:10. If a different time is used please write down what time you asked them 
to complete. We are following the scoring guidelines from the MoCA. In the current CRF version this item is split into 3 
subpoints: 
• Face: the clock face must be a circle with only minor distortion acceptable (e.g. Slight imperfection on 
closing the circle) 
• Numbers: all clock numbers must be present with no additional numbers; numbers must be in the correct 
order and placed in the approximate quadrants on the clock face; Roman numerals are acceptable; 
numbers can be placed outside the circle contour 
• Hands: there must be two hands jointly indicating the correct time; the hour hand must be clearly shorter 




13. Months  
backwards 
In order to pass, the patient must say a string of minimum 7 consecutive months correctly. A mistake is recorded if a 
patient does not mention a particular month(s) at all and/or lists a month(s) in an incorrect order. If a patient 
mentions a particular month more than once, and it is not an attempt at self-correction, this will also mean that at 
least on one occasion the month appeared in the wrong order. This should be however treated as a single error, not to 
penalise the patient for the same mistake twice. Overall, to simplify scoring, we suggest a rule that 1 particular month 
can account for 1 error maximum, meaning a highest possible total of 12 mistakes. Correctness of order should be 
assessed based on the preceding month. For example, if a patient says: “December, September, August, October, 
September, July, June, May, April, March, February, January”, it’s a pass (a correct sequence including 7 months, from 
July to January), with 4 errors (omitting November, September mentioned after December, October mentioned after 
August, July mentioned after September). Self-correction is allowed. 
We find that it’s always easier to write down what the patient says and then score it later. If you’re struggling with 
scoring we can do this if you have written down what the patient said.  
14. One letter 
fluency 
As mentioned in earlier instructions, if a patient says words with the same core but different suffixes, only 1 point is 
given – for the first word, e.g. 1 point for love, but 0 for lover and loving. However, if the first part of the words is the 
same, but the second part makes the words unrelated in terms of meaning, a point is awarded for each of these words 
e.g. for saying aircraft, airway and airtight a patient should receive 3 points. 




Appendix 16: Chapter 7 linear regression plots 
Normal probability plots for EQ-5D, log CESD-R, mRS outcomes. All three models 
include age, sex, NIHSS, pre-morbid mRS, years in education (log) and 









Appendix 17: Chapter 7 full regression results 
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Standardised beta (95% CI) Odds ratio (95% CI) 
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Log CESD-R EQ-5D mRS Barthel Lawton 
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